2023
Prevalence of Potentially Clinically Significant Drug-Drug Interactions With Antiretrovirals Against HIV Over Three Decades: A Systematic Review of the Literature (Journal article)
Hodge, D., Hodel, E. M., Hughes, E., Hazenberg, P., Granana Castillo, S., Gibbons, S., . . . Khoo, S. (2023). Prevalence of Potentially Clinically Significant Drug-Drug Interactions With Antiretrovirals Against HIV Over Three Decades: A Systematic Review of the Literature. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 92(2), 97-105. doi:10.1097/QAI.0000000000003122DOI: 10.1097/QAI.0000000000003122
2022
Marzolini, C., Kuritzkes, D. R., Marra, F., Boyle, A., Gibbons, S., Flexner, C., . . . Khoo, S. (2022). Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications. CLINICAL PHARMACOLOGY & THERAPEUTICS, 112(6), 1191-1200. doi:10.1002/cpt.2646DOI: 10.1002/cpt.2646
Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions (Journal article)
Marzolini, C., Kuritzkes, D. R., Marra, F., Boyle, A., Gibbons, S., Flexner, C., . . . Khoo, S. (2022). Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions. ANNALS OF INTERNAL MEDICINE, 175(5), 744-+. doi:10.7326/M22-0281DOI: 10.7326/M22-0281
Marzolini, C., Marra, F., Boyle, A., Khoo, S., & Back, D. J. (2022). Fluvoxamine for the treatment of COVID-19. LANCET GLOBAL HEALTH, 10(3), E331. Retrieved from https://www.webofscience.com/
Jacobs, T. G., Marzolini, C., Back, D. J., & Burger, D. M. (2022). Dexamethasone is a dose-dependent perpetrator of drug-drug interactions: implications for use in people living with HIV. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(3), 568-573. doi:10.1093/jac/dkab412DOI: 10.1093/jac/dkab412
2021
The intersection of drug interactions and adverse reactions in contemporary antiretroviral therapy. (Journal article)
Nhean, S., Tseng, A., & Back, D. (2021). The intersection of drug interactions and adverse reactions in contemporary antiretroviral therapy.. Current opinion in HIV and AIDS, 16(6), 292-302. doi:10.1097/coh.0000000000000701DOI: 10.1097/coh.0000000000000701
Hodge, D., Back, D. J., Gibbons, S., Khoo, S. H., & Marzolini, C. (2021). Pharmacokinetics and Drug-Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine. CLINICAL PHARMACOKINETICS, 60(7), 835-853. doi:10.1007/s40262-021-01005-1DOI: 10.1007/s40262-021-01005-1
Boffito, M., Back, D. J., Flexner, C., Sjo, P., Blaschke, T. F., Horby, P. W., . . . Owen, A. (2021). Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development. CLINICAL PHARMACOLOGY & THERAPEUTICS, 110(1), 64-68. doi:10.1002/cpt.2099DOI: 10.1002/cpt.2099
Prescribing in COVID-19 patients: Should we take into account inflammation? (Journal article)
Marzolini, C., Battegay, M., Sendi, P., & Back, D. J. (2021). Prescribing in COVID-19 patients: Should we take into account inflammation?. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87(3), 719-721. doi:10.1111/bcp.14524DOI: 10.1111/bcp.14524
Marra, F., Smolders, E. J., El-Sherif, O., Boyle, A., Davidson, K., Sommerville, A. J., . . . Back, D. (2021). Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment. DRUGS IN R&D, 21(1), 9-27. doi:10.1007/s40268-020-00333-0DOI: 10.1007/s40268-020-00333-0
Back, D., Marzolini, C., Hodge, C., Marra, F., Boyle, A., Gibbons, S., . . . Khoo, S. (2021). COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87(1), 212-213. doi:10.1111/bcp.14358DOI: 10.1111/bcp.14358
2020
Hodge, D., Marra, F., Marzolini, C., Boyle, A., Gibbons, S., Siccardi, M., . . . Khoo, S. (2020). Drug interactions: a review of the unseen danger of experimental COVID-19 therapies. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(12), 3417-3424. doi:10.1093/jac/dkaa340DOI: 10.1093/jac/dkaa340
Safety perspectives on presently considered drugs for the treatment of COVID‐19 (Journal article)
Penman, S. L., Kiy, R. T., Jensen, R. L., Beoku‐Betts, C., Alfirevic, A., Back, D., . . . Chadwick, A. E. (n.d.). Safety perspectives on presently considered drugs for the treatment of COVID‐19. British Journal of Pharmacology. doi:10.1111/bph.15204DOI: 10.1111/bph.15204
Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect (Journal article)
Stader, F., Khoo, S., Stoeckle, M., Back, D., Hirsch, H. H., Battegay, M., & Marzolini, C. (2020). Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(10), 3084-3086. doi:10.1093/jac/dkaa253DOI: 10.1093/jac/dkaa253
Siccardi, M., Schapiro, J., Di Perri, G., & Back, D. J. (2020). The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(9), 2381-2383. doi:10.1093/jac/dkaa272DOI: 10.1093/jac/dkaa272
Arshad, U., Pertinez, H., Box, H., Tatham, L., Rajoli, R. K., Curley, P., . . . Owen, A. (2020). Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.. Clinical pharmacology and therapeutics. doi:10.1002/cpt.1909DOI: 10.1002/cpt.1909
Drug–drug interactions with direct‐acting antivirals: when do we need to care? (Chapter)
Marra, F., & Back, D. (2020). Drug–drug interactions with direct‐acting antivirals: when do we need to care?. In Unknown Book (pp. 86-93). Wiley. doi:10.1002/9781119533481.ch15DOI: 10.1002/9781119533481.ch15
Schulte, B., Wuebbolding, M., Marra, F., Port, K., Manns, M. P., Back, D., . . . Maasoumy, B. (2020). Frequency of Potential Drug-Drug Interactions in the Changing Field of HCV Therapy. OPEN FORUM INFECTIOUS DISEASES, 7(2). doi:10.1093/ofid/ofaa040DOI: 10.1093/ofid/ofaa040
Back, D., & Marzolini, C. (2020). The challenge of HIV treatment in an era of polypharmacy.. Journal of the International AIDS Society, 23(2), e25449. doi:10.1002/jia2.25449DOI: 10.1002/jia2.25449
2019
Smolders, E. J., Jansen, A. M. E., ter Horst, P. G. J., Rockstroh, J., Back, D. J., & Burger, D. M. (2019). Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update. CLINICAL PHARMACOKINETICS, 58(10), 1237-1263. doi:10.1007/s40262-019-00774-0DOI: 10.1007/s40262-019-00774-0
Cranston, R. D., Dezzutti, C. S., Siegel, A., Engstrom, J., Shetler, C., Richardson-Harman, N., . . . McGowan, I. (2019). A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIV. AIDS RESEARCH AND HUMAN RETROVIRUSES, 35(9), 794-804. doi:10.1089/aid.2018.0265DOI: 10.1089/aid.2018.0265
Back, D., Belperio, P., Bondin, M., Negro, F., Talal, A. H., Park, C., . . . Marra, F. (2019). Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis. JOURNAL OF VIRAL HEPATITIS, 26(8), 951-960. doi:10.1111/jvh.13110DOI: 10.1111/jvh.13110
Ferenci, P., Bourgeois, S., Buggisch, P., Norris, S., Curescu, M., Larrey, D., . . . Flisiak, R. (2019). Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in hepatitis C virus genotype 1-and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries. JOURNAL OF VIRAL HEPATITIS, 26(6), 685-696. doi:10.1111/jvh.13080DOI: 10.1111/jvh.13080
Rajoli, R. K. R., Curley, P., Chiong, J., Back, D., Flexner, C., Owen, A., & Siccardi, M. (2019). Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling. JOURNAL OF INFECTIOUS DISEASES, 219(11), 1735-1742. doi:10.1093/infdis/jiy726DOI: 10.1093/infdis/jiy726
Successful HCV treatment of patients on contraindicated anti-epileptic drugs: Role of drug level monitoring (Journal article)
van Seyen, M., Smolders, E. J., van Wijngaarden, P., Drenth, J. P. H., Wouthuyzen-Bakker, M., de Knegt, R. J., . . . Burger, D. M. (2019). Successful HCV treatment of patients on contraindicated anti-epileptic drugs: Role of drug level monitoring. JOURNAL OF HEPATOLOGY, 70(3), 552-554. doi:10.1016/j.jhep.2018.10.010DOI: 10.1016/j.jhep.2018.10.010
Antiretroviral drug-drug interactions in an era of polypharmacy (Journal article)
Back, D. (2019). Antiretroviral drug-drug interactions in an era of polypharmacy. GERMS, 9(3), 123-124. doi:10.18683/germs.2019.1166.DOI: 10.18683/germs.2019.1166.
2018
Gini, J., Amara, A., Penchala, S. D., Back, D. J., Else, L., Egan, D., . . . Khoo, S. H. (2018). Widespread use of herbal medicines by people living with human immunodeficiency virus and contamination of herbal medicines with antiretrovirals in Nigeria.. International journal of STD & AIDS, 956462418809749. doi:10.1177/0956462418809749DOI: 10.1177/0956462418809749
Marra, F., zu Siederdissen, C. H., Khoo, S., Back, D., Schlag, M., Ouwerkerk-Mahadevan, S., . . . Cornberg, M. (2018). Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 84(5), 961-971. doi:10.1111/bcp.13519DOI: 10.1111/bcp.13519
Cirrincione, L. R., Penchala, S. D., Scarsi, K. K., Podany, A. T., Winchester, L. C., Back, D. J., . . . Else, L. J. (2018). Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1084, 106-112. doi:10.1016/j.jchromb.2018.03.023DOI: 10.1016/j.jchromb.2018.03.023
Pushpakom, S. P., Adaikalakoteswari, A., Owen, A., Back, D. J., Tripathi, G., Kumar, S., . . . Pirmohamed, M. (2018). Telmisartan reverses antiretroviral-induced adipocyte toxicity and insulin resistance in vitro.. Diabetes & vascular disease research, 15(3), 233-242. doi:10.1177/1479164118757924DOI: 10.1177/1479164118757924
Kidney Diseases Associated with Human Immunodeficiency Virus Infection (Journal article)
Back, D. J. (2018). Kidney Diseases Associated with Human Immunodeficiency Virus Infection. NEW ENGLAND JOURNAL OF MEDICINE, 378(17), 1654-+. Retrieved from https://www.webofscience.com/
Roberts, O., Rajoli, R. K. R., Back, D. J., Owen, A., Darin, K. M., Fletcher, C. V., . . . Siccardi, M. (2018). Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug–drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART. Journal of Antimicrobial Chemotherapy, 73(4), 1004-1012. doi:10.1093/jac/dkx515DOI: 10.1093/jac/dkx515
Rajoli, R. K. R., Back, D. J., Rannard, S., Meyers, C. F., Flexner, C., Owen, A., & Siccardi, M. (2018). In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents.. Clinical pharmacokinetics, 57(02), 255-266. doi:10.1007/s40262-017-0557-xDOI: 10.1007/s40262-017-0557-x
Jackson, A., Else, L., Higgs, C., Karolia, Z., Khoo, S., Back, D., . . . Boffito, M. (2018). Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naive HIV-1-infected individuals. HIV CLINICAL TRIALS, 19(1), 31-37. doi:10.1080/15284336.2017.1408928DOI: 10.1080/15284336.2017.1408928
2017
Negredo, E., Back, D., Blanco, J. -R., Blanco, J., Erlandson, K. M., Garolera, M., . . . Clotet, B. (2017). Aging in HIV-Infected Subjects: A New Scenario and a New View.. BioMed research international, 2017, 5897298. doi:10.1155/2017/5897298DOI: 10.1155/2017/5897298
A Call for a Consortium for Optimal Management of Drug-Drug Interactions in Patient Care (Journal article)
Burger, D. M., Smolders, E. J., Schapiro, J., Drenth, J. P. H., & Back, D. J. (2017). A Call for a Consortium for Optimal Management of Drug-Drug Interactions in Patient Care. CLINICAL PHARMACOLOGY & THERAPEUTICS, 102(3), 391-394. doi:10.1002/cpt.648DOI: 10.1002/cpt.648
Neary, M., Lamorde, M., Olagunju, A., Darin, K. M., Merry, C., Byakika-Kibwika, P., . . . Scarsi, K. K. (2017). The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine. CLINICAL PHARMACOLOGY & THERAPEUTICS, 102(3), 529-536. doi:10.1002/cpt.667DOI: 10.1002/cpt.667
Marzolini, C., Rajoli, R., Battegay, M., Elzi, L., Back, D., & Siccardi, M. (2017). Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes. CLINICAL PHARMACOKINETICS, 56(4), 409-420. doi:10.1007/s40262-016-0447-7DOI: 10.1007/s40262-016-0447-7
Seden, K., Gibbons, S., Marzolini, C., Schapiro, J. M., Burger, D. M., Back, D. J., & Khoo, S. H. (2017). Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection. PLOS ONE, 12(3). doi:10.1371/journal.pone.0173509DOI: 10.1371/journal.pone.0173509
Use of a physiologically based pharmacokinetic model to simulate drug–drug interactions between antineoplastic and antiretroviral drugs (Journal article)
Molto, J., Rajoli, R., Back, D. J., Valle, M., Miranda, C., Owen, A., . . . Siccardi, M. (2017). Use of a physiologically based pharmacokinetic model to simulate drug–drug interactions between antineoplastic and antiretroviral drugs. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(3), 805-811. doi:10.1093/jac/dkw485DOI: 10.1093/jac/dkw485
2-Drug regimens in HIV treatment: pharmacological considerations (Journal article)
Back, D. (n.d.). 2-Drug regimens in HIV treatment: pharmacological considerations. Germs, 7(3), 113-114. doi:10.18683/germs.2017.1115DOI: 10.18683/germs.2017.1115
Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 Study (Journal article)
Amara, A. B., Else, L. J., Carey, D., Khoo, S., Back, D. J., Amin, J., . . . Puls, R. L. (2017). Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 Study. THERAPEUTIC DRUG MONITORING, 39(6), 654-658. doi:10.1097/FTD.0000000000000448DOI: 10.1097/FTD.0000000000000448
2016
Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection. (Journal article)
Degasperi, E., Caprioli, F., El Sherif, O., Back, D., Colombo, M., & Aghemo, A. (2016). Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection.. Expert review of gastroenterology & hepatology, 10(12), 1373-1383. doi:10.1080/17474124.2016.1246181DOI: 10.1080/17474124.2016.1246181
McGowan, I., Dezzutti, C. S., Siegel, A., Engstrom, J., Nikiforov, A., Duffill, K., . . . Cranston, R. D. (2016). Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment. LANCET HIV, 3(12), E569-E578. doi:10.1016/S2352-3018(16)30113-8DOI: 10.1016/S2352-3018(16)30113-8
Fox, J., Tiraboschi, J. M., Herrera, C., Else, L., Egan, D., Dickinson, L., . . . Boffito, M. (2016). Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis.. Journal of acquired immune deficiency syndromes (1999), 73(3), 252-257. doi:10.1097/qai.0000000000001108DOI: 10.1097/qai.0000000000001108
Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G -> T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis (Journal article)
Nightingale, S., Chau, T. T. H., Fisher, M., Nelson, M., Winston, A., Else, L., . . . Grp, P. -V. S. (2016). Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G -> T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis. Antimicrobial Agents and Chemotherapy, 60(8), 4511-4518. doi:10.1128/AAC.00280-16DOI: 10.1128/AAC.00280-16
Pregnancy affects nevirapine pharmacokinetics: evidence from a <i>CYP2B6</i> genotype-guided observational study (Journal article)
Olagunju, A., Bolaji, O., Neary, M., Back, D., Khoo, S., & Owen, A. (2016). Pregnancy affects nevirapine pharmacokinetics: evidence from a <i>CYP2B6</i> genotype-guided observational study. PHARMACOGENETICS AND GENOMICS, 26(8), 381-389. doi:10.1097/FPC.0000000000000227DOI: 10.1097/FPC.0000000000000227
Penchala, S. D., Fawcett, S., Else, L., Egan, D., Amara, A., Elliot, E., . . . Khoo, S. (2016). The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1027, 174-180. doi:10.1016/j.jchromb.2016.05.040DOI: 10.1016/j.jchromb.2016.05.040
Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications (Journal article)
Marzolini, C., Gibbons, S., Khoo, S., & Back, D. (2016). Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(7), 1755-1758. doi:10.1093/jac/dkw032DOI: 10.1093/jac/dkw032
Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . Puls, R. (2016). Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naive HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study. CLINICAL PHARMACOKINETICS, 55(7), 861-873. doi:10.1007/s40262-015-0360-5DOI: 10.1007/s40262-015-0360-5
Distinct Pharmacodynamic Activity of Rilpivirine in Ectocervical and Colonic Explant Tissue (Journal article)
Dezzutti, C. S., Else, L. J., Yandura, S. E., Shetler, C., Russo, J., Back, D. J., & McGowan, I. (2016). Distinct Pharmacodynamic Activity of Rilpivirine in Ectocervical and Colonic Explant Tissue. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(5), 2765-2770. doi:10.1128/AAC.00167-16DOI: 10.1128/AAC.00167-16
Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake (Journal article)
Elliot, E., Amara, A., Jackson, A., Moyle, G., Else, L., Khoo, S., . . . Boffito, M. (2016). Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(4), 1031-1036. doi:10.1093/jac/dkv425DOI: 10.1093/jac/dkv425
Dickinson, L., Winston, A., Boffito, M., Khoo, S., Back, D., & Siccardi, M. (2016). Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(4), 1041-1045. doi:10.1093/jac/dkv439DOI: 10.1093/jac/dkv439
Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA). (Journal article)
Penrose, K. J., Parikh, U. M., Hamanishi, K. A., Else, L., Back, D., Boffito, M., . . . Mellors, J. W. (2016). Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA).. The Journal of infectious diseases, 213(6), 1013-1017. doi:10.1093/infdis/jiv528DOI: 10.1093/infdis/jiv528
Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks (Journal article)
Scarsi, K. K., Darin, K. M., Nakalema, S., Back, D. J., Byakika-Kibwika, P., Else, L. J., . . . Lamorde, M. (2016). Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks. CLINICAL INFECTIOUS DISEASES, 62(6), 675-682. doi:10.1093/cid/civ1001DOI: 10.1093/cid/civ1001
Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort (Journal article)
Siederdissen, C. H. Z., Maasoumy, B., Marra, F., Deterding, K., Port, K., Manns, M. P., . . . Wedemeyer, H. (2016). Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort. CLINICAL INFECTIOUS DISEASES, 62(5), 561-567. doi:10.1093/cid/civ973DOI: 10.1093/cid/civ973
Tenofovir Disoproxil Fumarate Fails to Prevent HIV Acquisition or the Establishment of a Viral Reservoir: Two Case Reports (Journal article)
Fox, J., Brady, M., Alexander, H., Davies, O., Robinson, N., Pace, M., . . . Frater, J. (2016). Tenofovir Disoproxil Fumarate Fails to Prevent HIV Acquisition or the Establishment of a Viral Reservoir: Two Case Reports. INFECTIOUS DISEASES AND THERAPY, 5(1), 65-71. doi:10.1007/s40121-015-0102-xDOI: 10.1007/s40121-015-0102-x
Interaction of Darunavir/Ritonavir and Darunavir/Cobicistat With Rifampicin In Vitro (Conference Paper)
Roberts, O., Back, D., Khoo, S., Owen, A., & Siccardi, M. (2016). Interaction of Darunavir/Ritonavir and Darunavir/Cobicistat With Rifampicin In Vitro. In CROI. Boston, USA.
Effect of nondisclosure of HIV status in sexual health clinics on unlinked anonymous HIV prevalence estimates in England, 2005-2009 (Journal article)
Savage, E. J., Lowndes, C. M., Sullivan, A. K., Back, D. J., Else, L. J., Murphy, G., & Gill, O. N. (2016). Effect of nondisclosure of HIV status in sexual health clinics on unlinked anonymous HIV prevalence estimates in England, 2005-2009. AIDS, 30(1), 145-149. doi:10.1097/QAD.0000000000000868DOI: 10.1097/QAD.0000000000000868
2015
Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV (Journal article)
Rajoli, R. K. R., Back, D. J., Rannard, S., Meyers, C. L. F., Flexner, C., Owen, A., & Siccardi, M. (2015). Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV. CLINICAL PHARMACOKINETICS, 54(6), 639-650. doi:10.1007/s40262-014-0227-1DOI: 10.1007/s40262-014-0227-1
Prevalence and type of drug-drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda (Journal article)
Seden, K., Merry, C., Hewson, R., Siccardi, M., Lamorde, M., Byakika-Kibwika, P., . . . Khoo, S. H. (2015). Prevalence and type of drug-drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(12), 3317-3322. doi:10.1093/jac/dkv259DOI: 10.1093/jac/dkv259
Reply to "Debilitating fatigue as a treatment indication in chronic hepatitis C". (Journal article)
Pawlotsky, J. -M., Aghemo, A., Back, D., Dusheiko, G., Forns, X., Puoti, M., . . . EASL Recommendations on Treatment of Hepatitis C 2015 panel. (2015). Reply to "Debilitating fatigue as a treatment indication in chronic hepatitis C".. Journal of hepatology, 63(6), 1535-1536. doi:10.1016/j.jhep.2015.09.004DOI: 10.1016/j.jhep.2015.09.004
Predicting Utility of Long-Acting Injectables in Paediatric Patients With PBPK Models (Conference Paper)
Rajoli, R. K. R., Siccardi, M., Owen, A., Back, D., & Rannard, S. (2016, February 22). Predicting Utility of Long-Acting Injectables in Paediatric Patients With PBPK Models. In Conference on Retroviral and Opportunistic Infections. Boston, MA. Retrieved from http://www.croiconference.org/
Interaction Between Amiodarone and Sofosbuvir-based Treatment for Hepatitis C Virus Infection: Potential Mechanisms and Lessons to be Learned (Journal article)
Back, D. J., & Burger, D. M. (2015). Interaction Between Amiodarone and Sofosbuvir-based Treatment for Hepatitis C Virus Infection: Potential Mechanisms and Lessons to be Learned. GASTROENTEROLOGY, 149(6), 1315-1317. doi:10.1053/j.gastro.2015.09.031DOI: 10.1053/j.gastro.2015.09.031
Twenty years of boosting antiretroviral agents: where are we today? (Journal article)
Boffito, M., Back, D., & Gatell, J. M. (2015). Twenty years of boosting antiretroviral agents: where are we today?. AIDS (London, England), 29(17), 2229-2233. doi:10.1097/qad.0000000000000800DOI: 10.1097/qad.0000000000000800
Single oral dose of maraviroc does not prevent ex-vivo HIV infection of rectal mucosa in HIV-1 negative human volunteers. (Journal article)
Coll, J., Moltó, J., Boix, J., Gómez-Mora, E., Else, L., García, E., . . . Cabrera, C. (2015). Single oral dose of maraviroc does not prevent ex-vivo HIV infection of rectal mucosa in HIV-1 negative human volunteers.. AIDS (London, England), 29(16), 2149-2154. doi:10.1097/qad.0000000000000769DOI: 10.1097/qad.0000000000000769
Dickinson, L., Yapa, H. M., Jackson, A., Moyle, G., Else, L., Amara, A., . . . Boffito, M. (2015). Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(10), 6080-6086. doi:10.1128/AAC.01441-15DOI: 10.1128/AAC.01441-15
Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots (Journal article)
Olagunju, A., Amara, A., Waitt, C., Else, L., Penchala, S. D., Bolaji, O., . . . Khoo, S. (2015). Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(10), 2816-2822. doi:10.1093/jac/dkv174DOI: 10.1093/jac/dkv174
Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . Puls, R. (2015). Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.. Clinical pharmacology and therapeutics, 98(4), 406-416. doi:10.1002/cpt.156DOI: 10.1002/cpt.156
Drug Interactions of Hepatitis C Direct-Acting Antivirals in the HIV-Infected Person (Journal article)
El-Sherif, O., & Back, D. (2015). Drug Interactions of Hepatitis C Direct-Acting Antivirals in the HIV-Infected Person. CURRENT HIV/AIDS REPORTS, 12(3), 336-343. doi:10.1007/s11904-015-0277-5DOI: 10.1007/s11904-015-0277-5
Increasing use of 'party drugs' in people living with HIV on antiretrovirals: a concern for patient safety (Journal article)
Bracchi, M., Stuart, D., Castles, R., Khoo, S., Back, D., & Boffito, M. (2015). Increasing use of 'party drugs' in people living with HIV on antiretrovirals: a concern for patient safety. AIDS, 29(13), 1585-1592. doi:10.1097/QAD.0000000000000786DOI: 10.1097/QAD.0000000000000786
Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study (Journal article)
Olagunju, A., Bolaji, O., Amara, A., Waitt, C., Else, L., Adejuyigbe, E., . . . Owen, A. (2015). Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study. Clin Infect Dis, 61(3), 453-463. doi:10.1093/cid/civ317DOI: 10.1093/cid/civ317
EASL Recommendations on Treatment of Hepatitis C 2015. (Journal article)
European Association for Study of Liver. (2015). EASL Recommendations on Treatment of Hepatitis C 2015.. Journal of hepatology, 63(1), 199-236. doi:10.1016/j.jhep.2015.03.025DOI: 10.1016/j.jhep.2015.03.025
Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study (Journal article)
Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . R Puls, O. B. O. T. E. S. G. (2015). Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study. Clin Pharmacol Ther, 98(4), 406-416.
A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers (Journal article)
Mora-Peris, B., Else, L., Goldmeier, D., Mears, A., Weston, R., Cooke, G., . . . Winston, A. (2015). A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(6), 1812-1815. doi:10.1093/jac/dkv035DOI: 10.1093/jac/dkv035
Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression. (Journal article)
Di Yacovo, M. S., Moltó, J., Ferrer, E., Curran, A., Else, L., Gisslén, M., . . . Podzamczer, D. (2015). Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression.. The Journal of antimicrobial chemotherapy, 70(5), 1513-1516. doi:10.1093/jac/dku558DOI: 10.1093/jac/dku558
Else, L., Back, D., Khoo, S. H., & Merry, C. (2015). Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults.. The Journal of Antimicrobial Chemotherapy, 70(5), 1482-1486. doi:10.1093/jac/dku575DOI: 10.1093/jac/dku575
Amara, A. B., Else, L. J., Tjia, J., Olagunju, A., Puls, R. L., Khoo, S., & Back, D. J. (2015). A Validated Method for Quantification of Efavirenz in Dried Blood Spots Using High-Performance Liquid Chromatography-Mass Spectrometry. THERAPEUTIC DRUG MONITORING, 37(2), 220-228. doi:10.1097/FTD.0000000000000127DOI: 10.1097/FTD.0000000000000127
Pharmacogenetics of Pregnancy-Induced Changes in Efavirenz Pharmacokinetics (Journal article)
Olagunju, A., Bolaji, O., Amara, A., Else, L., Okafor, O., Adejuyigbe, E., . . . Owen, A. (2015). Pharmacogenetics of Pregnancy-Induced Changes in Efavirenz Pharmacokinetics. CLINICAL PHARMACOLOGY & THERAPEUTICS, 97(3), 298-306. doi:10.1002/cpt.43DOI: 10.1002/cpt.43
Olagunju, A., Bolaji, O. O., Amara, A., Waitt, C., Else, L., Soyinka, J., . . . Khoo, S. (2015). Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(2), 555-561. doi:10.1093/jac/dku420DOI: 10.1093/jac/dku420
Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravir (Journal article)
Reynolds, H. E., Chrdle, A., Egan, D., Chaponda, M., Else, L., Chiong, J., . . . Khoo, S. H. (2015). Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravir. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(2), 550-554. doi:10.1093/jac/dku376DOI: 10.1093/jac/dku376
The pharmacokinetic profile of raltegravircontaining antiretroviral therapy in HIV-infected individuals over 60 years of age (Journal article)
Vera, J. H., Jackson, A., Dickinson, L., Else, L., Barber, T., Mora-Peris, B., . . . Winston, A. (2015). The pharmacokinetic profile of raltegravircontaining antiretroviral therapy in HIV-infected individuals over 60 years of age. HIV CLINICAL TRIALS, 16(1), 39-42. doi:10.1179/1528433614Z.0000000006DOI: 10.1179/1528433614Z.0000000006
The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age. (Journal article)
Vera, J. H., Jackson, A., Dickinson, L., Else, L., Barber, T., Mora-Peris, B., . . . Winston, A. (2015). The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age.. HIV clinical trials, 16(1), 39-42.
Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults (Journal article)
Lamorde, M., Walimbwa, S., Byakika-Kibwika, P., Katwere, M., Mukisa, L., Sempa, J. B., . . . Merry, C. (2015). Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults. J Antimicrob Chemother, 70(5), 1482-1486.
Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapy. (Journal article)
Waters, L., Jackson, A., Else, L., Rockwood, N., Newell, S., Back, D., . . . Boffito, M. (2015). Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapy.. Antiviral therapy, 20(2), 157-163. doi:10.3851/imp2817DOI: 10.3851/imp2817
Use of In Vitro to In Vivo Extrapolation to Predict the Optimal Strategy for Patients Switching from Efavirenz to Maraviroc or Nevirapine (Journal article)
Schipani, A., Back, D., Owen, A., Davies, G., Khoo, S., & Siccardi, M. (2015). Use of In Vitro to In Vivo Extrapolation to Predict the Optimal Strategy for Patients Switching from Efavirenz to Maraviroc or Nevirapine. CLINICAL PHARMACOKINETICS, 54(1), 107-116. doi:10.1007/s40262-014-0184-8DOI: 10.1007/s40262-014-0184-8
2014
Antiretroviral drugs for prevention of mother-to-child transmission: pharmacologic considerations for a public health approach (Journal article)
Lamorde, M., Schapiro, J. M., Burger, D., & Back, D. J. (2014). Antiretroviral drugs for prevention of mother-to-child transmission: pharmacologic considerations for a public health approach. AIDS, 28(17), 2551-2563. doi:10.1097/QAD.0000000000000439DOI: 10.1097/QAD.0000000000000439
Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant (Journal article)
Scarsi, K., Lamorde, M., Darin, K., Dilly Penchala, S., Else, L., Nakalema, S., . . . Back, D. (2014). Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant. J Int AIDS Soc, 17(4 Supp), 19484.
Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV‐infected patients: a population PK approach (Journal article)
Dickinson, L., Winston, A., Boffito, M., Khoo, S., Back, D., & Siccardi, M. (2014). Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV‐infected patients: a population PK approach. Journal of the International AIDS Society, 17(4S3). doi:10.7448/ias.17.4.19586DOI: 10.7448/ias.17.4.19586
Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy (Journal article)
Else, L. J., Jackson, V., Brennan, M., Back, D. J., Khoo, S. H., Coulter-Smith, S., & Lambert, J. S. (2014). Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy. HIV MEDICINE, 15(10), 604-610. doi:10.1111/hiv.12164DOI: 10.1111/hiv.12164
No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individuals (Journal article)
Singh, G. J., Jackson, A., D'Avolio, A., Else, L., De Nicolo, A., Bonora, S., . . . Boffito, M. (2014). No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individuals. AIDS, 28(13), 1993-1995. doi:10.1097/QAD.0000000000000356DOI: 10.1097/QAD.0000000000000356
Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers. (Journal article)
Jackson, A., D'Avolio, A., Moyle, G., Bonora, S., Di Perri, G., Else, L., . . . Boffito, M. (2014). Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers.. The Journal of antimicrobial chemotherapy, 69(7), 1911-1915. doi:10.1093/jac/dku060DOI: 10.1093/jac/dku060
Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy (Journal article)
Mora-Peris, B., Watson, V., Vera, J. H., Weston, R., Waldman, A. D., Kaye, S., . . . Winston, A. (2014). Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 69(6), 1642-1647. doi:10.1093/jac/dku018DOI: 10.1093/jac/dku018
Abacavir forms novel cross-linking abacavir protein adducts in patients (Journal article)
Meng, X., Lawrenson, A. S., Berry, N. G., Maggs, J. L., French, N. S., Back, D. J., . . . Park, B. K. (2014). Abacavir forms novel cross-linking abacavir protein adducts in patients. Chemical Research in Toxicology, 27(04), 524-535. doi:10.1021/tx400406pDOI: 10.1021/tx400406p
<i>CYP3A4</i>*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults (Journal article)
Olagunju, A., Schipani, A., Siccardi, M., Egan, D., Khoo, S., Back, D., & Owen, A. (2014). <i>CYP3A4</i>*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults. PHARMACOGENETICS AND GENOMICS, 24(9), 459-463. doi:10.1097/FPC.0000000000000073DOI: 10.1097/FPC.0000000000000073
A Compartmental Pharmacokinetic Evaluation of Long-Acting Rilpivirine in HIV-Negative Volunteers for Pre-Exposure Prophylaxis (Journal article)
Jackson, A. G. A., Else, L. J., Mesquita, P. M. M., Egan, D., Back, D. J., Karolia, Z., . . . Boffito, M. (2014). A Compartmental Pharmacokinetic Evaluation of Long-Acting Rilpivirine in HIV-Negative Volunteers for Pre-Exposure Prophylaxis. CLINICAL PHARMACOLOGY & THERAPEUTICS, 96(3), 314-323. doi:10.1038/clpt.2014.118DOI: 10.1038/clpt.2014.118
Quantification of rilpivirine in human plasma, cervicovaginal fluid, rectal fluid and genital/rectal mucosal tissues using liquid chromatography-tandem mass spectrometry (Journal article)
Else, L. J., Tjia, J., Jackson, A., Penchala, S. D., Egan, D., Boffito, M., . . . Back, D. J. (2014). Quantification of rilpivirine in human plasma, cervicovaginal fluid, rectal fluid and genital/rectal mucosal tissues using liquid chromatography-tandem mass spectrometry. BIOANALYSIS, 6(14), 1907-1921. doi:10.4155/BIO.14.59DOI: 10.4155/BIO.14.59
Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors? (Journal article)
Hill, A., Khoo, S., Back, D., Pozniak, A., & Boffito, M. (2014). Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors?. J Int AIDS Soc, 17(4 Supp), 19583.
Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach (Journal article)
Dickinson, L., Winston, A., Boffito, M., Khoo, S., Back, D., & Siccardi, M. (2014). Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach. J Int AIDS Soc, 17(4 Supp), 19586.
2013
Induction of Influx and Efflux Transporters and Cytochrome P450 3A4 in Primary Human Hepatocytes by Rifampin, Rifabutin, and Rifapentine (Journal article)
Williamson, B., Dooley, K. E., Zhang, Y., Back, D. J., & Owen, A. (2013). Induction of Influx and Efflux Transporters and Cytochrome P450 3A4 in Primary Human Hepatocytes by Rifampin, Rifabutin, and Rifapentine. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(12), 6366-6369. doi:10.1128/AAC.01124-13DOI: 10.1128/AAC.01124-13
Article Commentary: Drug–Drug Interactions in HIV Therapy: Is it All Clear? (Journal article)
Burger, D., & Back, D. (2013). Article Commentary: Drug–Drug Interactions in HIV Therapy: Is it All Clear?. Antiviral Therapy, 18(5), 649-650. doi:10.3851/imp2688DOI: 10.3851/imp2688
Interactions between tenofovir and nevirapine in CD4+T cells and monocyte-derived macrophages restrict their intracellular accumulation (Journal article)
Liptrott, N. J., Curley, P., Moss, D., Back, D. J., Khoo, S. H., & Owen, A. (2013). Interactions between tenofovir and nevirapine in CD4+T cells and monocyte-derived macrophages restrict their intracellular accumulation. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 68(11), 2545-2549. doi:10.1093/jac/dkt225DOI: 10.1093/jac/dkt225
Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 <i>In Vitro</i> (Journal article)
Moss, D. M., Liptrott, N. J., Curley, P., Siccardi, M., Back, D. J., & Owen, A. (2013). Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 <i>In Vitro</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(11), 5612-5618. doi:10.1128/AAC.01421-13DOI: 10.1128/AAC.01421-13
The importance of drug-drug interactions in the DAA era. (Journal article)
Back, D., & Else, L. (2013). The importance of drug-drug interactions in the DAA era.. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 45 Suppl 5, S343-S348. doi:10.1016/j.dld.2013.07.008DOI: 10.1016/j.dld.2013.07.008
Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokinetics. (Journal article)
Moyle, G., Else, L., Jackson, A., Back, D., Yapa, M. H., Seymour, N., . . . Boffito, M. (2013). Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokinetics.. Antimicrobial agents and chemotherapy, 57(8), 3640-3644. doi:10.1128/aac.00357-13DOI: 10.1128/aac.00357-13
Validation of an electrospray ionisation LC-MS/MS method for quantitative analysis of telaprevir and its R-diastereomer (Journal article)
Penchala, S. D., Tjia, J., El Sherif, O., Back, D. J., Khoo, S. H., & Else, L. J. (2013). Validation of an electrospray ionisation LC-MS/MS method for quantitative analysis of telaprevir and its R-diastereomer. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 932, 100-110. doi:10.1016/j.jchromb.2013.06.013DOI: 10.1016/j.jchromb.2013.06.013
Santos, J. R., Muñoz-Moreno, J. A., Moltó, J., Prats, A., Curran, A., Domingo, P., . . . Clotet, B. (2013). Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study.. PloS one, 8(7), e70201. doi:10.1371/journal.pone.0070201DOI: 10.1371/journal.pone.0070201
Predicting intestinal absorption of raltegravir using a population-based ADME simulation (Journal article)
Moss, D. M., Siccardi, M., Back, D. J., & Owen, A. (2013). Predicting intestinal absorption of raltegravir using a population-based ADME simulation. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 68(7), 1627-1634. doi:10.1093/jac/dkt084DOI: 10.1093/jac/dkt084
Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach (Journal article)
Siccardi, M., Marzolini, C., Seden, K., Almond, L., Kirov, A., Khoo, S., . . . Back, D. (2013). Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach. CLINICAL PHARMACOKINETICS, 52(7), 583-592. doi:10.1007/s40262-013-0056-7DOI: 10.1007/s40262-013-0056-7
Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. (Journal article)
Winston, A., Jose, S., Gibbons, S., Back, D., Stohr, W., Post, F., . . . UK Collaborative HIV Cohort Study. (2013). Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring.. The Journal of antimicrobial chemotherapy, 68(6), 1354-1359. doi:10.1093/jac/dkt029DOI: 10.1093/jac/dkt029
Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects. (Journal article)
Mora-Peris, B., Croucher, A., Else, L. J., Vera, J. H., Khoo, S., Scullard, G., . . . Winston, A. (2013). Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.. The Journal of antimicrobial chemotherapy, 68(6), 1348-1353. doi:10.1093/jac/dkt006DOI: 10.1093/jac/dkt006
Detection of Drug Bioactivation in Vivo: Mechanism of Nevirapine-Albumin Conjugate Formation in Patients (Journal article)
Meng, X., Howarth, A., Earnshaw, C. J., Jenkins, R. E., French, N. S., Back, D. J., . . . Park, B. K. (2013). Detection of Drug Bioactivation in Vivo: Mechanism of Nevirapine-Albumin Conjugate Formation in Patients. CHEMICAL RESEARCH IN TOXICOLOGY, 26(4), 575-583. doi:10.1021/tx4000107DOI: 10.1021/tx4000107
Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. (Journal article)
Burger, D., Back, D., Buggisch, P., Buti, M., Craxí, A., Foster, G., . . . Zeuzem, S. (2013). Clinical management of drug-drug interactions in HCV therapy: challenges and solutions.. Journal of hepatology, 58(4), 792-800. doi:10.1016/j.jhep.2012.10.027DOI: 10.1016/j.jhep.2012.10.027
Rilpivirine concentrations in seminal plasma in HIV infected patients (Poster)
Watson, V., Mora-Peris, B., Tjia, J., Vera, J. H., Weston, R., Khoo, S., . . . Winston, A. (2013). Rilpivirine concentrations in seminal plasma in HIV infected patients. Poster session presented at the meeting of 14th International Workshop on Clinical Pharmacology of HIV Therapy. Netherlands.
Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment (Journal article)
Lamorde, M., Byakika-Kibwika, P., Mayito, J., Nabukeera, L., Ryan, M., Hanpithakpong, W., . . . Merry, C. (2013). Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment. AIDS, 27(6), 961-965. doi:10.1097/QAD.0b013e32835cae3bDOI: 10.1097/QAD.0b013e32835cae3b
Drug-drug interactions between antiretrovirals and drugs used in the management of neglected tropical diseases: important considerations in the WHO 2020 Roadmap and London Declaration on Neglected Tropical Diseases. (Journal article)
Seden, K., Khoo, S., Back, D., Prevatt, N., Lamorde, M., Byakika-Kibwika, P., . . . Merry, C. (2013). Drug-drug interactions between antiretrovirals and drugs used in the management of neglected tropical diseases: important considerations in the WHO 2020 Roadmap and London Declaration on Neglected Tropical Diseases.. AIDS (London, England), 27(5), 675-686. doi:10.1097/qad.0b013e32835ca9b4DOI: 10.1097/qad.0b013e32835ca9b4
Non-disclosure of HIV status in UK sexual health clinics-a pilot study to identify non-disclosure within a national unlinked anonymous seroprevalence survey (Journal article)
Sullivan, A. K., Savage, E. J., Lowndes, C. M., Paul, G., Murphy, G., Carne, S., . . . Gill, O. N. (2013). Non-disclosure of HIV status in UK sexual health clinics-a pilot study to identify non-disclosure within a national unlinked anonymous seroprevalence survey. SEXUALLY TRANSMITTED INFECTIONS, 89(2), 120-121. doi:10.1136/sextrans-2012-050801DOI: 10.1136/sextrans-2012-050801
Tenofovir, Emtricitabine Intracellular and Plasma, and Efavirenz Plasma Concentration Decay Following Drug Intake Cessation: Implications for HIV Treatment and Prevention (Journal article)
Jackson, A., Moyle, G., Watson, V., Tjia, J., Ammara, A., Back, D., . . . Boffito, M. (2013). Tenofovir, Emtricitabine Intracellular and Plasma, and Efavirenz Plasma Concentration Decay Following Drug Intake Cessation: Implications for HIV Treatment and Prevention. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 62(3), 275-281. doi:10.1097/QAI.0b013e3182829bd0DOI: 10.1097/QAI.0b013e3182829bd0
Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention (Journal article)
Jackson, A., Moyle, G., Watson, V., Tjia, J., Amara, A., Back, D., . . . Boffito, M. (2013). Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 62(3), 275-281. doi:10.1097/QAI.0b013e3182829bd0DOI: 10.1097/QAI.0b013e3182829bd0
Pushpakom, S. P., Owen, A., Back, D. J., & Pirmohamed, M. (2013). <i>RXR</i> gene variants are associated with HIV lipodystrophy. PHARMACOGENETICS AND GENOMICS, 23(8), 438-441. doi:10.1097/FPC.0b013e328362cfc6DOI: 10.1097/FPC.0b013e328362cfc6
Global patient safety and antiretroviral drug-drug interactions in the resource-limited setting. (Journal article)
Seden, K., Khoo, S. H., Back, D., Byakika-Kibwika, P., Lamorde, M., Ryan, M., & Merry, C. (2013). Global patient safety and antiretroviral drug-drug interactions in the resource-limited setting.. The Journal of antimicrobial chemotherapy, 68(1), 1-3. doi:10.1093/jac/dks346DOI: 10.1093/jac/dks346
Prediction of Etravirine Pharmacogenetics using a Physiologically Based Pharmacokinetic approach (Conference Paper)
Siccardi, M., Olagunju, A., Curley, P., Hobson, J., Khoo, S., Back, D., & Owen, A. (2013). Prediction of Etravirine Pharmacogenetics using a Physiologically Based Pharmacokinetic approach. In 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, USA.
Simultaneous Population Pharmacokinetic Modelling of Atazanavir and Ritonavir in HIV-Infected Adults and Assessment of Different Dose Reduction Strategies (Journal article)
Schipani, A., Dickinson, L., Boffito, M., Austin, R., Owen, A., Back, D., . . . Davies, G. (2013). Simultaneous Population Pharmacokinetic Modelling of Atazanavir and Ritonavir in HIV-Infected Adults and Assessment of Different Dose Reduction Strategies. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 62(1), 60-66. doi:10.1097/QAI.0b013e3182737231DOI: 10.1097/QAI.0b013e3182737231
Utilising In Vitro-In Vivo extrapolation to investigate efavirenz penetration into the central nervous system (Poster)
Curley, P., Martin, P., Liptrott, N., Back, D., Owen, A., & Siccardi, M. (2013). Utilising In Vitro-In Vivo extrapolation to investigate efavirenz penetration into the central nervous system. Poster session presented at the meeting of 14th International Workshop on Clinical Pharmacology of HIV Therapy. Netherlands.
2012
Efavirenz in an obese HIV-infected patient - a report and an <i>in vitro</i>-<i>in vivo</i> extrapolation model indicate risk of underdosing (Journal article)
de Roche, M., Siccardi, M., Stoeckle, M., Livio, F., Back, D., Battegay, M., & Marzolini, C. (2012). Efavirenz in an obese HIV-infected patient - a report and an <i>in vitro</i>-<i>in vivo</i> extrapolation model indicate risk of underdosing. ANTIVIRAL THERAPY, 17(7), 1381-1384. doi:10.3851/IMP2107DOI: 10.3851/IMP2107
Effect of food on the steady-state pharmacokinetics of tenofovir and emtricitabine plus efavirenz in ugandan adults (Journal article)
Lamorde, M., Byakika-Kibwika, P., Tamale, W. S., Kiweewa, F., Ryan, M., Amara, A., . . . Merry, C. (2012). Effect of food on the steady-state pharmacokinetics of tenofovir and emtricitabine plus efavirenz in ugandan adults. AIDS Research and Treatment, 2012. doi:10.1155/2012/105980DOI: 10.1155/2012/105980
Development and validation of a LC‐MS/MS assay to quantify intracellular tenofovir‐diphosphate (TFV‐DP) and emtricitabine‐triphosphate (FTC‐TP) (Journal article)
Watson, V., Else, L., Tjia, J., Khoo, S., & Back, D. (2012). Development and validation of a LC‐MS/MS assay to quantify intracellular tenofovir‐diphosphate (TFV‐DP) and emtricitabine‐triphosphate (FTC‐TP). Journal of the International AIDS Society, 15(S4), 1. doi:10.7448/ias.15.6.18336DOI: 10.7448/ias.15.6.18336
Dickinson, L., Jackson, A., Garvey, L., Watson, V., Khoo, S., Boffito, M., . . . Back, D. (2012). Simultaneous population pharmacokinetic modelling of darunavir and ritonavir Once daily in HIV-infected patients: evaluation of lower ritonavir dose. Journal of the International AIDS Society, 15(4).
Anti-retroviral drugs do not facilitate hepatitis C virus (HCV) infection in vitro. (Journal article)
Sandmann, L., Wilson, M., Back, D., Wedemeyer, H., Manns, M. P., Steinmann, E., . . . Ciesek, S. (2012). Anti-retroviral drugs do not facilitate hepatitis C virus (HCV) infection in vitro.. Antiviral research, 96(1), 51-58. doi:10.1016/j.antiviral.2012.07.005DOI: 10.1016/j.antiviral.2012.07.005
Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an <i>In Vitro</i>-<i>In Vivo</i> Extrapolation Model (Journal article)
Siccardi, M., Almond, L., Schipani, A., Csajka, C., Marzolini, C., Wyen, C., . . . Back, D. (2012). Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an <i>In Vitro</i>-<i>In Vivo</i> Extrapolation Model. CLINICAL PHARMACOLOGY & THERAPEUTICS, 92(4), 494-502. doi:10.1038/clpt.2012.61DOI: 10.1038/clpt.2012.61
Estimation of the effect of <i>SLCO1B1</i> polymorphisms on lopinavir plasma concentration in HIV-infected adults (Journal article)
Schipani, A., Egan, D., Dickinson, L., Davies, G., Boffito, M., Youle, M., . . . Owen, A. (2012). Estimation of the effect of <i>SLCO1B1</i> polymorphisms on lopinavir plasma concentration in HIV-infected adults. ANTIVIRAL THERAPY, 17(5), 861-868. doi:10.3851/IMP2095DOI: 10.3851/IMP2095
Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval (Journal article)
Yilmaz, A., Watson, V., Dickinson, L., & Back, D. (2012). Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval. Antimicrobial Agents and Chemotherapy, 56(9), 4583-4585.
Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval. (Journal article)
Yilmaz, A., Watson, V., Dickinson, L., & Back, D. (2012). Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval.. Antimicrobial agents and chemotherapy, 56(9), 4583-4585. doi:10.1128/aac.06311-11DOI: 10.1128/aac.06311-11
Byakika-Kibwika, P., Lamorde, M., Mayito, J., Nabukeera, L., Namakula, R., Mayanja-Kizza, H., . . . Merry, C. (2012). Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults.. The Journal of antimicrobial chemotherapy, 67(9), 2213-2221. doi:10.1093/jac/dks207DOI: 10.1093/jac/dks207
Steady-state pharmacokinetics of lopinavir plus ritonavir when administered under different meal conditions in HIV-infected Ugandan adults. (Journal article)
Lamorde, M., Byakika-Kibwika, P., Boffito, M., Nabukeera, L., Mayito, J., Ogwal-Okeng, J., . . . Merry, C. (2012). Steady-state pharmacokinetics of lopinavir plus ritonavir when administered under different meal conditions in HIV-infected Ugandan adults.. Journal of acquired immune deficiency syndromes (1999), 60(3), 295-298. doi:10.1097/qai.0b013e3182567a35DOI: 10.1097/qai.0b013e3182567a35
Divalent Metals and pH Alter Raltegravir Disposition <i>In Vitro</i> (Journal article)
Moss, D. M., Siccardi, M., Murphy, M., Piperakis, M. M., Khoo, S. H., Back, D. J., & Owen, A. (2012). Divalent Metals and pH Alter Raltegravir Disposition <i>In Vitro</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(6), 3020-3026. doi:10.1128/AAC.06407-11DOI: 10.1128/AAC.06407-11
Byakika-Kibwika, P., Lamorde, M., Okaba-Kayom, V., Mayanja-Kizza, H., Katabira, E., Hanpithakpong, W., . . . Merry, C. (2012). Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults.. The Journal of antimicrobial chemotherapy, 67(5), 1217-1223. doi:10.1093/jac/dkr596DOI: 10.1093/jac/dkr596
Development and validation of a LC-MS/MS assay to quantify 10 anti-retroviral (ARV) drugs in cerebral spinal fluid (CSF) (Poster)
Watson, V., Tjia, J., Szwandt, S., Else, L., Khoo, S., & Back, D. (2012). Development and validation of a LC-MS/MS assay to quantify 10 anti-retroviral (ARV) drugs in cerebral spinal fluid (CSF). Poster session presented at the meeting of 13th International Workshop on Clinical Pharmacology of HIV Therapy. Barcelona, Spain.
Intrapatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting (Journal article)
Siccardi, M., D'Avolio, A., Rodriguez-Novoa, S., Cuenca, L., Simiele, M., Baietto, L., . . . Di Perri, G. (2012). Intrapatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting. THERAPEUTIC DRUG MONITORING, 34(2), 232-235. doi:10.1097/FTD.0b013e31824aa50aDOI: 10.1097/FTD.0b013e31824aa50a
Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies (Journal article)
Taylor, S., Jayasuriya, A., Fisher, M., Allan, S., Wilkins, E., Gilleran, G., . . . Smit, E. (2012). Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 67(3), 675-680. doi:10.1093/jac/dkr491DOI: 10.1093/jac/dkr491
Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies (Journal article)
Taylor, S., Jayasuriya, A., Fisher, M., Allan, S., Wilkins, E., Gilleran, G., . . . Smit, E. (2012). Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies. Journal of Antimicrobial Chemotherapy, 67(3), 675-680. doi:10.1093/jac/dkr491DOI: 10.1093/jac/dkr491
Pharmacokinetics of Lamivudine and Lamivudine-Triphosphate after Administration of 300 Milligrams and 150 Milligrams Once Daily to Healthy Volunteers: Results of the ENCORE 2 Study (Journal article)
Else, L. J., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of Lamivudine and Lamivudine-Triphosphate after Administration of 300 Milligrams and 150 Milligrams Once Daily to Healthy Volunteers: Results of the ENCORE 2 Study. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(3), 1427-1433. doi:10.1128/AAC.05599-11DOI: 10.1128/AAC.05599-11
Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study (Journal article)
Else, L., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. Antimicrobial Agents and Chemotherapy, 56(3), 1427-1433.
Improved Oral Bioavailability of Lopinavir in Melt-Extruded Tablet Formulation Reduces Impact of Third Trimester on Lopinavir Plasma Concentrations (Journal article)
Else, L. J., Douglas, M., Dickinson, L., Back, D. J., Khoo, S. H., & Taylor, G. P. (2012). Improved Oral Bioavailability of Lopinavir in Melt-Extruded Tablet Formulation Reduces Impact of Third Trimester on Lopinavir Plasma Concentrations. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(2), 816-824. doi:10.1128/AAC.05186-11DOI: 10.1128/AAC.05186-11
Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations. (Journal article)
Else, L., Douglas, M., Dickinson, L., Back, D., Khoo, S., & Taylor, G. P. (2012). Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.. Antimicrobial agents and chemotherapy, 56(2), 816-824.
Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects. (Journal article)
Jackson, A., Moyle, G., Dickinson, L., Back, D., Khoo, S., Taylor, J., . . . Boffito, M. (2012). Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.. Antiviral therapy, 17(1), 19-24. doi:10.3851/imp1910DOI: 10.3851/imp1910
Alterations in cerebrospinal fluid chemokines are associated with maraviroc exposure and in vivo metabolites measurable by magnetic resonance spectroscopy. (Journal article)
Vera, J. H., Garvey, L. J., Allsop, J. M., Kaye, S., McClure, M. O., Back, D., . . . Winston, A. (2012). Alterations in cerebrospinal fluid chemokines are associated with maraviroc exposure and in vivo metabolites measurable by magnetic resonance spectroscopy.. HIV clinical trials, 13(4), 222-227. doi:10.1310/hct1304-222DOI: 10.1310/hct1304-222
Association of <i>ABCC10</i> polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS (Journal article)
Liptrott, N. J., Pushpakom, S., Wyen, C., Faetkenheuer, G., Hoffmann, C., Mauss, S., . . . Owen, A. (2012). Association of <i>ABCC10</i> polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. PHARMACOGENETICS AND GENOMICS, 22(1), 10-19. doi:10.1097/FPC.0b013e32834dd82eDOI: 10.1097/FPC.0b013e32834dd82e
Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS (Journal article)
Liptrott, N. J., Pushpakom, S., Wyen, C., Fätkenheuer, G., Hoffmann, C., Mauss, S., . . . Owen, A. (2012). Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Pharmacogenetics and Genomics, 22(1), 10-19. doi:10.1097/fpc.0b013e32834dd82eDOI: 10.1097/fpc.0b013e32834dd82e
CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study. (Journal article)
Garvey, L., Nelson, M., Latch, N., Erlwein, O. W., Allsop, J. M., Mitchell, A., . . . Winston, A. (2012). CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study.. The Journal of antimicrobial chemotherapy, 67(1), 206-212. doi:10.1093/jac/dkr427DOI: 10.1093/jac/dkr427
Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults. (Journal article)
Byakika-Kibwika, P., Lamorde, M., Lwabi, P., Nyakoojo, W. B., Okaba-Kayom, V., Mayanja-Kizza, H., . . . Merry, C. (2012). Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults.. Chemotherapy Research and Practice.
Divalent metals and pH alter raltegravir disposition in vitro. (Journal article)
Moss, D. M., Siccardi, M., Murphy, M., Piperakis, M. M., Khoo, S. H., Back, D. J., & Owen, A. (2012). Divalent metals and pH alter raltegravir disposition in vitro.. Antimicrobial Agents and Chemotherapy.
Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval. (Journal article)
Yilmaz, A., Watson, V., Dickinson, L., & Back, D. (2012). Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval.. Antimicrobial Agents and Chemotherapy, 56, 4583-4585.
Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults (Journal article)
Lamorde, M., Byakika-Kibwika, P., Tamale, W. S., Kiweewa, F., Ryan, M., Amara, A., . . . Merry, C. (2012). Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults. AIDS Research and Treatment, 2012, 1-6. doi:10.1155/2012/105980DOI: 10.1155/2012/105980
Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults (Journal article)
Schipani, A., Egan, D., Dickinson, L., Davies, G., Boffito, M., Youle, M., . . . Owen, A. (2012). Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults. Antiviral Therapy, 17(5), 861-868.
Global patient safety and antiretroviral drug-drug interactions in the resource-limited setting (Journal article)
Seden, K., Khoo, S. H., Back, D., Byakika-Kibwika, P., Lamorde, M., Ryan, M., & Merry, C. (2012). Global patient safety and antiretroviral drug-drug interactions in the resource-limited setting. Journal of Antimicrobial Chemotherapy.
Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations. (Journal article)
Else, L. J., Douglas, M., Dickinson, L., Back, D. J., Khoo, S. H., & Taylor, G. P. (2012). Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.. Antimicrobial Agents and Chemotherapy, 56, 816-824.
Pharmacokinetics of Abacavir and its Anabolite Carbovir Triphosphate without and with Darunavir/ Ritonavir or Raltegravir in HIV-Infected Subjects (Journal article)
Jackson, A., Moyle, G., Dickinson, L., Back, D., Khoo, S., Taylor, J., . . . Boffito, M. (2012). Pharmacokinetics of Abacavir and its Anabolite Carbovir Triphosphate without and with Darunavir/ Ritonavir or Raltegravir in HIV-Infected Subjects. Antiviral Therapy, 17(1), 19-24. doi:10.3851/imp1910DOI: 10.3851/imp1910
Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects. (Journal article)
Jackson, A., Moyle, G., Dickinson, L., Back, D., Khoo, S., Taylor, J., . . . Boffito, M. (2012). Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.. Antiviral Therapy., 17, 19-24.
Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study (Journal article)
Else, L., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. Antimicrob Agents Chemother, 56(3), 1427-1433.
Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. (Journal article)
Else, L. J., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study.. Antimicrobial Agents and Chemotherapy, 56, 1427-1433.
Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies (Journal article)
Schipani, A., Dickinson, L., Boffito, M., Austin, R., Owen, A., Back, D., . . . Davies, G. (2012). Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies. Journal of Acquired Immune Deficiency Syndrome.
2011
Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid) (Journal article)
Else, L. J., Taylor, S., Back, D. J., & Khoo, S. H. (2011). Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid). ANTIVIRAL THERAPY, 16(8), 1139-1147. doi:10.3851/IMP1918DOI: 10.3851/IMP1918
Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract (Journal article)
Else, L. J., Taylor, S., Back, D. J., & Khoo, S. H. (2011). Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. ANTIVIRAL THERAPY, 16(8), 1149-1167. doi:10.3851/IMP1919DOI: 10.3851/IMP1919
IFN-γ 874A>T Genotype Is Associated With Higher CCR5 Expression in Peripheral Blood Mononuclear Cells From HIV plus Patients (Journal article)
Liptrott, N. J., Egan, D., Back, D. J., & Owen, A. (2011). IFN-γ 874A>T Genotype Is Associated With Higher CCR5 Expression in Peripheral Blood Mononuclear Cells From HIV plus Patients. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 58(5), 442-445. doi:10.1097/QAI.0b013e318236441cDOI: 10.1097/QAI.0b013e318236441c
Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals (Journal article)
Jackson, A., Watson, V., Back, D., Khoo, S., Liptrott, N., Egan, D., . . . Boffito, M. (2011). Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals. JAIDS Journal of Acquired Immune Deficiency Syndromes, 58(5), 450-457. doi:10.1097/qai.0b013e3182364c67DOI: 10.1097/qai.0b013e3182364c67
Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals (Journal article)
Jackson, A., Watson, V., Back, D., Khoo, S., Liptrott, N., Egan, D., . . . Boffito, M. (2011). Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 58(5), 450-457. doi:10.1097/QAI.0b013e3182364c67DOI: 10.1097/QAI.0b013e3182364c67
Should we switch to a 50-mg boosting dose of ritonavir for selected protease inhibitors? (Journal article)
Hill, A., Khoo, S., Boffito, M., & Back, D. (2011). Should we switch to a 50-mg boosting dose of ritonavir for selected protease inhibitors?. Journal of acquired immune deficiency syndromes (1999), 58(5), e137-e138. doi:10.1097/qai.0b013e318237ccaeDOI: 10.1097/qai.0b013e318237ccae
Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients. (Journal article)
Soriano, V., Sherman, K. E., Rockstroh, J., Dieterich, D., Back, D., Sulkowski, M., & Peters, M. (2011). Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients.. AIDS (London, England), 25(18), 2197-2208. doi:10.1097/qad.0b013e32834bbb90DOI: 10.1097/qad.0b013e32834bbb90
Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions. (Journal article)
Seden, K., & Back, D. (2011). Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.. Current opinion in HIV and AIDS, 6(6), 514-526. doi:10.1097/coh.0b013e32834b54dcDOI: 10.1097/coh.0b013e32834b54dc
Cytochrome P450 2B6 (<i>CYP2B6</i>) and constitutive androstane receptor (<i>CAR</i>) polymorphisms are associated with early discontinuation of efavirenz-containing regimens (Journal article)
Wyen, C., Hendra, H., Siccardi, M., Platten, M., Jaeger, H., Harrer, T., . . . Owen, A. (2011). Cytochrome P450 2B6 (<i>CYP2B6</i>) and constitutive androstane receptor (<i>CAR</i>) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 66(9), 2092-2098. doi:10.1093/jac/dkr272DOI: 10.1093/jac/dkr272
Pharmacokinetics of Once-Daily Darunavir-Ritonavir and Atazanavir-Ritonavir over 72 Hours following Drug Cessation (Journal article)
Boffito, M., Jackson, A., Amara, A., Back, D., Khoo, S., Higgs, C., . . . Moyle, G. (2011). Pharmacokinetics of Once-Daily Darunavir-Ritonavir and Atazanavir-Ritonavir over 72 Hours following Drug Cessation. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(9), 4218-4223. doi:10.1128/AAC.01747-10DOI: 10.1128/AAC.01747-10
Genetic Variants of <i>ABCC10</i>, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction (Journal article)
Pushpakom, S. P., Liptrott, N. J., Rodriguez-Novoa, S., Labarga, P., Soriano, V., Albalater, M., . . . Owen, A. (2011). Genetic Variants of <i>ABCC10</i>, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction. JOURNAL OF INFECTIOUS DISEASES, 204(1), 145-153. doi:10.1093/infdis/jir215DOI: 10.1093/infdis/jir215
Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction (Journal article)
Pushpakom, S. P., Liptrott, N. J., Rodríguez-Nóvoa, S., Labarga, P., Soriano, V., Albalater, M., . . . Owen, A. (2011). Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction. The Journal of Infectious Diseases, 204(1), 145-153. doi:10.1093/infdis/jir215DOI: 10.1093/infdis/jir215
Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals (Journal article)
Schipani, A., Wyen, C., Mahungu, T., Hendra, H., Egan, D., Siccardi, M., . . . Back, D. J. (2011). Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 66(6), 1332-1339. doi:10.1093/jac/dkr087DOI: 10.1093/jac/dkr087
Pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers. (Journal article)
Ashby, J., Garvey, L., Erlwein, O. W., Lamba, H., Weston, R., Legg, K., . . . Winston, A. (2011). Pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers.. The Journal of antimicrobial chemotherapy, 66(6), 1340-1345. doi:10.1093/jac/dkr093DOI: 10.1093/jac/dkr093
Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies (Journal article)
Dickinson, L., Boffito, M., Back, D., Else, L., von Hentig, N., Davies, G., . . . Aarons, L. (2011). Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(6), 2775-2782. doi:10.1128/AAC.00887-10DOI: 10.1128/AAC.00887-10
Biliary excretion of (14C) edrophonium and its glucuronide conjugate. (Journal article)
Calvey, T. N., & Back, D. J. (1971). Biliary excretion of (14C) edrophonium and its glucuronide conjugate.. The Journal of pharmacy and pharmacology, 23(8), 642-643. doi:10.1111/j.2042-7158.1971.tb08738.xDOI: 10.1111/j.2042-7158.1971.tb08738.x
POTENTIAL PROBLEMS WITH AQUEOUS STEROID SOLUTIONS (Journal article)
SIM, S. M., BACK, D. J., & TJIA, J. F. (1983). POTENTIAL PROBLEMS WITH AQUEOUS STEROID SOLUTIONS. JOURNAL OF PHARMACY AND PHARMACOLOGY, 35(3), 200. doi:10.1111/j.2042-7158.1983.tb04312.xDOI: 10.1111/j.2042-7158.1983.tb04312.x
THE EFFECT OF SOME BENZIMIDAZOLES ON THE DISPOSITION OF ANTIPYRINE AND TOLBUTAMIDE FROM THE RAT ISOLATED PERFUSED LIVER (Journal article)
WARD, S. A., MIHALY, G. W., TJIA, J. F., & BACK, D. J. (1985). THE EFFECT OF SOME BENZIMIDAZOLES ON THE DISPOSITION OF ANTIPYRINE AND TOLBUTAMIDE FROM THE RAT ISOLATED PERFUSED LIVER. JOURNAL OF PHARMACY AND PHARMACOLOGY, 37(1), 62-64. doi:10.1111/j.2042-7158.1985.tb04934.xDOI: 10.1111/j.2042-7158.1985.tb04934.x
Investigating variability in reported intracellular raltegravir concentrations: contribution of PBMC isolation methodology (Poster)
Watson, V., Liptrott, N., Egan, D., Dickinson, L., Tjia, J., Reynolds, H., . . . Back, D. (2011). Investigating variability in reported intracellular raltegravir concentrations: contribution of PBMC isolation methodology. Poster session presented at the meeting of 12th International Workshop on Clinical Pharmacology of HIV Therapy. Miami, USA.
Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers. (Journal article)
Jackson, A., D'Avolio, A., Watson, V., Bonora, S., Back, D., Taylor, J., . . . Boffito, M. (2011). Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers.. The Journal of antimicrobial chemotherapy, 66(4), 885-889. doi:10.1093/jac/dkq546DOI: 10.1093/jac/dkq546
Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy (Journal article)
Else, L. J., Lyons, F., O'Shea, S., Costello, S., Mullen, J., Lechelt, M., . . . de Ruiter, A. (2011). Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy. AIDS, 25(5), 722-725. doi:10.1097/QAD.0b013e3283445700DOI: 10.1097/QAD.0b013e3283445700
Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy. (Journal article)
Else, L., Lyons, F., O'shea, S., Costello, S., Mullen, J., Lechelt, M., . . . de Ruiter, A. (2011). Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy.. AIDS, 25(5), 722-725.
Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers. (Journal article)
Jackson, A., Hill, A., Puls, R., Else, L., Amin, J., Back, D., . . . Boffito, M. (2011). Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.. The Journal of antimicrobial chemotherapy, 66(3), 635-640. doi:10.1093/jac/dkq468DOI: 10.1093/jac/dkq468
Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy (Journal article)
Lambert, J. S., Else, L. J., Jackson, V., Breiden, J., Gibbons, S., Dickinson, L., . . . Khoo, S. H. (2011). Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. HIV Medicine, 12(3), 166-173. doi:10.1111/j.1468-1293.2010.00865.xDOI: 10.1111/j.1468-1293.2010.00865.x
Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy (Journal article)
Lambert, J. S., Else, L. J., Jackson, V., Breiden, J., Gibbons, S., Dickinson, L., . . . Khoo, S. H. (2011). Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. HIV MEDICINE, 12(3), 166-173. doi:10.1111/j.1468-1293.2010.00865.xDOI: 10.1111/j.1468-1293.2010.00865.x
Prevalence of Potential Drug-Drug Interactions Involving Antiretroviral Drugs in a Large Kenyan Cohort (Journal article)
Kigen, G., Kimaiyo, S., Nyandiko, W., Faragher, B., Sang, E., Jakait, B., . . . Khoo, S. H. (2011). Prevalence of Potential Drug-Drug Interactions Involving Antiretroviral Drugs in a Large Kenyan Cohort. PLOS ONE, 6(2). doi:10.1371/journal.pone.0016800DOI: 10.1371/journal.pone.0016800
Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir (Journal article)
Moss, D. M., Kwan, W. S., Liptrott, N. J., Smith, D. L., Siccardi, M., Khoo, S. H., . . . Owen, A. (2011). Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(2), 879-887. doi:10.1128/AAC.00623-10DOI: 10.1128/AAC.00623-10
. Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers (Journal article)
Jackson, A., D'Avolio, A., Watson, V., Bonora, S., Back, D., Taylor, J., . . . Boffito, M. (2011). . Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers. Journal of Antimicrobial Chemotherapy, 66, 885-889.
. Pharmacokinetic and safety profile of raltegravir and ribavirin when dosed separately and together in healthy volunteers (Journal article)
Ashby, J., Garvey, L., Erlwein, O. W., Lamba, H., Weston, R., Legg, K., . . . Winston, A. (2011). . Pharmacokinetic and safety profile of raltegravir and ribavirin when dosed separately and together in healthy volunteers. Journal of Antimicrobial Chemotherapy, 66, 1340-1345.
Adipogenic gene variants in patients with HIV-associated lipodystrophy (Journal article)
Pushpakom, S. P., Owen, A., Vilar, F. J., Castro, H., Dunn, D. T., Back, D. J., & Pirmohamed, M. (2011). Adipogenic gene variants in patients with HIV-associated lipodystrophy. PHARMACOGENETICS AND GENOMICS, 21(2), 76-83. doi:10.1097/FPC.0b013e328342a917DOI: 10.1097/FPC.0b013e328342a917
Ageing with HIV: medication use and risk for potential drug-drug interactions. (Journal article)
Marzolini, C., Back, D., Weber, R., Furrer, H., Cavassini, M., Calmy, A., . . . Swiss HIV Cohort Study Members. (2011). Ageing with HIV: medication use and risk for potential drug-drug interactions.. The Journal of antimicrobial chemotherapy, 66(9), 2107-2111. doi:10.1093/jac/dkr248DOI: 10.1093/jac/dkr248
Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. (Journal article)
Liptrott, N. J., Pushpakom, S., Wyen, C., Fatkenheur, G., Hoffmann, C., Mauss, S., . . . Owen, A. (2011). Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS.. Pharmacogenetics and genomics.
Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions. (Journal article)
Seden, K., & Back, D. (2011). Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.. Current Opinion in HIV and AIDS, 6, 514-526.
Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. (Journal article)
Lamorde, M., Byakika-Kibwika, P., Okaba-Kayom, V., Ryan, M., Coakley, P., Boffito, M., . . . Merry, C. (2011). Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin.. The Journal of antimicrobial chemotherapy, 66(1), 180-183. doi:10.1093/jac/dkq411DOI: 10.1093/jac/dkq411
Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers. (Journal article)
Jackson, A., Hill, A., Puls, R., Else, L., Amin, J., Back, D., . . . Boffito, M. (2011). Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.. Journal of Antimicrobial Chemotherapy., 66, 635-640.
Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid). (Journal article)
Else, L. J., Taylor, S., Back, D. J., & Khoo, S. H. (2011). Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).. Antiviral Therapy, 16, 1139-1147.
Pharmacokinetics of darunavir/ritonavir and atazanavir/ritonavir once daily over 72 hours following drug cessation (Journal article)
Boffito, M., Jackson, A., Amara, A., Back, D., Khoo, S., Higgs, C., . . . Moyle, G. (2011). Pharmacokinetics of darunavir/ritonavir and atazanavir/ritonavir once daily over 72 hours following drug cessation. Antimicrobial Agents and Chemotherapy, 55, 4218-4223.
Plasma and Intracellular (Peripheral Blood Mononuclear Cells) Pharmacokinetics of Once-Daily Raltegravir (800 Milligrams) in HIV-Infected Patients (Journal article)
Molto, J., Valle, M., Back, D., Cedeno, S., Watson, V., Liptrott, N., . . . Clotet, B. (2011). Plasma and Intracellular (Peripheral Blood Mononuclear Cells) Pharmacokinetics of Once-Daily Raltegravir (800 Milligrams) in HIV-Infected Patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(1), 72-75. doi:10.1128/AAC.00789-10DOI: 10.1128/AAC.00789-10
Plasma and intracellular (PBMCs) pharmacokinetics of once-daily raltegravir (800 mg) in HIV-infected patients. (Journal article)
Molto, J., Valle, M., Back, D., Cedeno, S., Watson, V., Liptrott, N., . . . Clotet, B. (2011). Plasma and intracellular (PBMCs) pharmacokinetics of once-daily raltegravir (800 mg) in HIV-infected patients.. Antimicrobial Agents & Chemotherapy, 55, 72-75.
Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals (Journal article)
Jackson, A., Watson, V., Back, D., Khoo, S., Liptrott, N., Egan, D., . . . Boffito, M. (2011). Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals. of Acquired Immune Deficiency Syndrome, 58, 450-457.
Sequential population pharmacokinetic modelling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies. (Journal article)
Dickinson, L., Boffito, M., Back, D., Else, L., von Hentig, N., Davies, G., . . . Aarons, L. (2011). Sequential population pharmacokinetic modelling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies.. Antimicrob Agents & Chemotherapy, 55, 2775-2782.
Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy (Journal article)
Else, L. J., Lyons, F., O'Shea, S., Costello, S., Mullen, J., Lechelt, M., . . . de Ruiter, A. (2011). Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy. AIDS, 25, 722-725.
2010
Grapefruit-Drug Interactions (Journal article)
Seden, K., Dickinson, L., Khoo, S., & Back, D. (2010). Grapefruit-Drug Interactions. Drugs, 70(18), 2373-2407. doi:10.2165/11585250-000000000-00000DOI: 10.2165/11585250-000000000-00000
Grapefruit-drug interactions. (Journal article)
Seden, K., Dickinson, L., Khoo, S., & Back, D. (2010). Grapefruit-drug interactions.. Drugs, 70(18), 2373-2407. doi:10.2165/11585250-000000000-00000DOI: 10.2165/11585250-000000000-00000
Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men (Journal article)
Randell, P. A., Jackson, A. G., Boffito, M., Back, D. J., Tjia, J. F., Taylor, J., . . . Moyle, G. J. (2010). Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men. ANTIVIRAL THERAPY, 15(8), 1125-1132. doi:10.3851/IMP1675DOI: 10.3851/IMP1675
Maraviroc is a substrate for OATP1B1 <i>in vitro</i> and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism (Journal article)
Siccardi, M., D'Avolio, A., Nozza, S., Simiele, M., Baietto, L., Stefani, F. R., . . . Owen, A. (2010). Maraviroc is a substrate for OATP1B1 <i>in vitro</i> and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. PHARMACOGENETICS AND GENOMICS, 20(12), 759-765. doi:10.1097/FPC.0b013e3283402efbDOI: 10.1097/FPC.0b013e3283402efb
Pharmacokinetic evaluation of etravirine (Journal article)
Dickinson, L., Khoo, S., & Back, D. (2010). Pharmacokinetic evaluation of etravirine. Expert Opinion on Drug Metabolism & Toxicology, 6(12), 1575-1585. doi:10.1517/17425255.2010.535811DOI: 10.1517/17425255.2010.535811
Pharmacokinetic evaluation of etravirine. (Journal article)
Dickinson, L., Khoo, S., & Back, D. (2010). Pharmacokinetic evaluation of etravirine.. Expert opinion on drug metabolism & toxicology, 6(12), 1575-1585.
Pharmacokinetic evaluation of etravirine. (Journal article)
Dickinson, L., Khoo, S., & Back, D. (2010). Pharmacokinetic evaluation of etravirine.. Expert opinion on drug metabolism & toxicology, 6(12), 1575-1585. doi:10.1517/17425255.2010.535811DOI: 10.1517/17425255.2010.535811
Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance (Journal article)
Schipani, A., Siccardi, M., D'Avolio, A., Baietto, L., Simiele, M., Bonora, S., . . . Owen, A. (2010). Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance. Antimicrobial Agents and Chemotherapy, 54(12), 5242-5250. doi:10.1128/aac.00781-10DOI: 10.1128/aac.00781-10
Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance (Journal article)
Schipani, A., Siccardi, M., D'Avolio, A., Baietto, L., Simiele, M., Bonora, S., . . . Owen, A. (2010). Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(12), 5242-5250. doi:10.1128/AAC.00781-10DOI: 10.1128/AAC.00781-10
Suboptimal Nevirapine Steady-State Pharmacokinetics During Intrapartum Compared With Postpartum in HIV-1-Seropositive Ugandan Women (Journal article)
Lamorde, M., Byakika-Kibwika, P., Okaba-Kayom, V., Flaherty, J. P., Boffito, M., Namakula, R., . . . Scarsi, K. K. (2010). Suboptimal Nevirapine Steady-State Pharmacokinetics During Intrapartum Compared With Postpartum in HIV-1-Seropositive Ugandan Women. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 55(3), 345-350. doi:10.1097/QAI.0b013e3181e9871bDOI: 10.1097/QAI.0b013e3181e9871b
Darunavir concentrations exceed the protein-corrected EC<sub>50</sub> for wild-type HIV in the semen of HIV-1-infected men (Journal article)
Taylor, S., Jayasuriya, A. N., Berry, A., Gilleran, G., Dufty, N. E., Else, L., . . . Smit, E. J. (2010). Darunavir concentrations exceed the protein-corrected EC<sub>50</sub> for wild-type HIV in the semen of HIV-1-infected men. AIDS, 24(16), 2574-2577. doi:10.1097/QAD.0b013e32833ead18DOI: 10.1097/QAD.0b013e32833ead18
Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds (Journal article)
Else, L., Watson, V., Tjia, J., Hughes, A., Siccardi, M., Khoo, S., & Back, D. (2010). Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 878(19), 1455-1465. doi:10.1016/j.jchromb.2010.03.036DOI: 10.1016/j.jchromb.2010.03.036
Recognition of Risk for Clinically Significant Drug Interactions among HIV-Infected Patients Receiving Antiretroviral Therapy (Journal article)
Evans-Jones, J. G., Cottle, L. E., Back, D. J., Gibbons, S., Beeching, N. J., Carey, P. B., & Khoo, S. H. (2010). Recognition of Risk for Clinically Significant Drug Interactions among HIV-Infected Patients Receiving Antiretroviral Therapy. CLINICAL INFECTIOUS DISEASES, 50(10), 1419-1421. doi:10.1086/652149DOI: 10.1086/652149
The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients. (Journal article)
Garvey, L., Latch, N., Erlwein, O. W., Mackie, N. E., Walsh, J., Scullard, G., . . . Winston, A. (2010). The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.. Antiviral therapy, 15(2), 213-218. doi:10.3851/imp1517DOI: 10.3851/imp1517
New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. (Journal article)
Seden, K., Back, D., & Khoo, S. (2010). New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals.. The Journal of antimicrobial chemotherapy, 65(6), 1079-1085. doi:10.1093/jac/dkq086DOI: 10.1093/jac/dkq086
Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes (Journal article)
Janneh, O., Bray, P. G., Jones, E., Wyen, C., Chiba, P., Back, D. J., & Khoo, S. H. (2010). Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 65(5), 906-916. doi:10.1093/jac/dkq082DOI: 10.1093/jac/dkq082
HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by <i>SLCO1B1</i> polymorphisms (Journal article)
Hartkoorn, R. C., San Kwan, W., Shallcross, V., Chaikan, A., Liptrott, N., Egan, D., . . . Owen, A. (2010). HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by <i>SLCO1B1</i> polymorphisms. PHARMACOGENETICS AND GENOMICS, 20(2), 112-120. doi:10.1097/FPC.0b013e328335b02dDOI: 10.1097/FPC.0b013e328335b02d
HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms (Journal article)
Hartkoorn, R. C., Kwan, W. S., Shallcross, V., Chaikan, A., Liptrott, N., Egan, D., . . . Owen, A. (2010). HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenetics and Genomics, 20(2), 112-120. doi:10.1097/fpc.0b013e328335b02dDOI: 10.1097/fpc.0b013e328335b02d
Association of ABCC10 Polymorphisms with Nevirapine Plasma Concentrations in the German Competence Network for HIV/AIDS (Conference Paper)
Liptrott, N. J., Pushpakom, S., Wyen, C., Rockstroh, J., Mauss, S., Knechten, H., . . . Owen, A. (2010). Association of ABCC10 Polymorphisms with Nevirapine Plasma Concentrations in the German Competence Network for HIV/AIDS. In 17th Conference on Retroviruses and Opportunistic Infections (pp. 286). San Francisco: Conference on Retroviruses and Opportunistic Infections.
Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 cells and primary human lymphocytes (Journal article)
Janneh, O., Bray, P. G., Jones, E., Wyen, C., Chiba, P., Back, D. J., & Khoo, S. H. (2010). Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 cells and primary human lymphocytes. Journal of Antimicrobial Chemotherapy, 65, 906-916.
Darunavir concentrations exfeed the protein-corrected EC50 for wild-type HIV in the semen of HIV-1 infected men (Journal article)
Taylor, S., Jayasuriya, A. N., Berry, A., Gilleran, G., Dufty, N. E., Else, L., . . . Smit, E. J. (2010). Darunavir concentrations exfeed the protein-corrected EC50 for wild-type HIV in the semen of HIV-1 infected men. AIDS, 24, 2583-2587.
Effect of prototypical inducers on ligand activated nuclear receptor regulated drug disposition genes in rodent hepatic and intestinal cells (Journal article)
Martin, P., Riley, R., Thompson, P., Williams, D., Back, D., & Owen, A. (2010). Effect of prototypical inducers on ligand activated nuclear receptor regulated drug disposition genes in rodent hepatic and intestinal cells. ACTA PHARMACOLOGICA SINICA, 31(1), 51-65. doi:10.1038/aps.2009.187DOI: 10.1038/aps.2009.187
Effect of prototypical inducers on ligand activated nuclear receptor regulated drug disposition genes in rodent hepatic and intestinal cells (Journal article)
Martin, P., Riley, R., Thompson, P., Williams, D., Back, D., & Owen, A. (2010). Effect of prototypical inducers on ligand activated nuclear receptor regulated drug disposition genes in rodent hepatic and intestinal cells. Acta Pharmacologica, 31, 51-65.
Factors influencing lopinavir and atazanavir plasma concentration. (Journal article)
Stöhr, W., Back, D., Dunn, D., Sabin, C., Winston, A., Gilson, R., . . . UK CHIC Steering Committee. (2010). Factors influencing lopinavir and atazanavir plasma concentration.. The Journal of antimicrobial chemotherapy, 65(1), 129-137. doi:10.1093/jac/dkp408DOI: 10.1093/jac/dkp408
Genetic Variants of ABCC10 Are Associated with Kidney Tubular Dysfunction in Patients Treated with Tenofovir-containing Regimens (Conference Paper)
Pushpakom, S., Liptrott, N. J., RodrÃguez-Nóvoa, S., Labarga, P., Soriano, V., Albalater, M., . . . Owen, A. (2010). Genetic Variants of ABCC10 Are Associated with Kidney Tubular Dysfunction in Patients Treated with Tenofovir-containing Regimens. In 17th Conference on Retroviruses and Opportunistic Infections (pp. 352). San Francisco: Conference on Retroviruses and Opportunistic Infections.
Grapefruit juice drug interactions (Journal article)
Seden, K., Dickinson, L., Khoo, S., & Back, D. (2010). Grapefruit juice drug interactions. Drugs, 70(18), 2373-2407.
Investigation of low-dose ritonavir on human peripheral blood mononuclear cells using gene expression whole genome microarrays. (Journal article)
Yilmaz, S., Boffito, M., Collot-Teixeira, S., De Lorenzo, F., Waters, L., Fletcher, C., . . . McGregor, J. L. (2010). Investigation of low-dose ritonavir on human peripheral blood mononuclear cells using gene expression whole genome microarrays.. Genomics, 96(1), 57-65. doi:10.1016/j.ygeno.2010.03.011DOI: 10.1016/j.ygeno.2010.03.011
Nevirapine pharmacokinetics when inititate at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin (Journal article)
Lamorde, M., Byakika-Kbwika, P., Okaba-Kayom, V., Ryan, M., Coakley, P., Boffito, M., . . . Merry, C. (2010). Nevirapine pharmacokinetics when inititate at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. Journal of Antimicrobial Chemotherapy, 66, 180-183.
Pharmacokinetic evaluation of etravirine (Journal article)
Dickinson, L., Khoo, S., & Back, D. (2010). Pharmacokinetic evaluation of etravirine. Expert Opinion in Drug Metabolism & Toxicology, 6, 1575-1585.
Pharmacokinetics and drug-drug interactions of antiretrovirals: an update. (Journal article)
Dickinson, L., Khoo, S., & Back, D. (2010). Pharmacokinetics and drug-drug interactions of antiretrovirals: an update.. Antiviral research, 85(1), 176-189. doi:10.1016/j.antiviral.2009.07.017DOI: 10.1016/j.antiviral.2009.07.017
Pharmacokinetics and drug-drug interactions of antiretrovirals: an update. (Journal article)
Dickinson, L., Khoo, S., & Back, D. (2010). Pharmacokinetics and drug-drug interactions of antiretrovirals: an update.. Antiviral research, 85(1), 176-189.
Pharmacokinetics and drug–drug interactions of antiretrovirals: An update (Journal article)
Dickinson, L., Khoo, S., & Back, D. (2010). Pharmacokinetics and drug–drug interactions of antiretrovirals: An update. Antiviral Research, 85(1), 176-189. doi:10.1016/j.antiviral.2009.07.017DOI: 10.1016/j.antiviral.2009.07.017
Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers (Journal article)
Jackson, A., Hill, A., Puls, R., Else, L., Amin, J., Back, D., . . . Boffito, M. (2010). Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers. Journal of Antimicrobial Chemotherapy.
Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers. (Journal article)
Jackson, A., Hill, A., Puls, R., Else, L., Amin, J., Back, D., . . . Boffito, M. (2010). Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.. J Antimicrob Chemother..
Plasma and intracellular (PBMCs) pharmacokinetics of once-daily raltegravir (800 mg) in HIV-infected patients (Journal article)
Molto, J., Valle, M., Back, D., Cedeno, S., Watson, V., Liptrott, N., . . . Clotet, B. (2010). Plasma and intracellular (PBMCs) pharmacokinetics of once-daily raltegravir (800 mg) in HIV-infected patients. Antimicrobial Agents & Chemotherapy.
Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. (Journal article)
Marzolini, C., Elzi, L., Gibbons, S., Weber, R., Fux, C., Furrer, H., . . . Swiss HIV Cohort Study. (2010). Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study.. Antiviral therapy, 15(3), 413-423. doi:10.3851/imp1540DOI: 10.3851/imp1540
Raltegraivr is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir (Journal article)
Moss, D. M., Kwan, W. S., Liptortt, N. J., Smith, D. L., Siccardi, M., Khoo, S. H., . . . Owen, A. (2010). Raltegraivr is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir. Antimicrob Agents & Chemotherapy.
Raltegravir Is a Substrate for the Influx Transporters OAT1 and PEPT1 and the Efflux Transporter Pgp, but Is Not Transported by OATP1A2, OATP1B1, OATP1B3, OCT1, NTCP, or PEPT2 (Conference Paper)
Moss, D., Kwan, W., Liptrott, N., Siccardi, M., Anstee, D., Khoo, S., . . . Owen, A. (2010). Raltegravir Is a Substrate for the Influx Transporters OAT1 and PEPT1 and the Efflux Transporter Pgp, but Is Not Transported by OATP1A2, OATP1B1, OATP1B3, OCT1, NTCP, or PEPT2. In 17th Conference on Retroviruses and Opportunistic Infections (pp. 293). San Francisco: Conference on Retroviruses and Opportunistic Infections.
Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir (Journal article)
Moss, D. M., Kwan, W. S., Liptrott, N. J., Smith, D. L., Siccardi, M., Khoo, S. H., . . . Owen, A. (2010). Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir. Antimicrob Agents Chemother, 55(2), 879-887.
Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1 seropositive Ugandan women (Journal article)
Lamorde, M., Byakika-Kibwika, P., Okaba-Kayom, V., Flaherty, J. P., Boffito, M., Namakula, R., . . . Scarsi, K. K. (2010). Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1 seropositive Ugandan women. Journal of Acquired Immune Deficiency Syndrome, 55, 345-350.
Swiss Cohort Study. Prevelance of codedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study (Journal article)
Marzolini, C., Elzi, L., Gibbons, S., Weber, R., Fux, C., Furer, H., . . . Battegay, M. (2010). Swiss Cohort Study. Prevelance of codedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antiviral Therapy, 15, 413-423.
The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes (Journal article)
Janneh, O., Owen, A., Bray, P. G., Back, D. J., & Pirmohamed, M. (2010). The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes. British Journal of Pharmacology, 159, 484-493.
The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes (Journal article)
Janneh, O., Owen, A., Bray, P. G., Back, D. J., & Pirmohamed, M. (2010). The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes. BRITISH JOURNAL OF PHARMACOLOGY, 159(2), 484-493. doi:10.1111/j.1476-5381.2009.00552.xDOI: 10.1111/j.1476-5381.2009.00552.x
The effects of a nucleoside sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1 infected patients (Journal article)
Garvey, L., Latch, N., Erlwein, O. W., Mackie, N. E., Walsh, J., Scullard, G., . . . Winston, A. (2010). The effects of a nucleoside sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1 infected patients. Antiviral Therapy, 15, 213-218.
The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients. (Journal article)
Garvey, L., Latch, N., Erlwein, O. W., Mackie, N. E., Walsh, J., Scullard, G., . . . Winston, A. (2010). The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.. Antiviral therapy, 15(2), 213-218.
Validation of a rapid and sensitive high-performance liquid chromatography-tandme mass spectrometry (HPLC-MS/MS) assay for the simulataneous determination of existing and new antiretroviral compounds (Journal article)
Else, L., Watson, V., Tjia, J., Hughes, A., Siccardi, M., Khoo, S., & Back, D. (2010). Validation of a rapid and sensitive high-performance liquid chromatography-tandme mass spectrometry (HPLC-MS/MS) assay for the simulataneous determination of existing and new antiretroviral compounds. Journal of Chromatogr B Analytical Technology Biomedical Life Sciences, 878, 1455-1465.
2009
P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir (Journal article)
Janneh, O., Anwar, T., Jungbauer, C., Kopp, S., Khoo, S. H., Back, D. J., & Chiba, P. (2009). P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir. ANTIVIRAL THERAPY, 14(7), 965-974. doi:10.3851/IMP1399DOI: 10.3851/IMP1399
Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets. (Journal article)
Pollock, L., Else, L., Poerksen, G., Molyneux, E., Moons, P., Walker, S., . . . Khoo, S. (2009). Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets.. The Journal of antimicrobial chemotherapy, 64(6), 1251-1259. doi:10.1093/jac/dkp358DOI: 10.1093/jac/dkp358
Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes (Journal article)
Janneh, O., Chandler, B., Hartkoorn, R., Kwan, W. S., Jenkinson, C., Evans, S., . . . Khoo, S. (2009). Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother, 64(5), 1002-1007.
Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes (Journal article)
Janneh, O., Chandler, B., Hartkoorn, R., Kwan, W. S., Jenkinson, C., Evans, S., . . . Khoo, S. H. (2009). Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 64(5), 1002-1007. doi:10.1093/jac/dkp335DOI: 10.1093/jac/dkp335
Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population (Journal article)
Mahungu, T., Smith, C., Turner, F., Egan, D., Youle, M., Johnson, M., . . . Owen, A. (2009). Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV Med, 10(5), 310-317.
Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers. (Journal article)
Boffito, M., Jackson, A., Lamorde, M., Back, D., Watson, V., Taylor, J., . . . Pozniak, A. (2009). Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers.. Journal of acquired immune deficiency syndromes (1999), 52(2), 222-227. doi:10.1097/qai.0b013e3181b061d0DOI: 10.1097/qai.0b013e3181b061d0
Maraviroc: pharmacokinetics and drug interactions (Journal article)
Abel, S., Back, D. J., & Vourvahis, M. (2009). Maraviroc: pharmacokinetics and drug interactions. ANTIVIRAL THERAPY, 14(5), 607-618. Retrieved from https://www.webofscience.com/
Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC (Journal article)
Kwan, W. S., Janneh, O., Hartkoorn, R., Chandler, B., Khoo, S., Back, D., & Owen, A. (2009). Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 68(3), 375-380. doi:10.1111/j.1365-2125.2009.03462.xDOI: 10.1111/j.1365-2125.2009.03462.x
Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC (Journal article)
Kwan, W. S., Janneh, O., Hartkoorn, R., Chandler, B., Khoo, S., Back, D., & Owen, A. (2009). Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC. Br J Clin Pharmacol, 68(3), 375-380.
The Relationships of ABCB1 3435C>T and CYP2B6 516G>T With High-Density Lipoprotein Cholesterol in HIV-Infected Patients Receiving Efavirenz (Journal article)
Mahungu, T. W., Nair, D., Smith, C. J., Egan, D., Youle, M., Johnson, M. A., . . . Owen, A. (2009). The Relationships of ABCB1 3435C>T and CYP2B6 516G>T With High-Density Lipoprotein Cholesterol in HIV-Infected Patients Receiving Efavirenz. CLINICAL PHARMACOLOGY & THERAPEUTICS, 86(2), 204-211. doi:10.1038/clpt.2009.78DOI: 10.1038/clpt.2009.78
Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable. (Journal article)
Seden, K., Back, D., & Khoo, S. (2009). Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable.. The Journal of antimicrobial chemotherapy, 64(1), 5-8. doi:10.1093/jac/dkp152DOI: 10.1093/jac/dkp152
Etravirine plasma levels in a patient with decompensated liver disease. (Journal article)
Aboud, M., Castelino, S., Back, D., & Kulasegaram, R. (2009). Etravirine plasma levels in a patient with decompensated liver disease.. AIDS (London, England), 23(10), 1293-1295. doi:10.1097/qad.0b013e32832c9fb6DOI: 10.1097/qad.0b013e32832c9fb6
Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study (Journal article)
Rodriguez-Novoa, S., Labarga, P., Soriano, V., Egan, D., Albalater, M., Morello, J., . . . Owen, A. (2009). Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study. CLINICAL INFECTIOUS DISEASES, 48(11), E108-E116. doi:10.1086/598507DOI: 10.1086/598507
Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers (Journal article)
Dickinson, L., Boffito, M., Back, D., Waters, L., Else, L., Davies, G., . . . Aarons, L. (2009). Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 63(6), 1233-1243. doi:10.1093/jac/dkp102DOI: 10.1093/jac/dkp102
Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population (Journal article)
Mahungu, T. W., Smith, C. J., Turner, F., Egan, D., Youle, M., Johnson, M. A., . . . Owen, A. (2009). Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV MEDICINE, 10(5), 310-317. doi:10.1111/j.1468-1293.2008.00689.xDOI: 10.1111/j.1468-1293.2008.00689.x
Impact of different low-dose ritonavir regimens on lipids, CD36, and adipophilin expression. (Journal article)
Collot-Teixeira, S., De Lorenzo, F., Waters, L., Fletcher, C., Back, D., Mandalia, S., . . . Boffito, M. (2009). Impact of different low-dose ritonavir regimens on lipids, CD36, and adipophilin expression.. Clinical pharmacology and therapeutics, 85(4), 375-378. doi:10.1038/clpt.2008.243DOI: 10.1038/clpt.2008.243
The impact of pharmacogenetics on HIV therapy (Journal article)
Mahungu, T. W., Johnson, M. A., Owen, A., & Back, D. J. (2009). The impact of pharmacogenetics on HIV therapy. INTERNATIONAL JOURNAL OF STD & AIDS, 20(3), 145-151. doi:10.1258/ijsa.2008.008369DOI: 10.1258/ijsa.2008.008369
The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC (Journal article)
Liptrott, N. J., Penny, M., Bray, P. G., Sathish, J., Khoo, S. H., Back, D. J., & Owen, A. (2009). The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. British Journal of Pharmacology, 156(3), 497-508. doi:10.1111/j.1476-5381.2008.00050.xDOI: 10.1111/j.1476-5381.2008.00050.x
The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC (Journal article)
Liptrott, N. J., Penny, M., Bray, P. G., Sathish, J., Khoo, S. H., Back, D. J., & Owen, A. (2009). The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. BRITISH JOURNAL OF PHARMACOLOGY, 156(3), 497-508. doi:10.1111/j.1476-5381.2008.00050.xDOI: 10.1111/j.1476-5381.2008.00050.x
Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons (Journal article)
Dickinson, L., Khoo, S., & Back, D. (2009). Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Current Opinion in HIV & AIDS, (in pr.
Drug-Drug Interactions Involving Antiretrovirals (Journal article)
Seden, K., Back, D. J., & Khoo, S. H. (2009). Drug-Drug Interactions Involving Antiretrovirals. Journal of Antimicrobial Chemotherapy, (in pr.
Integrase as a Novel Target for the Inhibition of Human Immunodeficiency Virus Type 1 Infection: Current Status and Future Perspectives (Chapter)
Vandekerckhove, L. P. R., Christ, F., Debyser, Z., Owen, A., Back, D., Voet, A., . . . Vogelaers, D. (2009). Integrase as a Novel Target for the Inhibition of Human Immunodeficiency Virus Type 1 Infection: Current Status and Future Perspectives. In ANTIVIRAL RESEARCH: STRATEGIES IN ANTIVIRAL DRUG DISCOVERY (pp. 71-+). Retrieved from https://www.webofscience.com/
Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study (Journal article)
Rodriguez-Novoa, S., Labarga, P., Soriano, V., Egan, D., Albalater, M., Morello, J., . . . Owen, A. (2009). Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis, 48(11), e108-e116.
2008
Detection of ABCC2, CYP2B6 and CYP3A4 in human peripheral blood mononuclear cells using flow cytometry (Journal article)
Liprott, N. J., Khoo, S. H., Back, D. J., & Owen, A. (2008). Detection of ABCC2, CYP2B6 and CYP3A4 in human peripheral blood mononuclear cells using flow cytometry. JOURNAL OF IMMUNOLOGICAL METHODS, 339(2), 270-274. doi:10.1016/j.jim.2008.09.010DOI: 10.1016/j.jim.2008.09.010
Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation. (Journal article)
Boffito, M., Else, L., Back, D., Taylor, J., Khoo, S., Sousa, M., . . . Moyle, G. (2008). Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.. Antiviral therapy, 13(7), 901-907. doi:10.1177/135965350801300702DOI: 10.1177/135965350801300702
Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals. (Journal article)
Dickinson, L., Boffito, M., Back, D., Khoo, S., Pozniak, A. L., Mugyenyi, P., . . . Aarons, L. J. (2008). Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals.. The Journal of antimicrobial chemotherapy, 62(6), 1344-1355.
Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals (Journal article)
Dickinson, L., Boffito, M., Back, D. J., Khoo, S. H., Pozniak, A. L., Mugyenyi, P., . . . Aarons, L. J. (2008). Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 62(6), 1344-1355. doi:10.1093/jac/dkn399DOI: 10.1093/jac/dkn399
Association of a single-nucleotide polymorphism in the pregnane X receptor (<i>PXR</i> 63396C→T) with reduced concentrations of unboosted atazanavir (Journal article)
Siccardi, M., D'Avolio, A., Baietto, L., Gibbons, S., Sciandra, M., Colucci, D., . . . Owen, A. (2008). Association of a single-nucleotide polymorphism in the pregnane X receptor (<i>PXR</i> 63396C→T) with reduced concentrations of unboosted atazanavir. CLINICAL INFECTIOUS DISEASES, 47(9), 1222-1225. doi:10.1086/592304DOI: 10.1086/592304
Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir (Journal article)
Janneh, O., Hartkoorn, R. C., Jones, E., Owen, A., Ward, S. A., Davey, R., . . . Khoo, S. H. (2008). Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir. BRITISH JOURNAL OF PHARMACOLOGY, 155(6), 875-883. doi:10.1038/bjp.2008.320DOI: 10.1038/bjp.2008.320
Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients. (Journal article)
Moltó, J., Santos, J. R., Pérez-Alvarez, N., Cedeño, S., Miranda, C., Khoo, S., . . . Clotet, B. (2008). Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.. Antimicrobial agents and chemotherapy, 52(11), 3928-3932. doi:10.1128/aac.00520-08DOI: 10.1128/aac.00520-08
Mycophenolate mofetil inhibits T-cell proliferation in kidney transplant recipients without lowering intracellular dGTP and GTP (Journal article)
Sankatsing, S. U. C., Prins, J. M., Yong, S. -L. L., Roelofsen, J., van Kuilenburg, A. B. P., Kewn, S., . . . ten Berge, I. J. M. (2008). Mycophenolate mofetil inhibits T-cell proliferation in kidney transplant recipients without lowering intracellular dGTP and GTP. TRANSPLANT INTERNATIONAL, 21(11), 1066-1071. doi:10.1111/j.1432-2277.2008.00739.xDOI: 10.1111/j.1432-2277.2008.00739.x
Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults. (Journal article)
Byakika-Kibwika, P., Lamorde, M., Kalemeera, F., D'Avolio, A., Mauro, S., Di Perri, G., . . . Merry, C. (2008). Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults.. The Journal of antimicrobial chemotherapy, 62(5), 1113-1117. doi:10.1093/jac/dkn290DOI: 10.1093/jac/dkn290
HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options (Journal article)
Mallewa, J. E., Wilkins, E., Vilar, J., Mallewa, M., Doran, D., Back, D., & Pirmohamed, M. (2008). HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 62(4), 648-660. doi:10.1093/jac/dkn251DOI: 10.1093/jac/dkn251
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. (Journal article)
Stöhr, W., Back, D., Dunn, D., Sabin, C., Winston, A., Gilson, R., . . . UK CHIC Study. (2008). Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.. Antiviral therapy, 13(5), 675-685. doi:10.1177/135965350801300507DOI: 10.1177/135965350801300507
Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes (Journal article)
Jones, S. P., Waitt, C., Sutton, R., Back, D. J., & Pirmohamed, M. (2008). Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes. AIDS, 22(11), 1293-1298. doi:10.1097/QAD.0b013e3283021a4fDOI: 10.1097/QAD.0b013e3283021a4f
Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes (Journal article)
Jones, S. P., Waitt, C., Sutton, R., Back, D. J., & Pirmohamed, M. (2008). Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes. AIDS, 22(11), 1293-1298. doi:10.1097/qad.0b013e3283021a4fDOI: 10.1097/qad.0b013e3283021a4f
Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing (Journal article)
Dickinson, L., Boffito, M., Khoo, S. H., Schutz, M., Aarons, L. J., Pozniak, A. L., & Back, D. J. (2008). Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 62(1), 161-167. doi:10.1093/jac/dkn187DOI: 10.1093/jac/dkn187
Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing (Journal article)
Dickinson, L., Boffito, M., Khoo, S. H., Schutz, M., Aarons, L. J., Pozniak, A. L., & Back, D. J. (n.d.). Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing. Journal of Antimicrobial Chemotherapy, 62(1), 161-167. doi:10.1093/jac/dkn187DOI: 10.1093/jac/dkn187
Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis. (Journal article)
Micheli, V., Regazzi, M., Dickinson, L., Meraviglia, P., Villani, P., Khoo, S., . . . Cargnel, A. (2008). Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis.. Therapeutic drug monitoring, 30(3), 306-313.
Lopinavir/ritonavir pharmacokinetics in HN/HCV-coinfected patients with or without cirrhosis (Journal article)
Micheli, V., Regazzi, M., Dickinson, L., Meraviglia, P., Villani, P., Khoo, S. H., . . . Cargnel, A. (2008). Lopinavir/ritonavir pharmacokinetics in HN/HCV-coinfected patients with or without cirrhosis. THERAPEUTIC DRUG MONITORING, 30(3), 306-313. doi:10.1097/FTD.0b013e318177209eDOI: 10.1097/FTD.0b013e318177209e
Lopinavir/ritonavir pharmacokinetics in HN/HCV-coinfected patients with or without cirrhosis (Journal article)
Micheli, V., Regazzi, M., Dickinson, L., Meraviglia, P., Villani, P., Khoo, S. H., . . . Cargnel, A. (2008). Lopinavir/ritonavir pharmacokinetics in HN/HCV-coinfected patients with or without cirrhosis. THERAPEUTIC DRUG MONITORING, 30(3), 306-313.
Pharmacokinetics and Safety of Saquinavir/Ritonavir and Omeprazole in HIV-infected Subjects (Journal article)
Singh, K., Dickinson, L., Chaikan, A., Back, D., Fletcher, C., Pozniak, A., . . . Boffito, M. (2008). Pharmacokinetics and Safety of Saquinavir/Ritonavir and Omeprazole in HIV-infected Subjects. Clinical Pharmacology & Therapeutics, 83(6), 867-872. doi:10.1038/sj.clpt.6100375DOI: 10.1038/sj.clpt.6100375
Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects. (Journal article)
Singh, K., Dickinson, L., Chaikan, A., Back, D., Fletcher, C., Pozniak, A., . . . Boffito, M. (2008). Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects.. Clinical pharmacology and therapeutics, 83(6), 867-872.
Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects. (Journal article)
Singh, K., Dickinson, L., Chaikan, A., Back, D., Fletcher, C., Pozniak, A., . . . Boffito, M. (2008). Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects.. Clinical pharmacology and therapeutics, 83(6), 867-872. doi:10.1038/sj.clpt.6100375DOI: 10.1038/sj.clpt.6100375
Influence of Environmental Chemicals on Drug Therapy in Humans: Studies with Contraceptive Steroids (Chapter)
Breckenridge, A. M., Back, D. J., Cross, K., Crawford, F., MacIver, M., L'E Orme, M., . . . Smith, E. (1980). Influence of Environmental Chemicals on Drug Therapy in Humans: Studies with Contraceptive Steroids. In Unknown Book (pp. 289-306). Wiley. doi:10.1002/9780470720592.ch16DOI: 10.1002/9780470720592.ch16
Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons (Journal article)
Dickinson, L., Khoo, S., & Back, D. (2008). Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Current Opinion in HIV and AIDS, 3(3), 296-305. doi:10.1097/COH.0b013e3282f82bf1DOI: 10.1097/COH.0b013e3282f82bf1
Darunavir: pharmacokinetics and drug interactions. (Journal article)
Back, D., Sekar, V., & Hoetelmans, R. M. W. (2008). Darunavir: pharmacokinetics and drug interactions.. Antiviral therapy, 13(1), 1-13. doi:10.1177/135965350801300101DOI: 10.1177/135965350801300101
Impact of <i>CYP2B6</i> 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients (Journal article)
Wyen, C., Hendra, H., Vogel, M., Hoffmann, C., Knechten, H., Brockmeyer, N. H., . . . Owen, A. (2008). Impact of <i>CYP2B6</i> 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 61(4), 914-918. doi:10.1093/jac/dkn029DOI: 10.1093/jac/dkn029
Response to 'communicating information about drug interactions' (Journal article)
Back, D. J., & Gibbons, S. E. (2008). Response to 'communicating information about drug interactions'. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 65(4), 617-618. doi:10.1111/j.1365-2125.2007.03043.xDOI: 10.1111/j.1365-2125.2007.03043.x
Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells (Journal article)
Martin, P., Riley, R., Back, D. J., & Owen, A. (2008). Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells. BRITISH JOURNAL OF PHARMACOLOGY, 153(4), 805-819. doi:10.1038/sj.bjp.0707601DOI: 10.1038/sj.bjp.0707601
Differences in pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. (Journal article)
Dickinson, L., Khoo, S., & Back, D. (2008). Differences in pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons.. Current Opinion in HIV & AIDS, 3, 296-305.
Factors Influencing Efavirenz and Nevirapine Plasma Concentration: Effect of Ethnicity, Weight, and Co-Medication (Journal article)
Stöhr, W., Back, D., Dunn, D., Sabin, C., Winston, A., Gilson, R., . . . Khoo, S. (2008). Factors Influencing Efavirenz and Nevirapine Plasma Concentration: Effect of Ethnicity, Weight, and Co-Medication. Antiviral Therapy, 13(5), 675-685.
Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation (Journal article)
Back, D., Else, L., Khoo, S., Boffito, M., Taylor, J., Sousa, M., . . . Moyle, G. (2008). Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation. ANTIVIRAL THERAPY, 13(7), 901-907.
2007
Detection and quantification of minority HIV isolates harbouring the D30N mutation by real-time PCR amplification (Journal article)
Detsika, M. G., Chandler, B., Khoo, S. H., Winstanley, C., Cane, P., Back, D. J., & Owen, A. (2007). Detection and quantification of minority HIV isolates harbouring the D30N mutation by real-time PCR amplification. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 60(4), 881-884. doi:10.1093/jac/dkm281DOI: 10.1093/jac/dkm281
A rapid and sensitive HPLC-MS method for the detection of plasma and cellular rifampicin (Journal article)
Hartkoorn, R. C., Khoo, S., Back, D. J., Tjia, J. F., Waitt, C. J., Chaponda, M., . . . Ward, S. A. (2007). A rapid and sensitive HPLC-MS method for the detection of plasma and cellular rifampicin. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 857(1), 76-82. doi:10.1016/j.jchromb.2007.07.005DOI: 10.1016/j.jchromb.2007.07.005
Factors impacting the expression of membrane-bound proteins in lymphocytes from HIV-positive subjects (Journal article)
Chandler, B., Detsika, M., Khoo, S. H., Williams, J., Back, D. J., & Owen, A. (2007). Factors impacting the expression of membrane-bound proteins in lymphocytes from HIV-positive subjects. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 60(3), 685-689. doi:10.1093/jac/dkm230DOI: 10.1093/jac/dkm230
Stopping antiretroviral therapy. (Journal article)
Taylor, S., Boffito, M., Khoo, S., Smit, E., & Back, D. (2007). Stopping antiretroviral therapy.. AIDS (London, England), 21(13), 1673-1682. doi:10.1097/qad.0b013e3281c61394DOI: 10.1097/qad.0b013e3281c61394
Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients. (Journal article)
Waters, L. J., Moyle, G., Bonora, S., D'Avolio, A., Else, L., Mandalia, S., . . . Boffito, M. (2007). Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.. Antiviral therapy, 12(5), 825-830. doi:10.1177/135965350701200510DOI: 10.1177/135965350701200510
Effect of transporter modulation on the emergence of nelfinavir resistance <i>in vitro</i> (Journal article)
Chandler, B., Detsika, M., Owen, A., Evans, S., Hartkoorn, R. C., Cane, P. A., . . . Khoo, S. H. (2007). Effect of transporter modulation on the emergence of nelfinavir resistance <i>in vitro</i>. ANTIVIRAL THERAPY, 12(5), 831-834. Retrieved from https://www.webofscience.com/
Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals. (Journal article)
Dickinson, L., Back, D., Pozniak, A., Khoo, S., & Boffito, M. (2007). Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals.. Therapeutic drug monitoring, 29(3), 361-367.
Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals. (Journal article)
Dickinson, L., Back, D., Pozniak, A., Khoo, S., & Boffito, M. (2007). Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals.. Therapeutic drug monitoring, 29(3), 361-367. doi:10.1097/ftd.0b013e3180683b25DOI: 10.1097/ftd.0b013e3180683b25
Response to 'Nifedipine-Iopinavir/ritonavir severe interaction: a case report' (Journal article)
Back, D. J., & Gibbons, S. E. (2007). Response to 'Nifedipine-Iopinavir/ritonavir severe interaction: a case report'. AIDS, 21(9), 1226-1227. doi:10.1097/QAD.0b013e32811ebf8eDOI: 10.1097/QAD.0b013e32811ebf8e
Combining resistance and pharmacology for optimum patient care (Journal article)
Khoo, S. H., Winston, A., & Back, D. J. (2007). Combining resistance and pharmacology for optimum patient care. CURRENT OPINION IN HIV AND AIDS, 2(3), 157-168. doi:10.1097/COH.0b013e3280f31d27DOI: 10.1097/COH.0b013e3280f31d27
Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein (Journal article)
Hartkoorn, R. C., Chandler, B., Owen, A., Ward, S. A., Squire, S. B., Back, D. J., & Khoo, S. H. (2007). Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein. TUBERCULOSIS, 87(3), 248-255. doi:10.1016/j.tube.2006.12.001DOI: 10.1016/j.tube.2006.12.001
Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals. (Journal article)
Dickinson, L., Back, D., Pozniak, A., Khoo, S., & Boffito, M. (2007). Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals.. Ther Drug Monitoring, 29(3), 361-367.
Nifedipine-lopinavir/ritonavir severe interaction:a case report. (Journal article)
Back, D. J., & Gibbons, S. E. (2007). Nifedipine-lopinavir/ritonavir severe interaction:a case report.. AIDS, 21(9), 1226-1227.
2006
Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients. (Journal article)
Ford, J., Boffito, M., Maitland, D., Hill, A., Back, D., Khoo, S., . . . Pozniak, A. (2006). Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.. The Journal of antimicrobial chemotherapy, 58(5), 1009-1016. doi:10.1093/jac/dkl379DOI: 10.1093/jac/dkl379
Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug (Journal article)
Hider, S. L., Owen, A., Hartkoorn, R., Khoo, S., Back, D., Silman, A. J., & Bruce, I. N. (2006). Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug. ANNALS OF THE RHEUMATIC DISEASES, 65(10), 1390-1393. doi:10.1136/ard.2005.049189DOI: 10.1136/ard.2005.049189
Pharmacogenetics of HIV therapy (Journal article)
Owen, A., Pirmohamed, M., Khoo, S. H., & Back, D. J. (2006). Pharmacogenetics of HIV therapy. PHARMACOGENETICS AND GENOMICS, 16(10), 693-703. doi:10.1097/01.fpc.0000236338.41799.57DOI: 10.1097/01.fpc.0000236338.41799.57
Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses. (Journal article)
Boffito, M., Maitland, D., Dickinson, L., Back, D., Hill, A., Fletcher, C., . . . Pozniak, A. (2006). Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.. AIDS research and human retroviruses, 22(8), 749-756.
Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses. (Journal article)
Boffito, M., Maitland, D., Dickinson, L., Back, D., Hill, A., Fletcher, C., . . . Pozniak, A. (2006). Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.. AIDS research and human retroviruses, 22(8), 749-756. doi:10.1089/aid.2006.22.749DOI: 10.1089/aid.2006.22.749
Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. (Journal article)
Winston, A., Back, D., Fletcher, C., Robinson, L., Unsworth, J., Tolowinska, I., . . . Boffito, M. (2006). Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers.. AIDS (London, England), 20(10), 1401-1406. doi:10.1097/01.aids.0000233573.41597.8aDOI: 10.1097/01.aids.0000233573.41597.8a
An update on therapeutic drug monitoring for antiretroviral drugs. (Journal article)
Back, D., Gibbons, S., & Khoo, S. (2006). An update on therapeutic drug monitoring for antiretroviral drugs.. Therapeutic drug monitoring, 28(3), 468-473. doi:10.1097/01.ftd.0000211825.57984.41DOI: 10.1097/01.ftd.0000211825.57984.41
Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological response. (Journal article)
Winston, A., Patel, N., Back, D., Khoo, S., Bulbeck, S., Mandalia, S., . . . Boffito, M. (2006). Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological response.. Journal of acquired immune deficiency syndromes (1999), 41(5), 675-676. doi:10.1097/01.qui.0000209910.27997.d9DOI: 10.1097/01.qui.0000209910.27997.d9
Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN) - A randomized controlled trial of therapeutic drug monitoring and adherence support (Journal article)
Khoo, S. H., Lloyd, J., Dalton, M., Bonington, A., Hart, E., Gibbons, S., . . . Back, D. J. (2006). Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN) - A randomized controlled trial of therapeutic drug monitoring and adherence support. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 41(4), 461-467. doi:10.1097/01.qai.0000218345.65434.21DOI: 10.1097/01.qai.0000218345.65434.21
Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals (Journal article)
Back, D. J., Owen, A., & Khoo, S. H. (2006). Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. CLINICAL PHARMACOKINETICS, 45(2), 213-214. doi:10.2165/00003088-200645020-00006DOI: 10.2165/00003088-200645020-00006
Drug-drug interactions that matter. (Journal article)
Back, D. J. (2006). Drug-drug interactions that matter.. Topics in HIV medicine : a publication of the International AIDS Society, USA, 14(2), 88-92.
Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers (Journal article)
Winston, A., Back, D., Fletcher, C., Robinson, L., Unsworth, J., Tolowinska, I., . . . Boffito, M. (2006). Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. AIDS, 20(10), 401-406.
Pharmacokinetics of reverse transcriptase inhibitors (Chapter)
Hoggard, P., Kewn, S., Khoo, S., & Back, D. (2006). Pharmacokinetics of reverse transcriptase inhibitors. In G. Skowron, & R. Ogden (Eds.), Reverse Transcriptase Inhibitors in HIV/AIDS Therapy (pp. xxx). Totowa, New Jersey: Humana Press.
Pharmacological Optimization of PIs and NNRTIs (POPIN)- a randomised controlled trial of therapeutic drug monitoring and adherence support. (Journal article)
Khoo, S. H., Lloyd, J., Dalton, M., Bonington, A., Hart, E., Gibbons, S., . . . Back, D. J. (2006). Pharmacological Optimization of PIs and NNRTIs (POPIN)- a randomised controlled trial of therapeutic drug monitoring and adherence support.. J Acquir Immune Defic Syndr, 41(4), 461-467.
2005
Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. (Journal article)
Dickinson, L., Robinson, L., Tjia, J., Khoo, S., & Back, D. (2005). Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry.. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 829(1-2), 82-90.
Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. (Journal article)
Dickinson, L., Robinson, L., Tjia, J., Khoo, S., & Back, D. (2005). Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry.. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 829(1-2), 82-90. doi:10.1016/j.jchromb.2005.09.032DOI: 10.1016/j.jchromb.2005.09.032
Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudineand zidovudine-containing regimens (Journal article)
Jones, S. P., Qazi, N., Morelese, J., Lebrecht, D., Sutinen, J., Yki-Járvinen, H., . . . Moyle, G. J. (2005). Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudineand zidovudine-containing regimens. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 40(5), 565-572. doi:10.1097/01.qai.0000187443.30838.3eDOI: 10.1097/01.qai.0000187443.30838.3e
Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP (Journal article)
Janneh, O., Owen, A., Chandler, B., Hartkoorn, R. C., Hart, C. A., Bray, P. G., . . . Khoo, S. H. (2005). Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS, 19(18), 2097-2102. doi:10.1097/01.aids.0000194793.36175.40DOI: 10.1097/01.aids.0000194793.36175.40
Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study. (Journal article)
Rodriguez-Torres, M., Torriani, F. J., Soriano, V., Borucki, M. J., Lissen, E., Sulkowski, M., . . . Back, D. (2005). Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study.. Antimicrobial agents and chemotherapy, 49(10), 3997-4008. doi:10.1128/aac.49.10.3997-4008.2005DOI: 10.1128/aac.49.10.3997-4008.2005
Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals (Journal article)
Almond, L. M., Hoggard, P. G., Edirisinghe, D., Khoo, S. H., & Back, D. J. (2005). Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 56(4), 738-744. doi:10.1093/jac/dki308DOI: 10.1093/jac/dki308
In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine (Journal article)
Owen, A., Janneh, O., Hartkoorn, R. C., Chandler, B., Bray, P. G., Martin, P., . . . Back, D. J. (2005). In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 314(3), 1202-1209. doi:10.1124/jpet.105.086272DOI: 10.1124/jpet.105.086272
In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine. (Journal article)
Owen, A., Janneh, O., Hartkoorn, R. C., Chandler, B., Bray, P. G., Martin, P., . . . Back, D. J. (2005). In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine.. The Journal of pharmacology and experimental therapeutics, 314(3), 1202-1209. doi:10.1124/jpet.105.086272DOI: 10.1124/jpet.105.086272
Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors (Journal article)
Jones, S. P., Janneh, O., Back, D. J., & Pirmohamed, M. (2005). Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors. ANTIVIRAL THERAPY, 10(2), 207-213. Retrieved from https://www.webofscience.com/
Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy. (Journal article)
Boffito, M., Acosta, E., Burger, D., Fletcher, C. V., Flexner, C., Garaffo, R., . . . Back, D. (2005). Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy.. Antiviral therapy, 10(3), 375-392. doi:10.1177/135965350501000307DOI: 10.1177/135965350501000307
Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs. (Journal article)
Boffito, M., Acosta, E., Burger, D., Fletcher, C. V., Flexner, C., Garaffo, R., . . . Back, D. (2005). Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs.. Antiviral therapy, 10(4), 469-477. doi:10.1177/135965350501000413DOI: 10.1177/135965350501000413
Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals (Journal article)
Almond, L. M., Edirisinghe, D., Dalton, M., Bonington, A., Back, D. J., & Khoo, S. H. (2005). Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. CLINICAL PHARMACOLOGY & THERAPEUTICS, 78(2), 132-142. doi:10.1016/j.clpt.2005.04.004DOI: 10.1016/j.clpt.2005.04.004
The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors - Implications for once-daily dosing (Journal article)
Back, D. J., Burger, D. M., Flexner, C. W., & Gerber, J. G. (2005). The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors - Implications for once-daily dosing. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 39, S1-S23. doi:10.1097/01.qai.0000168882.67942.3fDOI: 10.1097/01.qai.0000168882.67942.3f
The potential for interactions between antimalarial and antiretroviral drugs (Journal article)
Khoo, S., Back, D., & Winstanley, P. (2005). The potential for interactions between antimalarial and antiretroviral drugs. AIDS, 19(10), 995-1005.
The potential for interactions between antimalarial and antiretroviral drugs. (Journal article)
Khoo, S., Back, D., & Winstanley, P. (2005). The potential for interactions between antimalarial and antiretroviral drugs.. AIDS (London, England), 19(10), 995-1005. doi:10.1097/01.aids.0000174445.40379.e0DOI: 10.1097/01.aids.0000174445.40379.e0
The implications of P-glycoprotein in HIV: friend or foe? (Journal article)
Owen, A., Chandler, B., & Back, D. J. (2005). The implications of P-glycoprotein in HIV: friend or foe?. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 19(3), 283-296. doi:10.1111/j.1472-8206.2005.00324.xDOI: 10.1111/j.1472-8206.2005.00324.x
Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily. (Journal article)
Boffito, M., Maitland, D., Dickinson, L., Back, D., Hill, A., Fletcher, C., . . . Pozniak, A. (2005). Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily.. The Journal of antimicrobial chemotherapy, 55(4), 542-545. doi:10.1093/jac/dki043DOI: 10.1093/jac/dki043
Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens (Journal article)
Jones, S. P., Qazi, N., Morelese, J., Lebrecht, D., Sutinen, J., Yki-Jarvinen, H., . . . Moyle, G. J. (2005). Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens. Journal of Acquired Immune Deficiency Syndromes, 40, 562-572.
Drug efflux transporters in rheumatoid arthritis: comment on the article by Kremer. (Journal article)
Hider, S. L., Hoggard, P., Khoo, S., Back, D., & Bruce, I. N. (2005). Drug efflux transporters in rheumatoid arthritis: comment on the article by Kremer.. Arthritis and rheumatism, 52(2), 670. doi:10.1002/art.20770DOI: 10.1002/art.20770
In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine (Journal article)
Owen, A., Janneh, O., Hartkoorn, R. C., Chandler, B., Bray, P. G., Martin, P., . . . Back, D. J. (2005). In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine. J Pharmacol Exp Ther, 314(3), 1202-1209.
Intracellular accumulation of human immunodeficiency virus protease inhibitors (Journal article)
Boffito, M., Acosta, E., Burger, D., Fletcher, C. V., Flexner, C., Garaffo, R., . . . Back, D. (2005). Intracellular accumulation of human immunodeficiency virus protease inhibitors. Antiviral Therapy, 10, 3228-3235. doi:10.1128/AAC.46.10.3228-3235.2002DOI: 10.1128/AAC.46.10.3228-3235.2002
Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP (Journal article)
Janneh, O., Owen, A., Chandler, B., Hartkoorn, R. C., Hart, C. A., Bray, P. G., . . . Khoo, S. (2005). Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS, 19(18), 2097-2102.
Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. (Journal article)
Janneh, O., Owen, A., Chandler, B., Hartkoorn, R. C., Hart, C. A., Bray, P. G., . . . Khoo, S. H. (2005). Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP.. AIDS, 19(18), 2097-2102. Retrieved from http://gateway.ut.ovid.com/
Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects. (Journal article)
Boffito, M., Back, D., Stainsby-Tron, M., Hill, A., Di Perri, G., Moyle, G., . . . Pozniak, A. (2005). Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.. British journal of clinical pharmacology, 59(1), 38-42. doi:10.1111/j.1365-2125.2004.02240.xDOI: 10.1111/j.1365-2125.2004.02240.x
Similtaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir in human plasma by high performance liquid chromatography-tandem mass spectrometry. (Journal article)
Dickinson, L., Robinson, L., Tjia, J., Khoo, S. H., & Back, D. (2005). Similtaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir in human plasma by high performance liquid chromatography-tandem mass spectrometry.. J Chromatogr B, 831, 258-266.
2004
A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients (Journal article)
Perucca, E., Hedges, A., Makki, K. A., Ruprah, M., Wilson, J. F., Richens, A., & Back, D. (2004). A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. British Journal of Clinical Pharmacology, 58(7 SPEC. ISS.).
Lipodystrophy in patients with HIV-1 infection:: effect of stopping protease inhibitors on TNF-α and TNF-receptor levels, and on metabolic parameters (Journal article)
Maher, B., Lloyd, J., Wilkins, E. G. L., Fraser, W. D., Back, D., Park, B. K., & Pirmohamed, M. (2004). Lipodystrophy in patients with HIV-1 infection:: effect of stopping protease inhibitors on TNF-α and TNF-receptor levels, and on metabolic parameters. ANTIVIRAL THERAPY, 9(6), 879-887. Retrieved from https://www.webofscience.com/
Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4 (Journal article)
Owen, A., Chandler, B., Bray, P. G., Ward, S. A., Hart, C. A., Back, D. J., & Khoo, S. H. (2004). Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4. JOURNAL OF VIROLOGY, 78(21), 12022-12029. doi:10.1128/JVI.78.21.12022-12029.2004DOI: 10.1128/JVI.78.21.12022-12029.2004
Steady-State Pharmacokinetics of Saquinavir Hard-Gel/Ritonavir/Fosamprenavir in HIV-1???Infected Patients (Journal article)
Boffito, M., Dickinson, L., Hill, A., Back, D., Moyle, G., Nelson, M., . . . Pozniak, A. (2004). Steady-State Pharmacokinetics of Saquinavir Hard-Gel/Ritonavir/Fosamprenavir in HIV-1???Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes, 37(3), 1376-1384. doi:10.1097/01.qai.0000136060.65716.1aDOI: 10.1097/01.qai.0000136060.65716.1a
Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients. (Journal article)
Boffito, M., Dickinson, L., Hill, A., Back, D., Moyle, G., Nelson, M., . . . Pozniak, A. (2004). Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients.. Journal of acquired immune deficiency syndromes (1999), 37(3), 1376-1384. doi:10.1097/01.qai.0000136060.65716.1aDOI: 10.1097/01.qai.0000136060.65716.1a
Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools (Journal article)
Sankatsing, S. U. C., Hoggard, P. G., Huitema, A. D. R., Sparidans, R. W., Kewn, S., Crommentuyn, K. M. L., . . . Prins, J. M. (2004). Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools. CLINICAL PHARMACOKINETICS, 43(12), 823-832. doi:10.2165/00003088-200443120-00004DOI: 10.2165/00003088-200443120-00004
Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA (Journal article)
Owen, A., Chandler, B., Back, D. J., & Khoo, S. H. (2004). Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA. ANTIVIRAL THERAPY, 9(5), 819-821. Retrieved from https://www.webofscience.com/
Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen (Journal article)
Isaac, A., Taylor, S., Cane, P., Smit, E., Gihbons, S. E., White, D. J., . . . Back, D. J. (2004). Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 54(2), 498-502. doi:10.1093/jac/dkh357DOI: 10.1093/jac/dkh357
Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients. (Journal article)
Ford, J., Boffito, M., Wildfire, A., Hill, A., Back, D., Khoo, S., . . . Pozniak, A. (2004). Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients.. Antimicrobial agents and chemotherapy, 48(7), 2388-2393. doi:10.1128/aac.48.7.2388-2393.2004DOI: 10.1128/aac.48.7.2388-2393.2004
The relationship between nevirapine plasma concentrations and abnormal liver function tests (Journal article)
Almond, L. M., Boffito, M., Hoggard, P. G., Bonora, S., Raiteri, R., Reynolds, H. E., . . . Di Perri, G. (2004). The relationship between nevirapine plasma concentrations and abnormal liver function tests. AIDS RESEARCH AND HUMAN RETROVIRUSES, 20(7), 716-722. doi:10.1089/0889222041524670DOI: 10.1089/0889222041524670
Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen. (Journal article)
Boffito, M., Dickinson, L., Hill, A., Back, D., Moyle, G., Nelson, M., . . . Pozniak, A. (2004). Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen.. Antiviral therapy, 9(3), 423-429.
Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen. (Journal article)
Boffito, M., Dickinson, L., Hill, A., Back, D., Moyle, G., Nelson, M., . . . Pozniak, A. (2004). Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen.. Antiviral therapy, 9(3), 423-429. doi:10.1177/135965350400900315DOI: 10.1177/135965350400900315
Clinical implications of stopping nevirapine-based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance. (Journal article)
Mackie, N. E., Fidler, S., Tamm, N., Clarke, J. R., Back, D., Weber, J. N., & Taylor, G. P. (2004). Clinical implications of stopping nevirapine-based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance.. HIV medicine, 5(3), 180-184. doi:10.1111/j.1468-1293.2004.00208.xDOI: 10.1111/j.1468-1293.2004.00208.x
Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals? (Journal article)
Winston, A., Pozniak, A., Smith, N., Fletcher, C., Mandalia, S., Parmar, D., . . . Nelson, M. (2004). Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?. AIDS (London, England), 18(3), 572-574. doi:10.1097/00002030-200402200-00029DOI: 10.1097/00002030-200402200-00029
Intracellular accumulation of nelfinavir and its relationship to P-glycoprotein expression and function in HIV-infected patients. (Journal article)
Hennessy, M., Clarke, S., Spiers, J. P., Kelleher, D., Mulcahy, F., Hoggard, P., . . . Barry, M. (2004). Intracellular accumulation of nelfinavir and its relationship to P-glycoprotein expression and function in HIV-infected patients.. Antiviral therapy, 9(1), 115-122. doi:10.1177/135965350400900103DOI: 10.1177/135965350400900103
Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression (Journal article)
Ford, J., Cornforth, D., Hoggard, P. G., Cuthbertson, Z., Meaden, E. R., Williams, I., . . . Khoo, S. H. (2004). Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression. ANTIVIRAL THERAPY, 9(1), 77-84. Retrieved from https://www.webofscience.com/
Lopinavir protein binding in vivo through the 12-hour dosing interval (Journal article)
Boffito, M., Hoggard, P. G., Lindup, W. E., Bonora, S., Sinicco, A., Khoo, S. H., . . . Back, D. J. (2004). Lopinavir protein binding in vivo through the 12-hour dosing interval. THERAPEUTIC DRUG MONITORING, 26(1), 35-39. doi:10.1097/00007691-200402000-00008DOI: 10.1097/00007691-200402000-00008
A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. 1984. (Journal article)
Perucca, E., Hedges, A., Makki, K. A., Ruprah, M., Wilson, J. F., & Richens, A. (2004). A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. 1984.. British journal of clinical pharmacology, 58(7), S854-S863. doi:10.1111/j.1365-2125.2004.02311.xDOI: 10.1111/j.1365-2125.2004.02311.x
Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA. (Journal article)
Owen, A., Chandler, B., Back, D. J., & Khoo, S. H. (2004). Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA.. Antiviral Therapy, 9(5), 819-821.
Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4 (Journal article)
Owen, A., Chandler, B., Bray, P. G., Ward, S. A., Hart, C. A., Back, D., & Khoo, S. (2004). Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4. J Virol, 78(21), 12022-12029.
Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression. (Journal article)
Ford, J., Cornforth, D., Hoggard, P. G., Cutherbertson, Z., Meaden, E. R., Williams, I., . . . Khoo, S. H. (2004). Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.. Antiviral Therapy, 9(1), 77-84.
Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen (Journal article)
Isaac, A., Taylor, S., Cane, P., Smit, E., Gibbons, S., White, D. J., . . . Back, D. (2004). Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen. J Antimicrob Chemother, 54(2), 498-502.
Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen. (Journal article)
Boffito, M., Dicckinson, L., Hill, A., Back, D., Moyle, G., Nelson, M., . . . Pozniak, A. (2004). Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen.. Antiviral Therapy, 9(3), 423-429.
Pharmacology update: drug-drug interactions and ethnic and sex differences. (Journal article)
Back, D. J., Dickinson, L., Canta, F., & Khoo, S. (2004). Pharmacology update: drug-drug interactions and ethnic and sex differences.. HIV/AIDS Annual Update 2004.
Steady-state pharmacokinetics of saquinavair hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients. (Journal article)
Boffito, M., Dickinson, L., Hill, A., Back, D., Moyle, G., Nelson, M., . . . Pozniak, A. (2004). Steady-state pharmacokinetics of saquinavair hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients.. Journal of Acquired Immune Deficiency Syndrome., 37(3), 1376-1384.
The intracellular pharmacology of antiretroviral protease inhibitors (Journal article)
Ford, J., Khoo, S. H., & Back, D. J. (2004). The intracellular pharmacology of antiretroviral protease inhibitors. Journal of Antimicrobial Chemotherapy.
2003
Treating Advanced HIV Infection (Journal article)
Boffito, M., Bonora, S., Sinicco, A., Raiteri, R., Milia, M. G., Khoo, S. H., . . . Di Perri, G. (2003). Treating Advanced HIV Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes, 34(3), 344-345. doi:10.1097/00126334-200311010-00014DOI: 10.1097/00126334-200311010-00014
Treating advanced HIV infection (Journal article)
Boffito, M., Bonora, S., Sinicco, A., Raiteri, R., Milia, M. G., Khoo, S. H., . . . Di Perri, G. (2003). Treating advanced HIV infection. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 34(3), 344-345. doi:10.1097/00126334-200311010-00014DOI: 10.1097/00126334-200311010-00014
Expression of P-glycoprotein, multidrug-resistance proteins 1 and 2 in CEM, CEM<sub>VBL</sub>, CEM<sub>E1000</sub>, MDCKII<sub>MRP1</sub> and MDCKII<sub>MRP2</sub> cell lines (Journal article)
Owen, A., Hartkoorn, R. C., Khoo, S., & Back, D. (2003). Expression of P-glycoprotein, multidrug-resistance proteins 1 and 2 in CEM, CEM<sub>VBL</sub>, CEM<sub>E1000</sub>, MDCKII<sub>MRP1</sub> and MDCKII<sub>MRP2</sub> cell lines. AIDS, 17(15), 2276-2278. doi:10.1097/00002030-200310170-00024DOI: 10.1097/00002030-200310170-00024
Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes (Journal article)
Janneh, O., Haggard, P., Tjia, J. F., Jones, S. P., Khoo, S. H., Maher, B., . . . Pirmohamed, M. (2003). Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes. ANTIVIRAL THERAPY, 8(5), 417-426. Retrieved from https://www.webofscience.com/
Ketoconazole and lopinavir/ritonavir coadministration: Boosting beyond boosting (Journal article)
Boffito, M., Bonora, S., Sales, P., Dal Conte, I., Sinicco, A., Hoggard, P. G., . . . Di Perri, G. (2003). Ketoconazole and lopinavir/ritonavir coadministration: Boosting beyond boosting. AIDS RESEARCH AND HUMAN RETROVIRUSES, 19(10), 941-942. doi:10.1089/088922203322493148DOI: 10.1089/088922203322493148
Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression (Journal article)
Ford, J., Meaden, E. R., Hoggard, P. G., Dalton, M., Newton, P., Williams, I., . . . Back, D. J. (2003). Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 52(3), 354-358. doi:10.1093/jac/dkg381DOI: 10.1093/jac/dkg381
Pharmacokinetic drug interactions with nevirapine. (Journal article)
Back, D., Gibbons, S., & Khoo, S. (2003). Pharmacokinetic drug interactions with nevirapine.. Journal of acquired immune deficiency syndromes (1999), 34 Suppl 1, S8-14. doi:10.1097/00126334-200309011-00003DOI: 10.1097/00126334-200309011-00003
Protein binding in antiretroviral therapies (Journal article)
Boffito, M., Back, D. J., Blaschke, T. F., Rowland, M., Bertz, R. J., Gerber, J. G., & Miller, V. (2003). Protein binding in antiretroviral therapies. AIDS RESEARCH AND HUMAN RETROVIRUSES, 19(9), 825-835. doi:10.1089/088922203769232629DOI: 10.1089/088922203769232629
The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells in vitro (Journal article)
Chandler, B., Almond, L., Ford, J., Owen, A., Hoggard, P., Khoo, S., & Back, D. (2003). The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells in vitro. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 33(5), 551-556. doi:10.1097/00126334-200308150-00001DOI: 10.1097/00126334-200308150-00001
A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy (Journal article)
Sephton, V., Farquharson, R. G., Topping, J., Quenby, S. M., Cowan, C., Back, D. J., & Toh, C. H. (2003). A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy. OBSTETRICS AND GYNECOLOGY, 101(6), 1307-1311. doi:10.1016/S0029-7844(03)00340-5DOI: 10.1016/S0029-7844(03)00340-5
Intracellular indinavir pharmacokinetics in HIV-infected patients: comparison with plasma pharmacokinetics. (Journal article)
Hennessy, M., Clarke, S., Spiers, J. P., Mulcahy, F., Kelleher, D., Meadon, E., . . . Barry, M. (2003). Intracellular indinavir pharmacokinetics in HIV-infected patients: comparison with plasma pharmacokinetics.. Antiviral therapy, 8(3), 191-198.
Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring (Journal article)
Boffito, M., Back, D. J., Hoggard, P. G., Caci, A., Bonora, S., Raiteri, R., . . . Di Perri, G. (2003). Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring. AIDS, 17(7), 1107-1108. doi:10.1097/00002030-200305020-00029DOI: 10.1097/00002030-200305020-00029
The role of clinical pharmacology in optimizing antiretroviral therapy (Journal article)
Back, D. J., & Khoo, S. H. (2003). The role of clinical pharmacology in optimizing antiretroviral therapy. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 55(5), 473-476. doi:10.1046/j.1365-2125.2003.01843.xDOI: 10.1046/j.1365-2125.2003.01843.x
A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets (Journal article)
Ford, J., Hoggard, P. G., Owen, A., Khoo, S. H., & Back, D. J. (2003). A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets. JOURNAL OF IMMUNOLOGICAL METHODS, 274(1-2), 129-137. doi:10.1016/S0022-1759(02)00509-4DOI: 10.1016/S0022-1759(02)00509-4
Differential expression of human immunodeficiency virus coreceptors, by CEM, CEM<sub>VBL</sub>, and CEM E<sub>1000</sub> cells (Journal article)
Owen, A., Chandler, B., Ford, J., Khoo, S., & Back, D. (2003). Differential expression of human immunodeficiency virus coreceptors, by CEM, CEM<sub>VBL</sub>, and CEM E<sub>1000</sub> cells. JOURNAL OF INFECTIOUS DISEASES, 187(5), 874-875. doi:10.1086/367902DOI: 10.1086/367902
Lopinavir/ritonavir absorption in a gastrectomized patient. (Journal article)
Boffito, M., Lucchini, A., Maiello, A., Dal Conte, I., Hoggard, P. G., Back, D. J., & Di Perri, G. (2003). Lopinavir/ritonavir absorption in a gastrectomized patient.. AIDS (London, England), 17(1), 136-137. doi:10.1097/00002030-200301030-00023DOI: 10.1097/00002030-200301030-00023
Enzymatic assay for measurement of intracellular DXG triphosphate concentrations in peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected patients (Journal article)
Kewn, S., Wang, L. H., Hoggard, P. G., Rousseau, F., Hart, R., MacNeela, J. P., . . . Back, D. J. (2003). Enzymatic assay for measurement of intracellular DXG triphosphate concentrations in peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 47(1), 255-261. doi:10.1128/AAC.47.1.255-261.2003DOI: 10.1128/AAC.47.1.255-261.2003
Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes (Journal article)
Janneh, O., Hoggard, P. G., Tjia, J. F., Jones, S. P., Khoo, S. H., Maher, B., . . . Pirmohamed, M. (2003). Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes. Antivir Ther, 8(5), 417-426. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/14640389
Intracellular disposition and metabolic effects of zidovudine, stavudine, and four protease inhibitors in cultured adipocytes (Journal article)
Janneh, O., Hoggard, P. G., Tjia, J. F., Jones, S. P., Khoo, S. H., Maher, B., . . . Pirmohamed, M. (2003). Intracellular disposition and metabolic effects of zidovudine, stavudine, and four protease inhibitors in cultured adipocytes. Antiviral Therapy, 8(5), 417-426.
Intracellular indinavir pharmacokinetics in HIV-infected patients; comparison with plasma pharmacokinetics. (Journal article)
Hennessy, M., Clarke, S., Spiers, J. P., Mulcahy, F., Kelleher, D., Meaden, E., . . . Barry, M. (2003). Intracellular indinavir pharmacokinetics in HIV-infected patients; comparison with plasma pharmacokinetics.. Antiviral Therapy, 8, 191-198.
Lopinavir/ritonavir absorption in a gastrectomized patient (Journal article)
Boffito, M., Lucchini, A., Maiello, A., Dal Conte, I., Hoggard, P. G., Back, D. J., & Di Perri, G. (2003). Lopinavir/ritonavir absorption in a gastrectomized patient. AIDS, 17(1), 136-137. doi:10.1097/00002030-200301030-00023DOI: 10.1097/00002030-200301030-00023
Pharmacokinetic drug interactions with nevirapine (Journal article)
Back, D., Gibbons, S., & Khoo, S. (2003). Pharmacokinetic drug interactions with nevirapine. J Acquir Immune Defic Syndr, 34 Sup, S8-S14. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/14562853
The relationship between nevirapine plasma concentrations and abnormal liver function tests. (Journal article)
Almond, L. M., Boffito, M., Hoggard, P. G., Bonora, S., Raiteri, R., Reynolds, H. E., . . . diPerri, G. (2003). The relationship between nevirapine plasma concentrations and abnormal liver function tests.. AIDS Research and Human Retroviruses, 20, 716-720.
2002
Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea (Journal article)
Hoggard, P. G., Kewn, S., Maherbe, A., Wood, R., Almond, L. M., Sales, S. D., . . . Khoo, S. H. (2002). Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea. AIDS, 16(18), 2439-2446. doi:10.1097/00002030-200212060-00009DOI: 10.1097/00002030-200212060-00009
Pharmacokinetics of saquinavir co-administered with cimetidine (Journal article)
Boffito, M., Carriero, P., Trentini, L., Raiteri, R., Bonora, S., Sinicco, A., . . . Di Perri, G. (2002). Pharmacokinetics of saquinavir co-administered with cimetidine. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 50(6), 1081-1084. doi:10.1093/jac/dkf232DOI: 10.1093/jac/dkf232
Lopinavir measurement in pleural effusion in a human immunodeficiency virus type 1-infected patient with Kaposi's sarcoma (Journal article)
Boffito, M., Hoggard, P. G., Back, D. J., Bonora, S., Maiello, S., Maiello, A., . . . Di Perri, G. (2002). Lopinavir measurement in pleural effusion in a human immunodeficiency virus type 1-infected patient with Kaposi's sarcoma. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 46(11), 3684-3685. doi:10.1128/AAC.46.11.3684-3685.2002DOI: 10.1128/AAC.46.11.3684-3685.2002
Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics (Journal article)
Boffito, M., Arnaudo, I., Raiteri, R., Bonora, S., Sinicco, A., Di Garbo, A., . . . Di Perri, G. (2002). Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics. AIDS, 16(15), 2081-2083. doi:10.1097/00002030-200210180-00015DOI: 10.1097/00002030-200210180-00015
Intracellular accumulation of human immunodeficiency virus protease inhibitors (Journal article)
Khoo, S. H., Hoggard, P. G., Williams, I., Meaden, E. R., Newton, P., Wilkins, E. G., . . . Back, D. J. (2002). Intracellular accumulation of human immunodeficiency virus protease inhibitors. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 46(10), 3228-3235. doi:10.1128/AAC.46.10.3228-3235.2002DOI: 10.1128/AAC.46.10.3228-3235.2002
P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals (Journal article)
Meaden, E. R., Hoggard, P. G., Newton, P., Tjia, J. F., Aldam, D., Cornforth, D., . . . Khoo, S. H. (2002). P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 50(4), 583-588. doi:10.1093/jac/dkf161DOI: 10.1093/jac/dkf161
Simultaneous determination of rifampicin and efavirenz in plasma. (Journal article)
Boffito, M., Tija, J., Reynolds, H. E., Hoggard, P. G., Bonora, S., Di Perri, G., & Back, D. J. (2002). Simultaneous determination of rifampicin and efavirenz in plasma.. Therapeutic drug monitoring, 24(5), 670-674. doi:10.1097/00007691-200210000-00015DOI: 10.1097/00007691-200210000-00015
The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects (Journal article)
Boffito, M., Hoggard, P. G., Reynolds, H. E., Bonora, S., Meaden, E. R., Sinicco, A., . . . Back, D. J. (2002). The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 54(3), 262-268. doi:10.1046/j.1365-2125.2002.01663.xDOI: 10.1046/j.1365-2125.2002.01663.x
The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. (Journal article)
Margolis, D. M., Kewn, S., Coull, J. J., Ylisastigui, L., Turner, D., Wise, H., . . . Back, D. (2002). The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA.. Journal of acquired immune deficiency syndromes (1999), 31(1), 45-49. doi:10.1097/00126334-200209010-00006DOI: 10.1097/00126334-200209010-00006
Pharmacokinetic evaluation of indinavir and indinavir/ritonavir-containing antiretroviral regimens in a clinical setting (Journal article)
Boffito, M., Bonora, S., Raiteri, R., Reynolds, H. E., Hoggard, P. G., Sinicco, A., . . . Di Perri, G. (2002). Pharmacokinetic evaluation of indinavir and indinavir/ritonavir-containing antiretroviral regimens in a clinical setting. THERAPEUTIC DRUG MONITORING, 24(4), 574-576. doi:10.1097/00007691-200208000-00021DOI: 10.1097/00007691-200208000-00021
Therapeutic drug monitoring. (Journal article)
Back, D., Khoo, S., & Gibbons, S. (2002). Therapeutic drug monitoring.. Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002), 1(3), 84-85. doi:10.1177/154510970200100301DOI: 10.1177/154510970200100301
α<sub>1</sub>-acid glycoprotein levels in human immunodeficiency virus-infected subjects on antiretroviral regimens (Journal article)
Boffito, M., Sciole, K., Raiteri, R., Bonora, S., Hoggard, P. G., Back, D. J., & Di Perri, G. (2002). α<sub>1</sub>-acid glycoprotein levels in human immunodeficiency virus-infected subjects on antiretroviral regimens. DRUG METABOLISM AND DISPOSITION, 30(7), 859-860. doi:10.1124/dmd.30.7.859DOI: 10.1124/dmd.30.7.859
Multidrug resistance and response to antiretroviral treatment. (Journal article)
Dietrich, C. G., Geier, A., Matern, S., & Gartung, C. (2002). Multidrug resistance and response to antiretroviral treatment.. Lancet (London, England), 359(9323), 2114. doi:10.1016/s0140-6736(02)08921-3DOI: 10.1016/s0140-6736(02)08921-3
Intracellular carbovir triphosphate levels in patients taking abacavir once a day. (Journal article)
Harris, M., Back, D., Kewn, S., Jutha, S., Marina, R., & Montaner, J. S. G. (2002). Intracellular carbovir triphosphate levels in patients taking abacavir once a day.. AIDS (London, England), 16(8), 1196-1197. doi:10.1097/00002030-200205240-00021DOI: 10.1097/00002030-200205240-00021
Therapeutic drug monitoring in HIV infection: current status and future directions. (Journal article)
Back, D., Gatti, G., Fletcher, C., Garaffo, R., Haubrich, R., Hoetelmans, R., . . . Perno, C. -F. (2002). Therapeutic drug monitoring in HIV infection: current status and future directions.. AIDS (London, England), 16 Suppl 1, S5-37. doi:10.1097/00002030-200203001-00002DOI: 10.1097/00002030-200203001-00002
Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir (Journal article)
Clarke, S., Mulcahy, F., Bergin, C., Reynolds, H., Boyle, N., Barry, M., & Back, D. J. (2002). Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir. CLINICAL INFECTIOUS DISEASES, 34(8), 1143-1145. doi:10.1086/339541DOI: 10.1086/339541
Determination of P-gp and MRP1 expression and function in peripheral blood mononuclear cells in vivo (Journal article)
Meaden, E. R., Hoggard, P. G., Khoo, S. H., & Back, D. J. (2002). Determination of P-gp and MRP1 expression and function in peripheral blood mononuclear cells in vivo. JOURNAL OF IMMUNOLOGICAL METHODS, 262(1-2), 159-165. doi:10.1016/S0022-1759(02)00020-0DOI: 10.1016/S0022-1759(02)00020-0
Undefined duration of opiate withdrawal induced by efavirenz in drug users with HIV infection and undergoing chronic methadone treatment (Journal article)
Boffito, M., Rossati, A., Reynolds, H. E., Hoggard, P. G., Back, D. J., & Di Perri, G. (2002). Undefined duration of opiate withdrawal induced by efavirenz in drug users with HIV infection and undergoing chronic methadone treatment. AIDS RESEARCH AND HUMAN RETROVIRUSES, 18(5), 341-342. doi:10.1089/088922202753519115DOI: 10.1089/088922202753519115
Erratum: Antiretroviral drug concentrations in semen of HIV-infected men: Differential penetration of indinavir, ritonavir and saquinavir (Journal of Antimicrobial Chemotherapy (2001) vol. 48 (351-354)) (Journal article)
Taylor, S., Back, D. J., Drake, S. M., Workman, J., Reynolds, H., Gibbons, S. E., . . . Pillay, D. (2002). Erratum: Antiretroviral drug concentrations in semen of HIV-infected men: Differential penetration of indinavir, ritonavir and saquinavir (Journal of Antimicrobial Chemotherapy (2001) vol. 48 (351-354)). Journal of Antimicrobial Chemotherapy, 49(1), 227.
CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir <i>in vitro</i> (Journal article)
Eagling, V. A., Wiltshire, H., Whitcombe, I. W. A., & Back, D. J. (2002). CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir <i>in vitro</i>. XENOBIOTICA, 32(1), 1-17. doi:10.1080/00498250110085845DOI: 10.1080/00498250110085845
Development of enzymatic assays for quantification of intracellular lamivudine and carbovir triphosphate levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients (Journal article)
Kewn, S., Hoggard, P. G., Sales, S. D., Jones, K., Maher, B., Khoo, S. H., & Back, D. J. (2002). Development of enzymatic assays for quantification of intracellular lamivudine and carbovir triphosphate levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 46(1), 135-143. doi:10.1128/AAC.46.1.135-143.2002DOI: 10.1128/AAC.46.1.135-143.2002
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study (Journal article)
Fellay, J., Marzolini, C., Meaden, E. R., Back, D. J., Buclin, T., Chave, J. P., . . . Telenti, A. (2002). Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. LANCET, 359(9300), 30-36. doi:10.1016/S0140-6736(02)07276-8DOI: 10.1016/S0140-6736(02)07276-8
Intracellular accumulation of human immunodeficiency virus protease inhibitors (Journal article)
Khoo, S., Hoggard, P. G., Williams, I., Meaden, E. R., Newton, P., Wilkins, E. G., . . . Back, D. (2002). Intracellular accumulation of human immunodeficiency virus protease inhibitors. Antimicrob Agents Chemother, 46(10), 3228-3235.
Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules (Journal article)
Hoggard, P. G., & Back, D. J. (2002). Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules. CURRENT OPINION IN INFECTIOUS DISEASES, 15(1), 3-8. doi:10.1097/00001432-200202000-00002DOI: 10.1097/00001432-200202000-00002
Observations of HIV-1 genotypic drug resistance in a trial of four reverse transcriptase inhibitors (Quattro Trial). (Journal article)
Observations of HIV-1 genotypic drug resistance in a trial of four reverse transcriptase inhibitors (Quattro Trial). (2002). Antiviral therapy, 7(1), 11-20.
Therapeutic Drug Monitoring in HIV infection:current status and future directions. (Journal article)
Back, D. J., Gatti, G., Fletcher, C., Garaffo, R., Haubrich, R., Hoetelmans, R., . . . Perno, C. F. (2002). Therapeutic Drug Monitoring in HIV infection:current status and future directions.. AIDS, 16(Suppl), S1-S35.
Therapeutic drug monitoring (Journal article)
Back, D., Khoo, S., & Gibbons, S. (2002). Therapeutic drug monitoring. J Int Assoc Physicians AIDS Care (Chic), 1(3), 84-85.
2001
Principles and practice of HIV-protease inhibitor pharmacoenhancement. (Journal article)
Moyle, G. J., & Back, D. (2001). Principles and practice of HIV-protease inhibitor pharmacoenhancement.. HIV medicine, 2(2), 105-113. doi:10.1046/j.1468-1293.2001.00063.xDOI: 10.1046/j.1468-1293.2001.00063.x
Therapeutic drug monitoring as a tool in treating HIV infection (Journal article)
Khoo, S. H., Gibbons, S. E., & Back, D. J. (2001). Therapeutic drug monitoring as a tool in treating HIV infection. AIDS, 15, S171-S181. doi:10.1097/00002030-200100005-00021DOI: 10.1097/00002030-200100005-00021
Zidovudine phosphorylation and mitochondrial toxicity <i>in vitro</i> (Journal article)
Sales, S. D., Hoggard, P. G., Sunderland, D., Khoo, S., Hart, C. A., & Back, D. J. (2001). Zidovudine phosphorylation and mitochondrial toxicity <i>in vitro</i>. TOXICOLOGY AND APPLIED PHARMACOLOGY, 177(1), 54-58. doi:10.1006/taap.2001.9288DOI: 10.1006/taap.2001.9288
Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users (Journal article)
Clarke, S. M., Mulcahy, F. M., Tjia, J., Reynolds, H. E., Gibbons, S. E., Barry, M. G., & Back, D. J. (2001). Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. CLINICAL INFECTIOUS DISEASES, 33(9), 1595-1597. doi:10.1086/322519DOI: 10.1086/322519
Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men (Journal article)
Taylor, S., Reynolds, H., Sabin, C. A., Drake, S. M., White, D. J., Back, D. J., & Pillay, D. (2001). Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men. AIDS, 15(15), 2051-2053. doi:10.1097/00002030-200110190-00022DOI: 10.1097/00002030-200110190-00022
Expression of P-glycoprotein and multidrug resistance-associated protein in healthy volunteers and HIV-infected patients (Journal article)
Meaden, E. R., Hoggard, P. G., Maher, B., Khoo, S. H., & Back, D. J. (2001). Expression of P-glycoprotein and multidrug resistance-associated protein in healthy volunteers and HIV-infected patients. AIDS RESEARCH AND HUMAN RETROVIRUSES, 17(14), 1329-1332. doi:10.1089/08892220152596588DOI: 10.1089/08892220152596588
P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? (Journal article)
Jones, K., Bray, P. G., Khoo, S. H., Davey, R. A., Meaden, E. R., Ward, S. A., & Back, D. J. (2001). P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?. AIDS, 15(11), 1353-1358. doi:10.1097/00002030-200107270-00004DOI: 10.1097/00002030-200107270-00004
The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz (Journal article)
Clarke, S. M., Mulcahy, F. M., Tjia, J., Reynolds, H. E., Gibbons, S. E., Barry, M. G., & Back, D. J. (2001). The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 51(3), 213-217. doi:10.1046/j.1365-2125.2001.00342.xDOI: 10.1046/j.1365-2125.2001.00342.x
The role of therapeutic drug monitoring in treatment of HIV infection (Journal article)
Back, D. J., Khoo, S. H., Gibbons, S. E., & Merry, C. (2001). The role of therapeutic drug monitoring in treatment of HIV infection. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 51(4), 301-308. doi:10.1046/j.1365-2125.2001.01380.xDOI: 10.1046/j.1365-2125.2001.01380.x
Differences in the intracellular accumulation of HIV protease inhibitors <i>in vitro</i> and the effect of active transport (Journal article)
Jones, K., Hoggard, P. G., Sales, S. D., Khoo, S., Davey, R., & Back, D. J. (2001). Differences in the intracellular accumulation of HIV protease inhibitors <i>in vitro</i> and the effect of active transport. AIDS, 15(6), 675-681. doi:10.1097/00002030-200104130-00002DOI: 10.1097/00002030-200104130-00002
Zidovudine phosphorylation determined sequentially over 12 months in human immunodeficiency virus-infected patients with or without previous exposure to antiretroviral agents (Journal article)
Hoggard, P. G., Lloyd, J., Khoo, S. H., Barry, M. G., Dann, L., Gibbons, S. E., . . . Back, D. J. (2001). Zidovudine phosphorylation determined sequentially over 12 months in human immunodeficiency virus-infected patients with or without previous exposure to antiretroviral agents. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 45(3), 976-980. doi:10.1128/AAC.35.3.976-980.2001DOI: 10.1128/AAC.35.3.976-980.2001
Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir (Journal article)
Holladay, J. W., Dewey, M. J., Michniak, B. B., Wiltshire, H., Halberg, D. L., Weigl, P., . . . Back, D. J. (2001). Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir. DRUG METABOLISM AND DISPOSITION, 29(3), 299-303. Retrieved from https://www.webofscience.com/
Effect of α<sub>1</sub>-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir <i>in vitro</i> (Journal article)
Jones, K., Hoggard, P. G., Khoo, S., Maher, B., & Back, D. J. (2001). Effect of α<sub>1</sub>-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir <i>in vitro</i>. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 51(1), 99-102. doi:10.1046/j.1365-2125.2001.01324.xDOI: 10.1046/j.1365-2125.2001.01324.x
Influence of prior exposure to zidovudine on stavudine phosphorylation in vivo and ex vivo (Journal article)
Hoggard, P. G., Sales, S. D., Phiboonbanakit, D., Lloyd, J., Maher, B. A., Khoo, S. H., . . . Back, D. J. (2001). Influence of prior exposure to zidovudine on stavudine phosphorylation in vivo and ex vivo. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 45(2), 577-582. doi:10.1128/AAC.45.2.577-582.2001DOI: 10.1128/AAC.45.2.577-582.2001
The pharmacogenomics of HIV therapy. (Journal article)
Pirmohamed, M., & Back, D. J. (2001). The pharmacogenomics of HIV therapy.. The pharmacogenomics journal, 1(4), 243-253. doi:10.1038/sj.tpj.6500069DOI: 10.1038/sj.tpj.6500069
The role of therapeutic drug monitoring in treatment of HIV infection. (Journal article)
Back, D. J., Khoo, S. H., Gibbons, S. E., & Merry, C. (2001). The role of therapeutic drug monitoring in treatment of HIV infection.. British journal of clinical pharmacology, 52 Suppl 1, 89S-96S. doi:10.1046/j.1365-2125.2001.0520s1089.xDOI: 10.1046/j.1365-2125.2001.0520s1089.x
Therapeutic drug monitoring of anti-HIV drugs (Journal article)
Back, D. J., Khoo, S. H., Gibbons, S. E., Reynolds, H., Tjia, J. F., & Merry, C. (2001). Therapeutic drug monitoring of anti-HIV drugs. OPTIMAL DOSE IDENTIFICATION, 1220, 145-160. doi:10.1016/S0531-5131(01)00294-1DOI: 10.1016/S0531-5131(01)00294-1
2000
The intracellular activation of lamivudine (3TC) and determination of 2′-deoxycytidine-5′-triphosphate (dCTP) pools in the presence and absence of various drugs in HepG2 cells (Journal article)
Kewn, S., Hoggard, P. G., Sales, S. D., Johnson, M. A., & Back, D. J. (2000). The intracellular activation of lamivudine (3TC) and determination of 2′-deoxycytidine-5′-triphosphate (dCTP) pools in the presence and absence of various drugs in HepG2 cells. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 50(6), 597-604. Retrieved from https://www.webofscience.com/
Pharmacokinetics of zidovudine phosphorylation in human immunodeficiency virus-positive Thai patients and healthy volunteers (Journal article)
Wattanagoon, Y., Bangchang, K. N., Hoggard, P. G., Khoo, S. H., Gibbons, S. E., Phiboonbhanakit, D., . . . Back, D. J. (2000). Pharmacokinetics of zidovudine phosphorylation in human immunodeficiency virus-positive Thai patients and healthy volunteers. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 44(7), 1986-1989. doi:10.1128/AAC.44.7.1986-1989.2000DOI: 10.1128/AAC.44.7.1986-1989.2000
Pharmacological implications of lengthened in-utero exposure to nevirapine. (Journal article)
Taylor, G. P., Lyall, E. G., Back, D., Ward, C., & Tudor-Williams, G. (2000). Pharmacological implications of lengthened in-utero exposure to nevirapine.. Lancet (London, England), 355(9221), 2134-2135. doi:10.1016/s0140-6736(00)02383-7DOI: 10.1016/s0140-6736(00)02383-7
Pharmacokinetics of nelfinavir and nevirapine in a patient with end-stage renal failure on continuous ambulatory peritoneal dialysis. (Journal article)
Taylor, S., Little, J., Halifax, K., Drake, S., & Back, D. (2000). Pharmacokinetics of nelfinavir and nevirapine in a patient with end-stage renal failure on continuous ambulatory peritoneal dialysis.. The Journal of antimicrobial chemotherapy, 45(5), 716-717. doi:10.1093/jac/45.5.716DOI: 10.1093/jac/45.5.716
Therapeutic drug monitoring of antiretrovirals in human immunodeficiency virus infection (Journal article)
Back, D. J., Khoo, S. H., Gibbons, S. E., Barry, M. G., & Merry, C. (2000). Therapeutic drug monitoring of antiretrovirals in human immunodeficiency virus infection. THERAPEUTIC DRUG MONITORING, 22(1), 122-126. doi:10.1097/00007691-200002000-00026DOI: 10.1097/00007691-200002000-00026
Correlation between intracellular pharmacological activation of nucleoside analogues and HIV suppression <i>in vitro</i> (Journal article)
Hoggard, P. G., Sales, S. D., Kewn, S., Sunderland, D., Khoo, S. H., Hart, C. A., & Back, D. J. (2000). Correlation between intracellular pharmacological activation of nucleoside analogues and HIV suppression <i>in vitro</i>. ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 11(6), 353-358. doi:10.1177/095632020001100601DOI: 10.1177/095632020001100601
Current uses and future hopes for clinical pharmacology in the management of HIV infection. (Journal article)
Back, D., Khoo, S., Maher, B., & Gibbons, S. (2000). Current uses and future hopes for clinical pharmacology in the management of HIV infection.. HIV medicine, 1 Suppl 2, 12-17. doi:10.1046/j.1468-1293.2000.00001.xDOI: 10.1046/j.1468-1293.2000.00001.x
Re: 'Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir'. (Journal article)
Back, D. J. (2000). Re: 'Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir'.. British journal of clinical pharmacology, 50(2), 85. doi:10.1046/j.1365-2125.2000.00246.xDOI: 10.1046/j.1365-2125.2000.00246.x
1999
Effect of tuberculosis therapy on nevirapine trough plasma concentrations (Journal article)
Dean, G. L., Back, D. J., & de Ruiter, A. (1999). Effect of tuberculosis therapy on nevirapine trough plasma concentrations. AIDS, 13(17), 2489-2490. doi:10.1097/00002030-199912030-00029DOI: 10.1097/00002030-199912030-00029
The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. (Journal article)
Moore, K. H., Barrett, J. E., Shaw, S., Pakes, G. E., Churchus, R., Kapoor, A., . . . Back, D. (1999). The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1.. AIDS (London, England), 13(16), 2239-2250. doi:10.1097/00002030-199911120-00006DOI: 10.1097/00002030-199911120-00006
Interaction of sildenafil and indinavir when co-administered to HIV-positive patients (Journal article)
Merry, C., Barry, M. G., Ryan, M., Tjia, J. F., Hennessy, M., Eagling, V. A., . . . Back, D. J. (1999). Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. AIDS, 13(15), F101-F107. Retrieved from https://www.webofscience.com/
Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components (Journal article)
Eagling, V. A., Profit, L., & Back, D. J. (1999). Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 48(4), 543-552. Retrieved from https://www.webofscience.com/
Pharmacological issues relating to viral resistance (Conference Paper)
Back, D. J. (1999). Pharmacological issues relating to viral resistance. In INFECTION Vol. 27 (pp. S42-S44). doi:10.1007/BF02561671DOI: 10.1007/BF02561671
Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors (Journal article)
Profit, L., Eagling, V. A., & Back, D. J. (1999). Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS, 13(13), 1623-1627. doi:10.1097/00002030-199909100-00004DOI: 10.1097/00002030-199909100-00004
The rabbit study: Ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients (Journal article)
Churchill, D. R., Pym, A. S., Galpin, S., Foxall, R., Stainsby, C., Clarke, J. R., . . . Weber, J. N. (1999). The rabbit study: Ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients. AIDS RESEARCH AND HUMAN RETROVIRUSES, 15(13), 1181-1189. doi:10.1089/088922299310278DOI: 10.1089/088922299310278
Hydroxyurea-induced neurotoxicity in HIV disease. (Journal article)
Barry, M., Clarke, S., Mulcahy, F., & Back, D. (1999). Hydroxyurea-induced neurotoxicity in HIV disease.. AIDS (London, England), 13(12), 1592-1594. doi:10.1097/00002030-199908200-00028DOI: 10.1097/00002030-199908200-00028
Intracellular activation of 2′,3′-dideoxyinosine and drug interactions <i>in vitro</i> (Journal article)
Kewn, S., Hoggard, P. G., Henry-Mowatt, J. S., Veal, G. J., Sales, S. D., Barry, M. G., & Back, D. J. (1999). Intracellular activation of 2′,3′-dideoxyinosine and drug interactions <i>in vitro</i>. AIDS RESEARCH AND HUMAN RETROVIRUSES, 15(9), 793-802. doi:10.1089/088922299310692DOI: 10.1089/088922299310692
Preclinical and <i>in vitro</i> assessment of the potential of D0870, an antifungal agent, for producing clinical drug interactions (Journal article)
McKillop, D., Back, D. J., McCormick, A. D., Evans, J. A., & Tjia, J. (1999). Preclinical and <i>in vitro</i> assessment of the potential of D0870, an antifungal agent, for producing clinical drug interactions. XENOBIOTICA, 29(4), 395-408. doi:10.1080/004982599238579DOI: 10.1080/004982599238579
Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. (Journal article)
Barry, M., Mulcahy, F., Merry, C., Gibbons, S., & Back, D. (1999). Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.. Clinical pharmacokinetics, 36(4), 289-304. doi:10.2165/00003088-199936040-00004DOI: 10.2165/00003088-199936040-00004
Poor penetration of the male genital tract by HIV-1 protease inhibitors (Journal article)
Taylor, S., Back, D. J., Workman, J., Drake, S. M., White, D. J., Choudhury, B., . . . Pillay, D. (1999). Poor penetration of the male genital tract by HIV-1 protease inhibitors. AIDS, 13(7), 859-860. doi:10.1097/00002030-199905070-00017DOI: 10.1097/00002030-199905070-00017
The effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole <i>N</i>-hydroxylation (Journal article)
Gill, H. J., Tjia, J. F., Kitteringham, N. R., Pirmohamed, M., Back, D. J., & Park, B. K. (1999). The effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole <i>N</i>-hydroxylation. PHARMACOGENETICS, 9(1), 43-53. doi:10.1097/00008571-199902000-00007DOI: 10.1097/00008571-199902000-00007
1998
Effect of ribavirin on zidovudine efficacy and toxicity <i>in vitro</i>:: A concentration-dependent interaction (Journal article)
Sim, S. M., Hoggard, P. G., Sales, S. D., Phiboonbanakit, D., Hart, C. A., & Back, D. J. (1998). Effect of ribavirin on zidovudine efficacy and toxicity <i>in vitro</i>:: A concentration-dependent interaction. AIDS RESEARCH AND HUMAN RETROVIRUSES, 14(18), 1661-1667. doi:10.1089/aid.1998.14.1661DOI: 10.1089/aid.1998.14.1661
Nelfinavir and nevirapine interaction? (Journal article)
Mulcahy, F., Barry, M., Merry, C., & Back, D. (1998). Nelfinavir and nevirapine interaction?. AIDS (London, England), 12(17), 2361.
The role of CYP2C in the <i>in vitro</i> bioactivation of the contraceptive steroid desogestrel (Journal article)
Gentile, D. M., Verhoeven, C. H. J., Shimada, T., & Back, D. J. (1998). The role of CYP2C in the <i>in vitro</i> bioactivation of the contraceptive steroid desogestrel. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 287(3), 975-982. Retrieved from https://www.webofscience.com/
Hyperlipidaemia following treatment with protease inhibitors in patients with HIV-I infection (Journal article)
Churchill, D. R., Pym, A. S., Babiker, A. G., Back, D. J., & Weber, J. N. (1998). Hyperlipidaemia following treatment with protease inhibitors in patients with HIV-I infection. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 46(5), 518-519. Retrieved from https://www.webofscience.com/
The pharmacokinetics of combination therapy with nelfinavir plus nevirapine (Journal article)
Merry, C., Barry, M. G., Mulcahy, F., Ryan, M., Tjia, J. F., Halifax, K. L., . . . Back, D. J. (1998). The pharmacokinetics of combination therapy with nelfinavir plus nevirapine. AIDS, 12(10), 1163-1167. doi:10.1097/00002030-199810000-00008DOI: 10.1097/00002030-199810000-00008
Variability in trough plasma saquinavir concentrations in HIV patients - a case for therapeutic drug monitoring (Journal article)
Barry, M. G., Merry, C., Lloyd, J., Halifax, K., Carey, P., Mulcahy, F., & Back, D. J. (1998). Variability in trough plasma saquinavir concentrations in HIV patients - a case for therapeutic drug monitoring. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 45(5), 501-502. Retrieved from https://www.webofscience.com/
Antiretroviral therapy for patients with HIV disease (Journal article)
Barry, M., Mulcahy, F., & Back, D. J. (1998). Antiretroviral therapy for patients with HIV disease. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 45(3), 221-228. doi:10.1046/j.1365-2125.1998.00673.xDOI: 10.1046/j.1365-2125.1998.00673.x
Ritonavir pharmacokinetics alone and in combination with saquinavir in HIV-infected patients (Journal article)
Merry, C., Barry, M. G., Mulcahy, F., Tjia, J. F., Halifax, K. L., Heavey, J., . . . Back, D. J. (1998). Ritonavir pharmacokinetics alone and in combination with saquinavir in HIV-infected patients. AIDS, 12(3), 325-327. Retrieved from https://www.webofscience.com/
Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes (Journal article)
Eagling, V. A., Tjia, J. F., & Back, D. J. (1998). Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 45(2), 107-114. doi:10.1046/j.1365-2125.1998.00679.xDOI: 10.1046/j.1365-2125.1998.00679.x
Effect of protease inhibitors on nucleoside analogue phosphorylation <i>in vitro</i> (Journal article)
Hoggard, P. G., Manion, V., Barry, M. G., & Back, D. J. (1998). Effect of protease inhibitors on nucleoside analogue phosphorylation <i>in vitro</i>. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 45(2), 164-167. doi:10.1046/j.1365-2125.1998.00660.xDOI: 10.1046/j.1365-2125.1998.00660.x
1997
Lack of effect of sibutramine an the efficacy of oral contraceptive steroids in healthy women (Journal article)
Back, D. J., Fearn, R., Oliver, S., Stott, D. A., & Wynne, R. D. (1997). Lack of effect of sibutramine an the efficacy of oral contraceptive steroids in healthy women. International Journal of Pharmaceutical Medicine, 11(2), 71-76.
In vitro metabolism of dexamethasone (DEX) in human liver and kidney: The involvement of CYP3A4 and CYP17 (17,20 LYASE) and molecular modelling studies (Journal article)
Tomlinson, E. S., Lewis, D. F. V., Maggs, J. L., Kroemer, H. K., Park, B. K., & Back, D. J. (1997). In vitro metabolism of dexamethasone (DEX) in human liver and kidney: The involvement of CYP3A4 and CYP17 (17,20 LYASE) and molecular modelling studies. BIOCHEMICAL PHARMACOLOGY, 54(5), 605-611. doi:10.1016/S0006-2952(97)00166-4DOI: 10.1016/S0006-2952(97)00166-4
Lamivudine (3TC) phosphorylation and drug interactions in vitro (Journal article)
Kewn, S., Veal, G. J., Hoggard, P. G., Barry, M. G., & Back, D. J. (1997). Lamivudine (3TC) phosphorylation and drug interactions in vitro. BIOCHEMICAL PHARMACOLOGY, 54(5), 589-595. doi:10.1016/S0006-2952(97)00189-5DOI: 10.1016/S0006-2952(97)00189-5
Dexamethasone metabolism in vitro: Species differences (Journal article)
Tomlinson, E. S., Maggs, J. L., Park, B. K., & Back, D. J. (1997). Dexamethasone metabolism in vitro: Species differences. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 62(4), 345-352. doi:10.1016/S0960-0760(97)00038-1DOI: 10.1016/S0960-0760(97)00038-1
In vitro screening of nucleoside analog combinations for potential use in anti-HIV therapy (Journal article)
Veal, G. J., Barry, M. G., Khoo, S. H., & Back, D. J. (1997). In vitro screening of nucleoside analog combinations for potential use in anti-HIV therapy. AIDS RESEARCH AND HUMAN RETROVIRUSES, 13(6), 481-484. doi:10.1089/aid.1997.13.481DOI: 10.1089/aid.1997.13.481
Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients (Journal article)
Merry, C., Barry, M. G., Mulcahy, F., Ryan, M., Heavey, J., Tjia, J. F., . . . Back, D. J. (1997). Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS, 11(4), F29-F33. doi:10.1097/00002030-199704000-00001DOI: 10.1097/00002030-199704000-00001
Saquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV disease. (Journal article)
Merry, C., Mulcahy, F., Barry, M., Gibbons, S., & Back, D. (1997). Saquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV disease.. AIDS (London, England), 11(2), 268-269.
Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir (Journal article)
Eagling, V. A., Back, D. J., & Barry, M. G. (1997). Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 44(2), 190-194. doi:10.1046/j.1365-2125.1997.00644.xDOI: 10.1046/j.1365-2125.1997.00644.x
Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro (Journal article)
Hoggard, P. G., Kewn, S., Barry, M. G., Khoo, S. H., & Back, D. J. (1997). Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 41(6), 1231-1236. doi:10.1128/AAC.41.6.1231DOI: 10.1128/AAC.41.6.1231
Erratum: 'Lack of effect of sibutramine on the efficacy of oral contraceptive steroids in healthy women' (International Journal of Pharmaceutical Medicine (1997) 11 (71-76)) (Journal article)
Back, D. J., Fearn, R., Stott, D. A., & Wynne, R. D. (1997). Erratum: 'Lack of effect of sibutramine on the efficacy of oral contraceptive steroids in healthy women' (International Journal of Pharmaceutical Medicine (1997) 11 (71-76)). International Journal of Pharmaceutical Medicine, 11(4), 244.
Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. (Journal article)
Barry, M., Gibbons, S., Back, D., & Mulcahy, F. (1997). Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.. Clinical pharmacokinetics, 32(3), 194-209. doi:10.2165/00003088-199732030-00003DOI: 10.2165/00003088-199732030-00003
Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients (Journal article)
Merry, C., Barry, M. G., Mulcahy, F., Halifax, K. L., & Back, D. J. (1997). Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients. AIDS, 11(15), F117-F120. doi:10.1097/00002030-199715000-00001DOI: 10.1097/00002030-199715000-00001
1996
Intracellular metabolism of zidovudine and stavudine in combination. (Journal article)
Hoggard, P., Khoo, S., Barry, M., & Back, D. (1996). Intracellular metabolism of zidovudine and stavudine in combination.. The Journal of infectious diseases, 174(3), 671-672. doi:10.1093/infdis/174.3.671DOI: 10.1093/infdis/174.3.671
Lack of association between schizophrenia and the CYP2D6 gene polymorphisms (Journal article)
Pirmohamed, M., Wild, M. J., Kitteringham, N. R., OBrien, K., Buchan, I. E., Back, D. J., & Park, B. K. (1996). Lack of association between schizophrenia and the CYP2D6 gene polymorphisms. AMERICAN JOURNAL OF MEDICAL GENETICS, 67(2), 236-237. doi:10.1002/ajmg.1320670205DOI: 10.1002/ajmg.1320670205
Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation (Journal article)
Gentile, D. M., Tomlinson, E. S., Maggs, J. L., Park, B. K., & Back, D. J. (1996). Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 277(1), 105-112. Retrieved from https://www.webofscience.com/
Theophylline metabolism in human liver microsomes: Inhibition studies (Journal article)
Tjia, J. F., Colbert, J., & Back, D. J. (1996). Theophylline metabolism in human liver microsomes: Inhibition studies. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 276(3), 912-917. Retrieved from https://www.webofscience.com/
Dexamethasone metabolism in vitro: Species differences in 6-hydroxylation (Journal article)
Tomlinson, E. S., Maggs, J. L., Park, B. K., & Back, D. J. (1996). Dexamethasone metabolism in vitro: Species differences in 6-hydroxylation. British Journal of Clinical Pharmacology, 41(5).
How important is the pharmacokinetics issue for the pharmacodynamic diversity of oral contraceptives? (Journal article)
Back, D. J. (1996). How important is the pharmacokinetics issue for the pharmacodynamic diversity of oral contraceptives?. Gynecological Endocrinology, 10(sup2), 31-34. doi:10.3109/09513599609045624DOI: 10.3109/09513599609045624
Impaired absorption of zidovudine in patients with AIDS-related small intestinal disease. (Journal article)
Kapembwa, M. S., Fleming, S. C., Orr, M., Wells, C., Bland, M., Back, D., & Griffin, G. E. (1996). Impaired absorption of zidovudine in patients with AIDS-related small intestinal disease.. AIDS (London, England), 10(13), 1509-1514. doi:10.1097/00002030-199611000-00008DOI: 10.1097/00002030-199611000-00008
Improved tolerability of ritonavir derived from pharmacokinetic principles. (Journal article)
Merry, C., Barry, M., Gibbons, S., Mulcahy, F., & Back, D. (1996). Improved tolerability of ritonavir derived from pharmacokinetic principles.. British journal of clinical pharmacology, 42(6), 787. doi:10.1046/j.1365-2125.1996.d01-3339.xDOI: 10.1046/j.1365-2125.1996.d01-3339.x
Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation (Journal article)
Veal, G. J., Hoggard, P. G., Barry, M. G., Khoo, S., & Back, D. J. (1996). Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation. AIDS, 10(5), 546-548. doi:10.1097/00002030-199605000-00016DOI: 10.1097/00002030-199605000-00016
The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites (Journal article)
Barry, M. G., Khoo, S. H., Veal, G. J., Hoggard, P. G., Gibbons, S. E., Wilkins, E. G. L., . . . Back, D. J. (1996). The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS, 10(12), 1361-1367. doi:10.1097/00002030-199610000-00008DOI: 10.1097/00002030-199610000-00008
1995
EFFECT OF AZOLES ON THE GLUCURONIDATION OF ZIDOVUDINE BY HUMAN LIVER UDP-GLUCURONOSYLTRANSFERASE (Journal article)
ASGARI, M., & BACK, D. J. (1995). EFFECT OF AZOLES ON THE GLUCURONIDATION OF ZIDOVUDINE BY HUMAN LIVER UDP-GLUCURONOSYLTRANSFERASE. JOURNAL OF INFECTIOUS DISEASES, 172(6), 1634-1635. doi:10.1093/infdis/172.6.1634DOI: 10.1093/infdis/172.6.1634
PARACETAMOL DISPOSITION IN THAI PATIENTS DURING AND AFTER TREATMENT OF FALCIPARUM-MALARIA (Journal article)
ISMAIL, S., BANGCHANG, K. N., KARBWANG, J., BACK, D. J., & EDWARDS, G. (1995). PARACETAMOL DISPOSITION IN THAI PATIENTS DURING AND AFTER TREATMENT OF FALCIPARUM-MALARIA. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 48(1), 65-69. Retrieved from https://www.webofscience.com/
DRUG-INTERACTIONS WITH ZIDOVUDINE PHOSPHORYLATION IN-VITRO (Journal article)
HOGGARD, P. G., VEAL, G. J., WILD, M. J., BARRY, M. G., & BACK, D. J. (1995). DRUG-INTERACTIONS WITH ZIDOVUDINE PHOSPHORYLATION IN-VITRO. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 39(6), 1376-1378. doi:10.1128/AAC.39.6.1376DOI: 10.1128/AAC.39.6.1376
INFLUENCE OF HIGH-DOSES OF VITAMIN-C ON THE BIOAVAILABILITY AND THE SERUM-PROTEIN BINDING OF LEVONORGESTREL IN WOMEN USING A COMBINATION ORAL-CONTRACEPTIVE (Journal article)
KUHNZ, W., LOUTON, T., HUMPEL, M., BACK, D. J., & ZAMAH, N. M. (1995). INFLUENCE OF HIGH-DOSES OF VITAMIN-C ON THE BIOAVAILABILITY AND THE SERUM-PROTEIN BINDING OF LEVONORGESTREL IN WOMEN USING A COMBINATION ORAL-CONTRACEPTIVE. CONTRACEPTION, 51(2), 111-116. doi:10.1016/0010-7824(94)00016-PDOI: 10.1016/0010-7824(94)00016-P
Metabolism of zidovudine (Journal article)
Veal, G. J., & Back, D. J. (1995). Metabolism of zidovudine. GENERAL PHARMACOLOGY, 26(7), 1469-1475. doi:10.1016/0306-3623(95)00047-XDOI: 10.1016/0306-3623(95)00047-X
Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection. (Journal article)
Gibb, D., Barry, M., Ormesher, S., Nokes, L., Seefried, M., Giaquinto, C., & Back, D. (1995). Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection.. British journal of clinical pharmacology, 39(5), 527-530. doi:10.1111/j.1365-2125.1995.tb04490.xDOI: 10.1111/j.1365-2125.1995.tb04490.x
ZALCITABINE (DDC) PHOSPHORYLATION AND DRUG-INTERACTIONS (Journal article)
VEAL, G. J., BARRY, M. G., & BACK, D. J. (1995). ZALCITABINE (DDC) PHOSPHORYLATION AND DRUG-INTERACTIONS. ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 6(6), 379-384. doi:10.1177/095632029500600605DOI: 10.1177/095632029500600605
ZIDOVUDINE THERAPY IN HIV-INFECTION - WHICH PATIENTS SHOULD BE TREATED AND WHEN (Journal article)
BARRY, M. G., BACK, D. J., & BRECKENRIDGE, A. M. (1995). ZIDOVUDINE THERAPY IN HIV-INFECTION - WHICH PATIENTS SHOULD BE TREATED AND WHEN. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 40(2), 107-110. doi:10.1111/j.1365-2125.1995.tb05765.xDOI: 10.1111/j.1365-2125.1995.tb05765.x
1994
An evaluation of the interaction between tiagabine and oral contraceptives in female volunteers (Journal article)
Mengel, H. B., Houston, A., & Back, D. J. (1994). An evaluation of the interaction between tiagabine and oral contraceptives in female volunteers. Journal of Pharmaceutical Medicine, 4(3), 141-150.
THE METABOLISM OF ZIDOVUDINE BY HUMAN LIVER-MICROSOMES IN-VITRO - FORMATION OF 3'-AMINO-3'-DEOXYTHYMIDINE (Journal article)
EAGLING, V. A., HOWE, J. L., BARRY, M. J., & BACK, D. J. (1994). THE METABOLISM OF ZIDOVUDINE BY HUMAN LIVER-MICROSOMES IN-VITRO - FORMATION OF 3'-AMINO-3'-DEOXYTHYMIDINE. BIOCHEMICAL PHARMACOLOGY, 48(2), 267-276. doi:10.1016/0006-2952(94)90097-3DOI: 10.1016/0006-2952(94)90097-3
PHARMACOKINETICS OF MEFLOQUINE ALONE OR IN COMBINATION WITH ARTESUNATE (Journal article)
KARBWANG, J., BANGCHANG, K. N., THANAVIBUL, A., BACK, D. J., BUNNAG, D., & HARINASUTA, T. (1994). PHARMACOKINETICS OF MEFLOQUINE ALONE OR IN COMBINATION WITH ARTESUNATE. BULLETIN OF THE WORLD HEALTH ORGANIZATION, 72(1), 83-87. Retrieved from https://www.webofscience.com/
EFFECT OF MALARIA INFECTION ON THE PHARMACOKINETICS OF PARACETAMOL IN RAT (Journal article)
ISMAIL, S., KOKWARO, G. O., BACK, D. J., & EDWARDS, G. (1994). EFFECT OF MALARIA INFECTION ON THE PHARMACOKINETICS OF PARACETAMOL IN RAT. XENOBIOTICA, 24(6), 527-533. doi:10.3109/00498259409043255DOI: 10.3109/00498259409043255
EFFECTS OF DIDEOXYINOSINE AND DIDEOXYCYTIDINE ON THE INTRACELLULAR PHOSPHORYLATION OF ZIDOVUDINE IN HUMAN MONONUCLEAR-CELLS (Journal article)
VEAL, G. J., WILD, M. J., BARRY, M. G., & BACK, D. J. (1994). EFFECTS OF DIDEOXYINOSINE AND DIDEOXYCYTIDINE ON THE INTRACELLULAR PHOSPHORYLATION OF ZIDOVUDINE IN HUMAN MONONUCLEAR-CELLS. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 38(4), 323-328. doi:10.1111/j.1365-2125.1994.tb04361.xDOI: 10.1111/j.1365-2125.1994.tb04361.x
PHARMACOKINETICS OF ZIDOVUDINE AND DIDEOXYINOSINE ALONE AND IN COMBINATION IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME (Journal article)
BARRY, M., HOWE, J. L., ORMESHER, S., BACK, D. J., BRECKENRIDGE, A. M., BERGIN, C., . . . NYE, F. (1994). PHARMACOKINETICS OF ZIDOVUDINE AND DIDEOXYINOSINE ALONE AND IN COMBINATION IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 37(5), 421-426. doi:10.1111/j.1365-2125.1994.tb05708.xDOI: 10.1111/j.1365-2125.1994.tb05708.x
PHARMACOKINETICS OF ZIDOVUDINE IN CHILDREN WITH SYMPTOMATIC HIV-INFECTION (Journal article)
BARRY, M., HOWE, J. L., BACK, D. J., HAN, I., & GIBB, D. (1994). PHARMACOKINETICS OF ZIDOVUDINE IN CHILDREN WITH SYMPTOMATIC HIV-INFECTION. DRUG INVESTIGATION, 7(3), 143-147. doi:10.1007/BF03258466DOI: 10.1007/BF03258466
ZIDOVUDINE PHARMACOKINETICS IN ZIDOVUDINE-INDUCED BONE-MARROW TOXICITY (Journal article)
BARRY, M., HOWE, J. L., BACK, D. J., SWART, A. M., BRECKENRIDGE, A. M., WELLER, I. V. D., . . . NYE, F. (1994). ZIDOVUDINE PHARMACOKINETICS IN ZIDOVUDINE-INDUCED BONE-MARROW TOXICITY. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 37(1), 7-12. doi:10.1111/j.1365-2125.1994.tb04231.xDOI: 10.1111/j.1365-2125.1994.tb04231.x
ZIDOVUDINE PHOSPHORYLATION IN HIV-INFECTED PATIENTS AND SERONEGATIVE VOLUNTEERS (Journal article)
BARRY, M., WILD, M., VEAL, G., BACK, D., BRECKENRIDGE, A., FOX, R., . . . TIMMINS, D. (1994). ZIDOVUDINE PHOSPHORYLATION IN HIV-INFECTED PATIENTS AND SERONEGATIVE VOLUNTEERS. AIDS, 8(8), F1-F5. doi:10.1097/00002030-199408000-00002DOI: 10.1097/00002030-199408000-00002
1993
Pharmacokinetics and protein binding of 3-ketodesogestrel and gestodene in the serum of women during 6 cycles of treatment with two low dose oral contraceptives. (Journal article)
Back, D. J., Power, J., Winkler, U., Schindler, A. E., Daume, E., Simon, A., . . . Hammerstein, J. (1993). Pharmacokinetics and protein binding of 3-ketodesogestrel and gestodene in the serum of women during 6 cycles of treatment with two low dose oral contraceptives.. Advances in contraception : the official journal of the Society for the Advancement of Contraception, 9(4), 319-330. doi:10.1007/bf01983210DOI: 10.1007/bf01983210
EFFECT OF CHLORMETHIAZOLE ON HEPATIC MONOOXYGENASES ACTIVITY INVIVO (Journal article)
MONIG, H., BACK, D. J., HEIDEMANN, H. T., OHNHAUS, E. E., BROCKMANN, B., & SCHULTE, H. M. (1993). EFFECT OF CHLORMETHIAZOLE ON HEPATIC MONOOXYGENASES ACTIVITY INVIVO. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 44(2), 203-204. doi:10.1007/BF00315482DOI: 10.1007/BF00315482
ABSENCE OF AN EFFECT OF HIGH VITAMIN-C DOSAGE ON THE SYSTEMIC AVAILABILITY OF ETHINYL ESTRADIOL IN WOMEN USING A COMBINATION ORAL-CONTRACEPTIVE (Journal article)
ZAMAH, N. M., HUMPEL, M., KUHNZ, W., LOUTON, T., RAFFERTY, J., & BACK, D. J. (1993). ABSENCE OF AN EFFECT OF HIGH VITAMIN-C DOSAGE ON THE SYSTEMIC AVAILABILITY OF ETHINYL ESTRADIOL IN WOMEN USING A COMBINATION ORAL-CONTRACEPTIVE. CONTRACEPTION, 48(4), 377-391. doi:10.1016/0010-7824(93)90083-JDOI: 10.1016/0010-7824(93)90083-J
CORTISOL METABOLISM BY HUMAN LIVER IN-VITRO .4. METABOLISM OF 9-ALPHA-FLUOROCORTISOL BY HUMAN LIVER-MICROSOMES AND CYTOSOL (Journal article)
ABEL, S. M., BACK, D. J., MAGGS, J. L., & PARK, B. K. (1993). CORTISOL METABOLISM BY HUMAN LIVER IN-VITRO .4. METABOLISM OF 9-ALPHA-FLUOROCORTISOL BY HUMAN LIVER-MICROSOMES AND CYTOSOL. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 46(6), 833-839. doi:10.1016/0960-0760(93)90326-RDOI: 10.1016/0960-0760(93)90326-R
CORTISOL METABOLISM IN-VITRO .3. INHIBITION OF MICROSOMAL 6-BETA-HYDROXYLASE AND CYTOSOLIC 4-ENE-REDUCTASE (Journal article)
ABEL, S. M., & BACK, D. J. (1993). CORTISOL METABOLISM IN-VITRO .3. INHIBITION OF MICROSOMAL 6-BETA-HYDROXYLASE AND CYTOSOLIC 4-ENE-REDUCTASE. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 46(6), 827-832. doi:10.1016/0960-0760(93)90325-QDOI: 10.1016/0960-0760(93)90325-Q
CORTISOL METABOLISM INVITRO .2. SPECIES-DIFFERENCE (Journal article)
ABEL, S. M., BACK, D. J., MAGGS, J. L., & PARK, B. K. (1993). CORTISOL METABOLISM INVITRO .2. SPECIES-DIFFERENCE. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 45(5), 445-453. doi:10.1016/0960-0760(93)90013-MDOI: 10.1016/0960-0760(93)90013-M
EFFECT OF ETRETINATE ON CYCLOSPORINE METABOLISM INVITRO (Journal article)
WEBBER, I. R., & BACK, D. J. (1993). EFFECT OF ETRETINATE ON CYCLOSPORINE METABOLISM INVITRO. BRITISH JOURNAL OF DERMATOLOGY, 128(1), 42-44. doi:10.1111/j.1365-2133.1993.tb00145.xDOI: 10.1111/j.1365-2133.1993.tb00145.x
INFLUENCE OF GESTODENE AND DESOGESTREL AS COMPONENTS OF LOW-DOSE ORAL-CONTRACEPTIVES ON THE PHARMACOKINETICS OF ETHINYL ESTRADIOL (EE2), ON SERUM CBG AND ON URINARY CORTISOL AND 6-BETA-HYDROXYCORTISOL (Journal article)
HAMMERSTEIN, J., DAUME, E., SIMON, A., WINKLER, U. H., SCHINDLER, A. E., BACK, D. J., . . . NEISS, A. (1993). INFLUENCE OF GESTODENE AND DESOGESTREL AS COMPONENTS OF LOW-DOSE ORAL-CONTRACEPTIVES ON THE PHARMACOKINETICS OF ETHINYL ESTRADIOL (EE2), ON SERUM CBG AND ON URINARY CORTISOL AND 6-BETA-HYDROXYCORTISOL. CONTRACEPTION, 47(3), 263-281. doi:10.1016/0010-7824(93)90043-7DOI: 10.1016/0010-7824(93)90043-7
METABOLISM OF DIDANOSINE (DDI) BY ERYTHROCYTES - PHARMACOKINETIC IMPLICATIONS (Journal article)
BARRY, M., BACK, D., ORMESHER, S., BEECHING, N., & NYE, F. (1993). METABOLISM OF DIDANOSINE (DDI) BY ERYTHROCYTES - PHARMACOKINETIC IMPLICATIONS. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 36(1), 87-88. doi:10.1111/j.1365-2125.1993.tb05899.xDOI: 10.1111/j.1365-2125.1993.tb05899.x
METABOLISM OF GESTODENE IN HUMAN LIVER CYTOSOL AND MICROSOMES IN-VITRO (Journal article)
WARD, S., & BACK, D. J. (1993). METABOLISM OF GESTODENE IN HUMAN LIVER CYTOSOL AND MICROSOMES IN-VITRO. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 46(2), 235-243. doi:10.1016/0960-0760(93)90299-CDOI: 10.1016/0960-0760(93)90299-C
METABOLISM OF THE ORAL-CONTRACEPTIVE STEROIDS ETHYNYLESTRADIOL, NORGESTIMATE AND 3-KETODESOGESTREL BY A HUMAN ENDOMETRIAL CANCER CELL-LINE (HEC-1A) AND ENDOMETRIAL TISSUE INVITRO (Journal article)
WILD, M. J., RUDLAND, P. S., & BACK, D. J. (1993). METABOLISM OF THE ORAL-CONTRACEPTIVE STEROIDS ETHYNYLESTRADIOL, NORGESTIMATE AND 3-KETODESOGESTREL BY A HUMAN ENDOMETRIAL CANCER CELL-LINE (HEC-1A) AND ENDOMETRIAL TISSUE INVITRO. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 45(5), 407-420. doi:10.1016/0960-0760(93)90010-TDOI: 10.1016/0960-0760(93)90010-T
Radioimmunological analysis of ethinylestradiol in human serum. Validation of the method and comparison with a gas chromatographic/mass spectrometric assay. (Journal article)
Kuhnz, W., Louton, T., Back, D. J., & Michaelis, K. (1993). Radioimmunological analysis of ethinylestradiol in human serum. Validation of the method and comparison with a gas chromatographic/mass spectrometric assay.. Arzneimittel-Forschung, 43(1), 16-21.
THE EFFECTS OF INDOMETHACIN AND NAPROXEN ON ZIDOVUDINE PHARMACOKINETICS (Journal article)
BARRY, M., HOWE, J., BACK, D., BRECKENRIDGE, A., BRETTLE, R., MITCHELL, R., . . . NYE, F. J. (1993). THE EFFECTS OF INDOMETHACIN AND NAPROXEN ON ZIDOVUDINE PHARMACOKINETICS. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 36(1), 82-85. doi:10.1111/j.1365-2125.1993.tb05898.xDOI: 10.1111/j.1365-2125.1993.tb05898.x
1992
THE EFFECT OF MALARIA INFECTION ON 3'-AZIDO-3'-DEOXYTHYMIDINE AND PARACETAMOL GLUCURONIDATION IN RAT-LIVER MICROSOMES (Journal article)
ISMAIL, S., BACK, D. J., & EDWARDS, G. (1992). THE EFFECT OF MALARIA INFECTION ON 3'-AZIDO-3'-DEOXYTHYMIDINE AND PARACETAMOL GLUCURONIDATION IN RAT-LIVER MICROSOMES. BIOCHEMICAL PHARMACOLOGY, 44(9), 1879-1882. doi:10.1016/0006-2952(92)90084-VDOI: 10.1016/0006-2952(92)90084-V
EFFECT OF TETRACYCLINE ON MEFLOQUINE PHARMACOKINETICS IN THAI MALES (Journal article)
KARBWANG, J., BANGCHANG, K. N., BACK, D. J., BUNNAG, D., & ROONEY, W. (1992). EFFECT OF TETRACYCLINE ON MEFLOQUINE PHARMACOKINETICS IN THAI MALES. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 43(5), 567-569. doi:10.1007/BF02285105DOI: 10.1007/BF02285105
PRIMAQUINE METABOLISM BY HUMAN LIVER-MICROSOMES - EFFECT OF OTHER ANTIMALARIAL-DRUGS (Journal article)
BANGCHANG, K. N., KARBWANG, J., & BACK, D. J. (1992). PRIMAQUINE METABOLISM BY HUMAN LIVER-MICROSOMES - EFFECT OF OTHER ANTIMALARIAL-DRUGS. BIOCHEMICAL PHARMACOLOGY, 44(3), 587-590. doi:10.1016/0006-2952(92)90453-PDOI: 10.1016/0006-2952(92)90453-P
Loss of taste and terbinafine. (Journal article)
Back, D. (1992). Loss of taste and terbinafine.. Lancet (London, England), 340(8813), 252. doi:10.1016/0140-6736(92)90528-bDOI: 10.1016/0140-6736(92)90528-b
MEFLOQUINE METABOLISM BY HUMAN LIVER-MICROSOMES - EFFECT OF OTHER ANTIMALARIAL-DRUGS (Journal article)
BANGCHANG, K. N., KARBWANG, J., & BACK, D. J. (1992). MEFLOQUINE METABOLISM BY HUMAN LIVER-MICROSOMES - EFFECT OF OTHER ANTIMALARIAL-DRUGS. BIOCHEMICAL PHARMACOLOGY, 43(9), 1957-1961. doi:10.1016/0006-2952(92)90638-YDOI: 10.1016/0006-2952(92)90638-Y
PHARMACOKINETICS OF MEFLOQUINE IN THE PRESENCE OF PRIMAQUINE (Journal article)
KARBWANG, J., BANGCHANG, K. N., THANAVIBUL, A., BACK, D. J., & BUNNAG, D. (1992). PHARMACOKINETICS OF MEFLOQUINE IN THE PRESENCE OF PRIMAQUINE. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 42(5), 559-560. doi:10.1007/BF00314870DOI: 10.1007/BF00314870
INVITRO INHIBITION STUDIES OF THE GLUCURONIDATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE CATALYZED BY HUMAN LIVER UDP-GLUCURONOSYL TRANSFERASE (Journal article)
MACLEOD, R., EAGLING, V. A., SIM, S. M., & BACK, D. J. (1992). INVITRO INHIBITION STUDIES OF THE GLUCURONIDATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE CATALYZED BY HUMAN LIVER UDP-GLUCURONOSYL TRANSFERASE. BIOCHEMICAL PHARMACOLOGY, 43(2), 382-386. doi:10.1016/0006-2952(92)90303-ZDOI: 10.1016/0006-2952(92)90303-Z
RELATIVE EXPRESSION OF CYTOCHROME P450 ISOENZYMES IN HUMAN LIVER AND ASSOCIATION WITH THE METABOLISM OF DRUGS AND XENOBIOTICS (Journal article)
FORRESTER, L. M., HENDERSON, C. J., GLANCEY, M. J., BACK, D. J., PARK, B. K., BALL, S. E., . . . WOLF, C. R. (1992). RELATIVE EXPRESSION OF CYTOCHROME P450 ISOENZYMES IN HUMAN LIVER AND ASSOCIATION WITH THE METABOLISM OF DRUGS AND XENOBIOTICS. BIOCHEMICAL JOURNAL, 281, 359-368. doi:10.1042/bj2810359DOI: 10.1042/bj2810359
AZOLES, ALLYLAMINES AND DRUG-METABOLISM (Journal article)
BACK, D. J., TJIA, J. F., & ABEL, S. M. (1992). AZOLES, ALLYLAMINES AND DRUG-METABOLISM. BRITISH JOURNAL OF DERMATOLOGY, 126, 14-18. doi:10.1111/j.1365-2133.1992.tb00003.xDOI: 10.1111/j.1365-2133.1992.tb00003.x
Bacterial and hepatic metabolism of zidovudine (AZT) to the toxic catabolite 3'-amino-3'-deoxythymidine (AMT) (Conference Paper)
Howe, J. L., Back, D. J., Eagling, V., & Hart, C. A. (1992). Bacterial and hepatic metabolism of zidovudine (AZT) to the toxic catabolite 3'-amino-3'-deoxythymidine (AMT). In British Journal of Clinical Pharmacology Vol. 34.
CORTISOL METABOLISM BY HUMAN LIVER INVITRO .1. METABOLITE IDENTIFICATION AND INTERINDIVIDUAL VARIABILITY (Journal article)
ABEL, S. M., MAGGS, J. L., BACK, D. J., & PARK, B. K. (1992). CORTISOL METABOLISM BY HUMAN LIVER INVITRO .1. METABOLITE IDENTIFICATION AND INTERINDIVIDUAL VARIABILITY. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 43(7), 713-719. doi:10.1016/0960-0760(92)90297-VDOI: 10.1016/0960-0760(92)90297-V
CYCLOSPORINE METABOLISM BY HUMAN GASTROINTESTINAL MUCOSAL MICROSOMES (Journal article)
WEBBER, I. R., PETERS, W. H. M., & BACK, D. J. (1992). CYCLOSPORINE METABOLISM BY HUMAN GASTROINTESTINAL MUCOSAL MICROSOMES. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 33(6), 661-664. doi:10.1111/j.1365-2125.1992.tb04098.xDOI: 10.1111/j.1365-2125.1992.tb04098.x
Cortisol metabolism by human liver in vitro (Conference Paper)
Abel, S. M., Maggs, J. L., Back, D. J., Newby, S., Colbert, J., & Park, B. K. (1992). Cortisol metabolism by human liver in vitro. In British Journal of Clinical Pharmacology Vol. 33.
EXTRAHEPATIC METABOLISM OF ZIDOVUDINE (Journal article)
HOWE, J. L., BACK, D. J., & COLBERT, J. (1992). EXTRAHEPATIC METABOLISM OF ZIDOVUDINE. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 33(2), 190-192. doi:10.1111/j.1365-2125.1992.tb04024.xDOI: 10.1111/j.1365-2125.1992.tb04024.x
METABOLISM OF 2',3'-DIDEOXYINOSINE (DDI) IN HUMAN BLOOD (Journal article)
BACK, D. J., ORMESHER, S., TJIA, J. F., & MACLEOD, R. (1992). METABOLISM OF 2',3'-DIDEOXYINOSINE (DDI) IN HUMAN BLOOD. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 33(3), 319-322. doi:10.1111/j.1365-2125.1992.tb04043.xDOI: 10.1111/j.1365-2125.1992.tb04043.x
Metabolism of contraceptive steroids by human endometrial tissue and an endometrial cancer cell-line (HEC-1A) in vitro (Conference Paper)
Wild, M. J., Back, D. J., & Rudland, P. S. (1992). Metabolism of contraceptive steroids by human endometrial tissue and an endometrial cancer cell-line (HEC-1A) in vitro. In British Journal of Clinical Pharmacology Vol. 33.
Metabolism of the oral contraceptive steroid gestodene by human liver in vitro (Conference Paper)
Ward, S., & Back, D. J. (1992). Metabolism of the oral contraceptive steroid gestodene by human liver in vitro. In British Journal of Clinical Pharmacology Vol. 34.
Pharmacokinetics and serum protein binding of 3-keto-desogestrel in women during three cycles of treatment with a low-dose combination oral contraceptive. (Journal article)
Kuhnz, W., al-Yacoub, G., Power, J., Ormesher, S. E., Back, D. J., & Jütting, G. (1992). Pharmacokinetics and serum protein binding of 3-keto-desogestrel in women during three cycles of treatment with a low-dose combination oral contraceptive.. Arzneimittel-Forschung, 42(9), 1142-1146.
Pharmacokinetics and serum protein binding of gestodene and 3-keto-desogestrel in women after single oral administration of two different contraceptive formulations. (Journal article)
Kuhnz, W., Schütt, B., Power, J., & Back, D. J. (1992). Pharmacokinetics and serum protein binding of gestodene and 3-keto-desogestrel in women after single oral administration of two different contraceptive formulations.. Arzneimittel-Forschung, 42(9), 1139-1141.
Species differences in the in vitro metabolism of cortisol (Conference Paper)
Abel, S. M., Back, D. J., Maggs, J. L., & Park, B. K. (1992). Species differences in the in vitro metabolism of cortisol. In British Journal of Clinical Pharmacology Vol. 34.
The in-vitro mucosal conjugation of ethinyloestradiol and the bioavailability of oral contraceptive steroids in patients with treated and untreated coeliac disease. (Journal article)
Grimmer, S. F., Back, D. J., Orme, M. L., Tjia, J. F., Gilmore, I. T., & Ellis, A. (1992). The in-vitro mucosal conjugation of ethinyloestradiol and the bioavailability of oral contraceptive steroids in patients with treated and untreated coeliac disease.. Alimentary pharmacology & therapeutics, 6(1), 79-85. doi:10.1111/j.1365-2036.1992.tb00547.xDOI: 10.1111/j.1365-2036.1992.tb00547.x
1991
EFFECT OF AMPICILLIN ON MEFLOQUINE PHARMACOKINETICS IN THAI MALES (Journal article)
KARBWANG, J., BANGCHANG, K. N., BACK, D. J., & BUNNAG, D. (1991). EFFECT OF AMPICILLIN ON MEFLOQUINE PHARMACOKINETICS IN THAI MALES. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 40(6), 631-633. Retrieved from https://www.webofscience.com/
UNINTENDED PREGNANCIES AND CONTRACEPTIVE USE (Journal article)
ORME, M., & BACK, D. J. (1991). UNINTENDED PREGNANCIES AND CONTRACEPTIVE USE. BRITISH MEDICAL JOURNAL, 302(6779), 789. Retrieved from https://www.webofscience.com/
COMPARATIVE EFFECTS OF THE ANTIMYCOTIC DRUGS KETOCONAZOLE, FLUCONAZOLE, ITRACONAZOLE AND TERBINAFINE ON THE METABOLISM OF CYCLOSPORINE BY HUMAN LIVER-MICROSOMES (Journal article)
BACK, D. J., & TJIA, J. F. (1991). COMPARATIVE EFFECTS OF THE ANTIMYCOTIC DRUGS KETOCONAZOLE, FLUCONAZOLE, ITRACONAZOLE AND TERBINAFINE ON THE METABOLISM OF CYCLOSPORINE BY HUMAN LIVER-MICROSOMES. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 32(5), 624-626. doi:10.1111/j.1365-2125.1991.tb03963.xDOI: 10.1111/j.1365-2125.1991.tb03963.x
CYCLOSPORINE METABOLISM BY THE GASTROINTESTINAL MUCOSA (Journal article)
TJIA, J. F., WEBBER, I. R., & BACK, D. J. (1991). CYCLOSPORINE METABOLISM BY THE GASTROINTESTINAL MUCOSA. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 31(3), 344-346. doi:10.1111/j.1365-2125.1991.tb05540.xDOI: 10.1111/j.1365-2125.1991.tb05540.x
Concentration of ethinyl estradiol in the serum of 31 young women following a treatment period of 3 months with two low-dose oral contraceptives in an intraindividual cross-over design. (Journal article)
Kuhnz, W., Back, D., Power, J., Schütt, B., & Louton, T. (1991). Concentration of ethinyl estradiol in the serum of 31 young women following a treatment period of 3 months with two low-dose oral contraceptives in an intraindividual cross-over design.. Hormone research, 36(1-2), 63-69. doi:10.1159/000182110DOI: 10.1159/000182110
EFFECT OF THE PROGESTOGENS, GESTODENE, 3-KETO DESOGESTREL, LEVONORGESTREL, NORETHISTERONE AND NORGESTIMATE ON THE OXIDATION OF ETHINYLESTRADIOL AND OTHER SUBSTRATES BY HUMAN LIVER-MICROSOMES (Journal article)
BACK, D. J., HOULGRAVE, R., TJIA, J. F., WARD, S., & ORME, M. L. (1991). EFFECT OF THE PROGESTOGENS, GESTODENE, 3-KETO DESOGESTREL, LEVONORGESTREL, NORETHISTERONE AND NORGESTIMATE ON THE OXIDATION OF ETHINYLESTRADIOL AND OTHER SUBSTRATES BY HUMAN LIVER-MICROSOMES. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 38(2), 219-225. doi:10.1016/0960-0760(91)90129-SDOI: 10.1016/0960-0760(91)90129-S
METABOLISM OF NORGESTIMATE BY HUMAN GASTROINTESTINAL MUCOSA AND LIVER-MICROSOMES INVITRO (Journal article)
MADDEN, S., & BACK, D. J. (1991). METABOLISM OF NORGESTIMATE BY HUMAN GASTROINTESTINAL MUCOSA AND LIVER-MICROSOMES INVITRO. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 38(4), 497-503. doi:10.1016/0960-0760(91)90338-6DOI: 10.1016/0960-0760(91)90338-6
METABOLISM OF THE ORAL-CONTRACEPTIVE STEROIDS ETHYNYLESTRADIOL AND NORGESTIMATE BY NORMAL (HUMA-7) AND MALIGNANT (MCF-7 AND ZR-75-1) HUMAN BREAST CELLS IN CULTURE (Journal article)
WILD, M. J., RUDLAND, P. S., & BACK, D. J. (1991). METABOLISM OF THE ORAL-CONTRACEPTIVE STEROIDS ETHYNYLESTRADIOL AND NORGESTIMATE BY NORMAL (HUMA-7) AND MALIGNANT (MCF-7 AND ZR-75-1) HUMAN BREAST CELLS IN CULTURE. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 39(4), 535-543. doi:10.1016/0960-0760(91)90248-4DOI: 10.1016/0960-0760(91)90248-4
Oral contraceptive steroids--pharmacological issues of interest to the prescribing physician. (Journal article)
Orme, M., & Back, D. J. (1991). Oral contraceptive steroids--pharmacological issues of interest to the prescribing physician.. Advances in contraception : the official journal of the Society for the Advancement of Contraception, 7(4), 325-331. doi:10.1007/bf02340178DOI: 10.1007/bf02340178
THE EFFECT OF METOCLOPRAMIDE ON MEFLOQUINE PHARMACOKINETICS (Journal article)
BANGCHANG, K. N., KARBWANG, J., BUNNAG, D., HARINASUTA, T., & BACK, D. J. (1991). THE EFFECT OF METOCLOPRAMIDE ON MEFLOQUINE PHARMACOKINETICS. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 32(5), 640-641. Retrieved from https://www.webofscience.com/
THE EFFECT OF VARIOUS DRUGS ON THE GLUCURONIDATION OF ZIDOVUDINE (AZIDOTHYMIDINE, AZT) BY HUMAN LIVER-MICROSOMES (Journal article)
SIM, S. M., BACK, D. J., & BRECKENRIDGE, A. M. (1991). THE EFFECT OF VARIOUS DRUGS ON THE GLUCURONIDATION OF ZIDOVUDINE (AZIDOTHYMIDINE, AZT) BY HUMAN LIVER-MICROSOMES. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 32(1), 17-21. doi:10.1111/j.1365-2125.1991.tb05607.xDOI: 10.1111/j.1365-2125.1991.tb05607.x
THE LACK OF INTERACTION BETWEEN TEMAFLOXACIN AND COMBINED ORAL-CONTRACEPTIVE STEROIDS (Journal article)
BACK, D. J., TJIA, J., MARTIN, C., MILLAR, E., MANT, T., MORRISON, P., & ORME, M. (1991). THE LACK OF INTERACTION BETWEEN TEMAFLOXACIN AND COMBINED ORAL-CONTRACEPTIVE STEROIDS. CONTRACEPTION, 43(4), 317-323. doi:10.1016/0010-7824(91)90070-VDOI: 10.1016/0010-7824(91)90070-V
THE PHARMACOKINETICS OF ETHYNYLESTRADIOL IN THE PRESENCE AND ABSENCE OF GESTODENE AND DESOGESTREL (Journal article)
ORME, M., BACK, D. J., WARD, S., & GREEN, S. (1991). THE PHARMACOKINETICS OF ETHYNYLESTRADIOL IN THE PRESENCE AND ABSENCE OF GESTODENE AND DESOGESTREL. CONTRACEPTION, 43(4), 305-316. doi:10.1016/0010-7824(91)90069-RDOI: 10.1016/0010-7824(91)90069-R
The interaction between clarithromycin and combined oral-contraceptive steroids (Journal article)
Back, D. J., Tjia, J., Martin, C., Millar, E., Salmon, P., & Orme, M. (1991). The interaction between clarithromycin and combined oral-contraceptive steroids. Journal of Pharmaceutical Medicine, 1(2), 81-87.
The lack of interaction between clarithromycin and oral contraceptive steroids (Conference Paper)
Orme, M., Back, D. J., Tjia, J., Martin, C., Millar, E., & Salmon, P. (1991). The lack of interaction between clarithromycin and oral contraceptive steroids. In British Journal of Clinical Pharmacology Vol. 31.
The lack of interaction between temafloxacin and oral contraceptive steroids (Conference Paper)
Orme, M., Back, D. J., Tjia, J., Martin, C., Millar, E., Mant, T., & Morrison, P. (1991). The lack of interaction between temafloxacin and oral contraceptive steroids. In British Journal of Clinical Pharmacology Vol. 31.
1990
PHARMACOKINETICS OF MEFLOQUINE IN COMBINATION WITH SULFADOXINE PYRIMETHAMINE AND PRIMAQUINE IN MALE THAI PATIENTS WITH FALCIPARUM-MALARIA (Journal article)
KARBWANG, J., BACK, D. J., BUNNAG, D., & BRECKENRIDGE, A. M. (1990). PHARMACOKINETICS OF MEFLOQUINE IN COMBINATION WITH SULFADOXINE PYRIMETHAMINE AND PRIMAQUINE IN MALE THAI PATIENTS WITH FALCIPARUM-MALARIA. BULLETIN OF THE WORLD HEALTH ORGANIZATION, 68(5), 633-638. Retrieved from https://www.webofscience.com/
DIFFERENCES IN THE CYTOCHROME-P-450 ISOENZYMES INVOLVED IN THE 2-HYDROXYLATION OF ESTRADIOL AND 17-ALPHA-ETHINYLESTRADIOL - RELATIVE ACTIVITIES OF RAT AND HUMAN LIVER-ENZYMES (Journal article)
BALL, S. E., FORRESTER, L. M., WOLF, C. R., & BACK, D. J. (1990). DIFFERENCES IN THE CYTOCHROME-P-450 ISOENZYMES INVOLVED IN THE 2-HYDROXYLATION OF ESTRADIOL AND 17-ALPHA-ETHINYLESTRADIOL - RELATIVE ACTIVITIES OF RAT AND HUMAN LIVER-ENZYMES. BIOCHEMICAL JOURNAL, 267(1), 221-226. doi:10.1042/bj2670221DOI: 10.1042/bj2670221
Azoles and allylamines: the clinical implications of interaction with cytochrome P-450 enzymes (Journal article)
Back, D., & Tija, J. (1990). Azoles and allylamines: the clinical implications of interaction with cytochrome P-450 enzymes. Journal of Dermatological Treatment, 1(sup2), 11-13. doi:10.3109/09546639009089023DOI: 10.3109/09546639009089023
Factors affecting the enterohepatic circulation of oral contraceptive steroids. (Journal article)
Orme, M. L., & Back, D. J. (1990). Factors affecting the enterohepatic circulation of oral contraceptive steroids.. American journal of obstetrics and gynecology, 163(6 Pt 2), 2146-2152. doi:10.1016/0002-9378(90)90555-lDOI: 10.1016/0002-9378(90)90555-l
Gastrointestinal metabolism of contraceptive steroids. (Journal article)
Back, D. J., Madden, S., & Orme, M. L. (1990). Gastrointestinal metabolism of contraceptive steroids.. American journal of obstetrics and gynecology, 163(6 Pt 2), 2138-2145. doi:10.1016/0002-9378(90)90554-kDOI: 10.1016/0002-9378(90)90554-k
METABOLISM OF THE CONTRACEPTIVE STEROID DESOGESTREL BY HUMAN LIVER INVITRO (Journal article)
MADDEN, S., BACK, D. J., & ORME, M. L. (1990). METABOLISM OF THE CONTRACEPTIVE STEROID DESOGESTREL BY HUMAN LIVER INVITRO. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 35(2), 281-288. doi:10.1016/0022-4731(90)90285-ZDOI: 10.1016/0022-4731(90)90285-Z
PHARMACOKINETIC DRUG-INTERACTIONS WITH ORAL-CONTRACEPTIVES (Journal article)
BACK, D. J., & ORME, M. L. E. (1990). PHARMACOKINETIC DRUG-INTERACTIONS WITH ORAL-CONTRACEPTIVES. CLINICAL PHARMACOKINETICS, 18(6), 472-484. doi:10.2165/00003088-199018060-00004DOI: 10.2165/00003088-199018060-00004
THE INTERACTION OF PHENYTOIN AND CARBAMAZEPINE WITH COMBINED ORAL-CONTRACEPTIVE STEROIDS (Journal article)
CRAWFORD, P., CHADWICK, D. J., MARTIN, C., TJIA, J., BACK, D. J., & ORME, M. (1990). THE INTERACTION OF PHENYTOIN AND CARBAMAZEPINE WITH COMBINED ORAL-CONTRACEPTIVE STEROIDS. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 30(6), 892-896. doi:10.1111/j.1365-2125.1990.tb05457.xDOI: 10.1111/j.1365-2125.1990.tb05457.x
THE INTERACTION OF PHENYTOIN AND CARBAMAZEPINE WITH ORAL-CONTRACEPTIVE STEROIDS (Conference Paper)
ORME, M., BACK, D. J., CHADWICK, D. J., CRAWFORD, P., MARTIN, C., & TJIA, J. (1990). THE INTERACTION OF PHENYTOIN AND CARBAMAZEPINE WITH ORAL-CONTRACEPTIVE STEROIDS. In EUROPEAN JOURNAL OF PHARMACOLOGY Vol. 183 (pp. 1029-1030). doi:10.1016/0014-2999(90)92884-LDOI: 10.1016/0014-2999(90)92884-L
1989
INHIBITION OF ESTROGEN 2-HYDROXYLASE ACTIVITY OF HUMAN-LIVER MICROSOMES BY CIMETIDINE INVITRO - EFFECT OF PREINCUBATION (Journal article)
WILD, M. J., & BACK, D. J. (1989). INHIBITION OF ESTROGEN 2-HYDROXYLASE ACTIVITY OF HUMAN-LIVER MICROSOMES BY CIMETIDINE INVITRO - EFFECT OF PREINCUBATION. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 28(6), P744-P745. Retrieved from https://www.webofscience.com/
Cyclosporin metabolites and neurotoxicity. (Journal article)
Trull, A. K., Tan, K. K., Roberts, N. B., Tjia, J. F., & Back, D. J. (1989). Cyclosporin metabolites and neurotoxicity.. Lancet (London, England), 2(8660), 448. doi:10.1016/s0140-6736(89)90626-0DOI: 10.1016/s0140-6736(89)90626-0
CALCIUM-CHANNEL ANTAGONISTS AND CYCLOSPORINE METABOLISM - INVITRO STUDIES WITH HUMAN-LIVER MICROSOMES (Journal article)
TJIA, J. F., BACK, D. J., & BRECKENRIDGE, A. M. (1989). CALCIUM-CHANNEL ANTAGONISTS AND CYCLOSPORINE METABOLISM - INVITRO STUDIES WITH HUMAN-LIVER MICROSOMES. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 28(3), 362-365. doi:10.1111/j.1365-2125.1989.tb05439.xDOI: 10.1111/j.1365-2125.1989.tb05439.x
COMPARATIVE EFFECTS OF 2 ANTIMYCOTIC AGENTS, KETOCONAZOLE AND TERBINAFINE ON THE METABOLISM OF TOLBUTAMIDE, ETHINYLESTRADIOL, CYCLOSPORINE AND ETHOXYCOUMARIN BY HUMAN-LIVER MICROSOMES INVITRO (Journal article)
BACK, D. J., STEVENSON, P., & TJIA, J. F. (1989). COMPARATIVE EFFECTS OF 2 ANTIMYCOTIC AGENTS, KETOCONAZOLE AND TERBINAFINE ON THE METABOLISM OF TOLBUTAMIDE, ETHINYLESTRADIOL, CYCLOSPORINE AND ETHOXYCOUMARIN BY HUMAN-LIVER MICROSOMES INVITRO. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 28(2), 166-170. doi:10.1111/j.1365-2125.1989.tb05410.xDOI: 10.1111/j.1365-2125.1989.tb05410.x
GENETIC-FACTORS INFLUENCING THE METABOLISM OF TOLBUTAMIDE (Journal article)
BACK, D. J., & ORME, M. L. (1989). GENETIC-FACTORS INFLUENCING THE METABOLISM OF TOLBUTAMIDE. PHARMACOLOGY & THERAPEUTICS, 44(2), 147-155. doi:10.1016/0163-7258(89)90064-8DOI: 10.1016/0163-7258(89)90064-8
INTERINDIVIDUAL VARIATION IN THE METABOLISM OF ETHYNYLESTRADIOL (Journal article)
ORME, M. L., BACK, D. J., & BALL, S. (1989). INTERINDIVIDUAL VARIATION IN THE METABOLISM OF ETHYNYLESTRADIOL. PHARMACOLOGY & THERAPEUTICS, 43(2), 251-260. doi:10.1016/0163-7258(89)90121-6DOI: 10.1016/0163-7258(89)90121-6
Intestinal metabolism of contraceptive steroids in man (Journal article)
Back, D. J., Orme 'E., M. L., & Rogers, S. M. (1989). Intestinal metabolism of contraceptive steroids in man. Progress in Pharmacology and Clinical Pharmacology, 7(2), 289-297.
METABOLISM OF THE CONTRACEPTIVE STEROID DESOGESTREL BY THE INTESTINAL-MUCOSA (Journal article)
MADDEN, S., BACK, D. J., MARTIN, C. A., & ORME, M. L. E. (1989). METABOLISM OF THE CONTRACEPTIVE STEROID DESOGESTREL BY THE INTESTINAL-MUCOSA. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 27(3), 295-299. doi:10.1111/j.1365-2125.1989.tb05368.xDOI: 10.1111/j.1365-2125.1989.tb05368.x
METABOLISM OF THE CONTRACEPTIVE STEROID NORGESTIMATE BY HUMAN GUT AND LIVER INVITRO (Journal article)
MADDEN, S., & BACK, D. J. (1989). METABOLISM OF THE CONTRACEPTIVE STEROID NORGESTIMATE BY HUMAN GUT AND LIVER INVITRO. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 28(6), P743-P744. Retrieved from https://www.webofscience.com/
The use of Ussing chambers for the study of intestinal metabolism in vitro (Journal article)
Rogers, S. M., & Back, D. J. (1989). The use of Ussing chambers for the study of intestinal metabolism in vitro. Progress in Pharmacology and Clinical Pharmacology, 7(2), 43-53.
1988
EFFECT OF ORAL-CONTRACEPTIVE STEROIDS ON THE CLINICAL COURSE OF MALARIA INFECTION AND ON THE PHARMACOKINETICS OF MEFLOQUINE IN THAI WOMEN (Journal article)
KARBWANG, J., LOOAREESUWAN, S., BACK, D. J., MIGASANA, S., BUNNAG, D., & BRECKENRIDGE, A. M. (1988). EFFECT OF ORAL-CONTRACEPTIVE STEROIDS ON THE CLINICAL COURSE OF MALARIA INFECTION AND ON THE PHARMACOKINETICS OF MEFLOQUINE IN THAI WOMEN. BULLETIN OF THE WORLD HEALTH ORGANIZATION, 66(6), 763-767. Retrieved from https://www.webofscience.com/
SULFATION AND GLUCURONIDATION OF PARACETAMOL IN HUMAN-LIVER - ASSAY CONDITIONS (Journal article)
PACIFICI, G. M., BACK, D. J., & ORME, M. L. (1988). SULFATION AND GLUCURONIDATION OF PARACETAMOL IN HUMAN-LIVER - ASSAY CONDITIONS. BIOCHEMICAL PHARMACOLOGY, 37(22), 4405-4407. doi:10.1016/0006-2952(88)90624-7DOI: 10.1016/0006-2952(88)90624-7
A COMPARISON OF THE PHARMACOKINETICS OF MEFLOQUINE IN HEALTHY THAI VOLUNTEERS AND IN THAI PATIENTS WITH FALCIPARUM-MALARIA (Journal article)
KARBWANG, J., BACK, D. J., BUNNAG, D., & BRECKENRIDGE, A. M. (1988). A COMPARISON OF THE PHARMACOKINETICS OF MEFLOQUINE IN HEALTHY THAI VOLUNTEERS AND IN THAI PATIENTS WITH FALCIPARUM-MALARIA. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 35(6), 677-680. doi:10.1007/BF00637607DOI: 10.1007/BF00637607
SELECTIVE-INHIBITION OF DRUG OXIDATION AFTER SIMULTANEOUS ADMINISTRATION OF 2 PROBE DRUGS, ANTIPYRINE AND TOLBUTAMIDE (Journal article)
BACK, D. J., TJIA, J., MONIG, H., OHNHAUS, E. E., & PARK, B. K. (1988). SELECTIVE-INHIBITION OF DRUG OXIDATION AFTER SIMULTANEOUS ADMINISTRATION OF 2 PROBE DRUGS, ANTIPYRINE AND TOLBUTAMIDE. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 34(2), 157-163. doi:10.1007/BF00614553DOI: 10.1007/BF00614553
CHARACTERIZATION AND INHIBITION OF ESTROGEN 2-HYDROXYLASE ACTIVITY IN HUMAN-LIVER MICROSOMES (Journal article)
BALL, S., BACK, D. J., & ORME, M. L. E. (1988). CHARACTERIZATION AND INHIBITION OF ESTROGEN 2-HYDROXYLASE ACTIVITY IN HUMAN-LIVER MICROSOMES. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 25(5), P643-P644. Retrieved from https://www.webofscience.com/
EVALUATION OF COMMITTEE ON SAFETY OF MEDICINES YELLOW CARD REPORTS ON ORAL CONTRACEPTIVE DRUG INTERACTIONS WITH ANTI-CONVULSANTS AND ANTIBIOTICS (Journal article)
BACK, D. J., GRIMMER, S. F. M., ORME, M. L. E., PROUDLOVE, C., MANN, R. D., & BRECKENRIDGE, A. M. (1988). EVALUATION OF COMMITTEE ON SAFETY OF MEDICINES YELLOW CARD REPORTS ON ORAL CONTRACEPTIVE DRUG INTERACTIONS WITH ANTI-CONVULSANTS AND ANTIBIOTICS. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 25(5), 527-532. doi:10.1111/j.1365-2125.1988.tb03341.xDOI: 10.1111/j.1365-2125.1988.tb03341.x
In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. (Journal article)
Back, D. J., Tjia, J. F., Karbwang, J., & Colbert, J. (1988). In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines.. British journal of clinical pharmacology, 26(1), 23-29. doi:10.1111/j.1365-2125.1988.tb03359.xDOI: 10.1111/j.1365-2125.1988.tb03359.x
Inhibition of tolbutamide metabolism by antimalarial drugs. (Journal article)
Karbwang, J., Back, D. J., Bunnag, D., & Breckenridge, A. M. (1988). Inhibition of tolbutamide metabolism by antimalarial drugs.. The Southeast Asian journal of tropical medicine and public health, 19(2), 235-241.
PRE-SYSTEMIC METABOLISM OF THE ORAL-CONTRACEPTIVE STEROID DESOGESTREL (Journal article)
BACK, D. J., MADDEN, S., & MARTIN, C. A. (1988). PRE-SYSTEMIC METABOLISM OF THE ORAL-CONTRACEPTIVE STEROID DESOGESTREL. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 25(5), P675-P676. Retrieved from https://www.webofscience.com/
SULFATION AND GLUCURONIDATION OF ETHINYLESTRADIOL IN HUMAN-LIVER INVITRO (Journal article)
PACIFICI, G. M., & BACK, D. J. (1988). SULFATION AND GLUCURONIDATION OF ETHINYLESTRADIOL IN HUMAN-LIVER INVITRO. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 31(3), 345-349. doi:10.1016/0022-4731(88)90360-3DOI: 10.1016/0022-4731(88)90360-3
1987
Inhibition of theophylline metabolism by interferon. (Journal article)
Winstanley, P. A., Back, D. J., & Breckenridge, A. M. (1987). Inhibition of theophylline metabolism by interferon.. Lancet (London, England), 2(8571), 1340. doi:10.1016/s0140-6736(87)91240-2DOI: 10.1016/s0140-6736(87)91240-2
SINGLE DOSE PRIMAQUINE HAS NO EFFECT ON PARACETAMOL CLEARANCE (Journal article)
BACK, D. J., & TJIA, J. F. (1987). SINGLE DOSE PRIMAQUINE HAS NO EFFECT ON PARACETAMOL CLEARANCE. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 32(2), 203-205. doi:10.1007/BF00542197DOI: 10.1007/BF00542197
THE PHARMACOKINETICS OF MEFLOQUINE WHEN GIVEN ALONE OR IN COMBINATION WITH SULFADOXINE AND PYRIMETHAMINE IN THAI MALE AND FEMALE SUBJECTS (Journal article)
KARBWANG, J., BUNNAG, D., BRECKENRIDGE, A. M., & BACK, D. J. (1987). THE PHARMACOKINETICS OF MEFLOQUINE WHEN GIVEN ALONE OR IN COMBINATION WITH SULFADOXINE AND PYRIMETHAMINE IN THAI MALE AND FEMALE SUBJECTS. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 32(2), 173-177. doi:10.1007/BF00542191DOI: 10.1007/BF00542191
COMPARATIVE PHARMACOKINETICS OF LEVONORGESTREL AND ETHINYLESTRADIOL FOLLOWING INTRAVENOUS, ORAL AND VAGINAL ADMINISTRATION (Journal article)
BACK, D. J., GRIMMER, S. F. M., ROGERS, S., STEVENSON, P. J., & ORME, M. L. B. (1987). COMPARATIVE PHARMACOKINETICS OF LEVONORGESTREL AND ETHINYLESTRADIOL FOLLOWING INTRAVENOUS, ORAL AND VAGINAL ADMINISTRATION. CONTRACEPTION, 36(4), 471-479. doi:10.1016/0010-7824(87)90095-3DOI: 10.1016/0010-7824(87)90095-3
INTESTINAL METABOLISM OF ETHINYLESTRADIOL AND PARACETAMOL INVITRO - STUDIES USING USSING CHAMBERS (Journal article)
ROGERS, S. M., BACK, D. J., & ORME, M. L. (1987). INTESTINAL METABOLISM OF ETHINYLESTRADIOL AND PARACETAMOL INVITRO - STUDIES USING USSING CHAMBERS. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 23(6), 727-734. doi:10.1111/j.1365-2125.1987.tb03108.xDOI: 10.1111/j.1365-2125.1987.tb03108.x
PARACETAMOL INTERACTION WITH ORAL-CONTRACEPTIVE STEROIDS - INCREASED PLASMA-CONCENTRATIONS OF ETHINYLESTRADIOL (Journal article)
ROGERS, S. M., BACK, D. J., STEVENSON, P. J., GRIMMER, S. F. M., & ORME, M. L. (1987). PARACETAMOL INTERACTION WITH ORAL-CONTRACEPTIVE STEROIDS - INCREASED PLASMA-CONCENTRATIONS OF ETHINYLESTRADIOL. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 23(6), 721-725. doi:10.1111/j.1365-2125.1987.tb03107.xDOI: 10.1111/j.1365-2125.1987.tb03107.x
PHARMACOKINETICS OF CONTRACEPTIVE STEROIDS IN PATIENTS WITH CYSTIC-FIBROSIS (Journal article)
STEAD, R. J., GRIMMER, S. F. M., ROGERS, S. M., BACK, D. J., ORME, M. L. E., HODSON, M. E., & BATTEN, J. C. (1987). PHARMACOKINETICS OF CONTRACEPTIVE STEROIDS IN PATIENTS WITH CYSTIC-FIBROSIS. THORAX, 42(1), 59-64. doi:10.1136/thx.42.1.59DOI: 10.1136/thx.42.1.59
PLASMA AND WHOLE-BLOOD MEFLOQUINE CONCENTRATIONS DURING TREATMENT OF CHLOROQUINE-RESISTANT FALCIPARUM-MALARIA WITH THE COMBINATION MEFLOQUINE-SULFADOXINE-PYRIMETHAMINE (Journal article)
KARBWANG, J., LOOAREESUWAN, S., PHILLIPS, R. E., WATTANAGOON, Y., MOLYNEUX, M. E., NAGACHINTA, B., . . . WARRELL, D. A. (1987). PLASMA AND WHOLE-BLOOD MEFLOQUINE CONCENTRATIONS DURING TREATMENT OF CHLOROQUINE-RESISTANT FALCIPARUM-MALARIA WITH THE COMBINATION MEFLOQUINE-SULFADOXINE-PYRIMETHAMINE. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 23(4), 477-481. doi:10.1111/j.1365-2125.1987.tb03079.xDOI: 10.1111/j.1365-2125.1987.tb03079.x
PLASMA-CONCENTRATIONS OF 3-KETO-DESOGESTREL AFTER ORAL-ADMINISTRATION OF DESOGESTREL AND INTRAVENOUS ADMINISTRATION OF 3-KETO-DESOGESTREL (Journal article)
BACK, D. J., GRIMMER, S. F. M., SHENOY, N., & ORME, M. L. E. (1987). PLASMA-CONCENTRATIONS OF 3-KETO-DESOGESTREL AFTER ORAL-ADMINISTRATION OF DESOGESTREL AND INTRAVENOUS ADMINISTRATION OF 3-KETO-DESOGESTREL. CONTRACEPTION, 35(6), 619-626. doi:10.1016/S0010-7824(87)80021-5DOI: 10.1016/S0010-7824(87)80021-5
Review: first-pass metabolism by the gastrointestinal mucosa. (Journal article)
Back, D. J., & Rogers, S. M. (1987). Review: first-pass metabolism by the gastrointestinal mucosa.. Alimentary pharmacology & therapeutics, 1(5), 339-357. doi:10.1111/j.1365-2036.1987.tb00634.xDOI: 10.1111/j.1365-2036.1987.tb00634.x
THE METABOLISM OF 17 ALPHA-ETHINYLESTRADIOL BY HUMAN-LIVER MICROSOMES - FORMATION OF CATECHOL AND CHEMICALLY REACTIVE METABOLITES (Journal article)
PURBA, H. S., MAGGS, J. L., ORME, M. L. E., BACK, D. J., & PARK, B. K. (1987). THE METABOLISM OF 17 ALPHA-ETHINYLESTRADIOL BY HUMAN-LIVER MICROSOMES - FORMATION OF CATECHOL AND CHEMICALLY REACTIVE METABOLITES. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 23(4), 447-453. doi:10.1111/j.1365-2125.1987.tb03074.xDOI: 10.1111/j.1365-2125.1987.tb03074.x
THE RELATIVE BIOAVAILABILITY OF LEVONORGESTREL AND ETHINYLESTRADIOL WHEN ADMINISTERED IN TABLET AND CAPSULE FORM (Journal article)
BACK, D. J., KILLICK, S. R., STEVENSON, P. J., SHENOY, N., ELSTEIN, M., & COHEN, M. (1987). THE RELATIVE BIOAVAILABILITY OF LEVONORGESTREL AND ETHINYLESTRADIOL WHEN ADMINISTERED IN TABLET AND CAPSULE FORM. CONTRACEPTION, 36(3), 321-326. doi:10.1016/0010-7824(87)90102-8DOI: 10.1016/0010-7824(87)90102-8
TOLBUTAMIDE 4-HYDROXYLASE ACTIVITY OF HUMAN-LIVER MICROSOMES - EFFECT OF INHIBITORS (Journal article)
PURBA, H. S., BACK, D. J., & ORME, M. L. (1987). TOLBUTAMIDE 4-HYDROXYLASE ACTIVITY OF HUMAN-LIVER MICROSOMES - EFFECT OF INHIBITORS. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 24(2), 230-234. doi:10.1111/j.1365-2125.1987.tb03167.xDOI: 10.1111/j.1365-2125.1987.tb03167.x
1986
USE OF ORAL-CONTRACEPTIVES BY WOMEN WITH EPILEPSY (Journal article)
ORME, M., BACK, D. J., & GUILLEBAUD, J. (1986). USE OF ORAL-CONTRACEPTIVES BY WOMEN WITH EPILEPSY. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 256(21), 2962. doi:10.1001/jama.1986.03380210057019DOI: 10.1001/jama.1986.03380210057019
INHIBITION OF ETHINYLESTRADIOL AND TOLBUTAMIDE METABOLISM BY QUINOLINE DERIVATIVES INVITRO (Journal article)
RIVIERE, J. H., & BACK, D. J. (1986). INHIBITION OF ETHINYLESTRADIOL AND TOLBUTAMIDE METABOLISM BY QUINOLINE DERIVATIVES INVITRO. CHEMICO-BIOLOGICAL INTERACTIONS, 59(3), 301-308. doi:10.1016/S0009-2797(86)80075-8DOI: 10.1016/S0009-2797(86)80075-8
DRUG-INTERACTIONS BETWEEN ORAL-CONTRACEPTIVE STEROIDS AND ANTIBIOTICS (Journal article)
ORME, M. L., & BACK, D. J. (1986). DRUG-INTERACTIONS BETWEEN ORAL-CONTRACEPTIVE STEROIDS AND ANTIBIOTICS. BRITISH DENTAL JOURNAL, 160(5), 169-170. doi:10.1038/sj.bdj.4805798DOI: 10.1038/sj.bdj.4805798
CONTRACEPTIVE STEROID CONCENTRATIONS IN WOMEN WITH EARLY ACTIVE SCHISTOSOMIASIS - LACK OF EFFECT OF ANTISCHISTOSOMAL DRUGS (Journal article)
ELRAGHY, I., BACK, D. J., OSMAN, F., ORME, M. L., & FATHALLA, M. (1986). CONTRACEPTIVE STEROID CONCENTRATIONS IN WOMEN WITH EARLY ACTIVE SCHISTOSOMIASIS - LACK OF EFFECT OF ANTISCHISTOSOMAL DRUGS. CONTRACEPTION, 33(4), 373-377. doi:10.1016/0010-7824(86)90099-5DOI: 10.1016/0010-7824(86)90099-5
INHIBITION OF ESTROGEN 2-HYDROXYLASE (Journal article)
PURBA, H. S., BACK, D. J., & BRECKENRIDGE, A. M. (1986). INHIBITION OF ESTROGEN 2-HYDROXYLASE. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 24(5), 1091-1093. doi:10.1016/0022-4731(86)90365-1DOI: 10.1016/0022-4731(86)90365-1
INTERACTIONS BETWEEN ORAL-CONTRACEPTIVE STEROIDS AND BROAD-SPECTRUM ANTIBIOTICS (Journal article)
ORME, M. L., & BACK, D. J. (1986). INTERACTIONS BETWEEN ORAL-CONTRACEPTIVE STEROIDS AND BROAD-SPECTRUM ANTIBIOTICS. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 11(4), 327-331. doi:10.1111/j.1365-2230.1986.tb00471.xDOI: 10.1111/j.1365-2230.1986.tb00471.x
INTESTINAL-ABSORPTION OF ESTRONE, ESTRONE GLUCURONIDE AND ESTRONE SULFATE IN THE RAT INSITU .2. STUDIES WITH THE DOLUISIO TECHNIQUE (Journal article)
SIM, S. M., & BACK, D. J. (1986). INTESTINAL-ABSORPTION OF ESTRONE, ESTRONE GLUCURONIDE AND ESTRONE SULFATE IN THE RAT INSITU .2. STUDIES WITH THE DOLUISIO TECHNIQUE. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 24(5), 1085-1089. Retrieved from https://www.webofscience.com/
PHARMACOKINETICS OF ORAL-CONTRACEPTIVE STEROIDS IN EGYPTIAN WOMEN - STUDIES WITH OVRAL, NORDETTE AND NORMINEST (Journal article)
ELRAGHY, I., BACK, D. J., MAKERAM, M., SALEM, H., OSMAN, F., FATHALLA, M., & ORME, M. L. (1986). PHARMACOKINETICS OF ORAL-CONTRACEPTIVE STEROIDS IN EGYPTIAN WOMEN - STUDIES WITH OVRAL, NORDETTE AND NORMINEST. CONTRACEPTION, 33(4), 379-384. doi:10.1016/0010-7824(86)90100-9DOI: 10.1016/0010-7824(86)90100-9
THE BIOAVAILABILITY OF ETHINYLESTRADIOL AND LEVONORGESTREL IN PATIENTS WITH AN ILEOSTOMY (Journal article)
GRIMMER, S. F. M., BACK, D. J., ORME, M. L., COWIE, A., GILMORE, I., & TJIA, J. (1986). THE BIOAVAILABILITY OF ETHINYLESTRADIOL AND LEVONORGESTREL IN PATIENTS WITH AN ILEOSTOMY. CONTRACEPTION, 33(1), 51-59. doi:10.1016/0010-7824(86)90032-6DOI: 10.1016/0010-7824(86)90032-6
THE LACK OF EFFECT OF SODIUM VALPROATE ON THE PHARMACOKINETICS OF ORAL-CONTRACEPTIVE STEROIDS (Journal article)
CRAWFORD, P., CHADWICK, D., CLELAND, P., TJIA, J., COWIE, A., BACK, D. J., & ORME, M. L. (1986). THE LACK OF EFFECT OF SODIUM VALPROATE ON THE PHARMACOKINETICS OF ORAL-CONTRACEPTIVE STEROIDS. CONTRACEPTION, 33(1), 23-29. doi:10.1016/0010-7824(86)90028-4DOI: 10.1016/0010-7824(86)90028-4
1985
EFFECT OF MEFLOQUINE ON HEPATIC DRUG-METABOLISM IN THE RAT - COMPARATIVE-STUDY WITH PRIMAQUINE (Journal article)
RIVIERE, J. H., & BACK, D. J. (1985). EFFECT OF MEFLOQUINE ON HEPATIC DRUG-METABOLISM IN THE RAT - COMPARATIVE-STUDY WITH PRIMAQUINE. BIOCHEMICAL PHARMACOLOGY, 34(4), 567-571. doi:10.1016/0006-2952(85)90191-1DOI: 10.1016/0006-2952(85)90191-1
A NON-CHROMATOGRAPHIC RADIOIMMUNOASSAY FOR 3-OXO DESOGESTREL (Journal article)
SHAW, M. A., BACK, D. J., COWIE, A. M., & ORME, M. C. L. (1985). A NON-CHROMATOGRAPHIC RADIOIMMUNOASSAY FOR 3-OXO DESOGESTREL. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 22(1), 111-113. doi:10.1016/0022-4731(85)90149-9DOI: 10.1016/0022-4731(85)90149-9
INHIBITION OF TOLBUTAMIDE METABOLISM BY SUBSTITUTED IMIDAZOLE DRUGS INVIVO - EVIDENCE FOR A STRUCTURE-ACTIVITY RELATIONSHIP (Journal article)
BACK, D. J., & TJIA, J. F. (1985). INHIBITION OF TOLBUTAMIDE METABOLISM BY SUBSTITUTED IMIDAZOLE DRUGS INVIVO - EVIDENCE FOR A STRUCTURE-ACTIVITY RELATIONSHIP. BRITISH JOURNAL OF PHARMACOLOGY, 85(1), 121-126. doi:10.1111/j.1476-5381.1985.tb08838.xDOI: 10.1111/j.1476-5381.1985.tb08838.x
INTESTINAL-ABSORPTION OF ESTRONE, ESTRONE GLUCURONIDE AND ESTRONE SULFATE IN THE RAT INSITU .1. IMPORTANCE OF HYDROLYTIC ENZYMES ON CONJUGATE ABSORPTION (Journal article)
SIM, S. M., & BACK, D. J. (1985). INTESTINAL-ABSORPTION OF ESTRONE, ESTRONE GLUCURONIDE AND ESTRONE SULFATE IN THE RAT INSITU .1. IMPORTANCE OF HYDROLYTIC ENZYMES ON CONJUGATE ABSORPTION. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 22(6), 781-788. Retrieved from https://www.webofscience.com/
LACK OF EFFECT OF HIGHLY PURIFIED SUBUNIT INFLUENZA VACCINATION ON THEOPHYLLINE METABOLISM (Journal article)
WINSTANLEY, P. A., TJIA, J., BACK, D. J., HOBSON, D., & BRECKENRIDGE, A. M. (1985). LACK OF EFFECT OF HIGHLY PURIFIED SUBUNIT INFLUENZA VACCINATION ON THEOPHYLLINE METABOLISM. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 20(1), 47-53. doi:10.1111/j.1365-2125.1985.tb02797.xDOI: 10.1111/j.1365-2125.1985.tb02797.x
NORETHISTERONE CONCENTRATION IN BREAST-MILK AND INFANT AND MATERNAL PLASMA DURING ETHYNODIOL DIACETATE ADMINISTRATION (Journal article)
COOKE, I. D., BACK, D. J., & SHROFF, N. E. (1985). NORETHISTERONE CONCENTRATION IN BREAST-MILK AND INFANT AND MATERNAL PLASMA DURING ETHYNODIOL DIACETATE ADMINISTRATION. CONTRACEPTION, 31(6), 611-621. doi:10.1016/0010-7824(85)90061-7DOI: 10.1016/0010-7824(85)90061-7
THE PHARMACOKINETICS OF ANTIPYRINE IN PATIENTS WITH GRADED SEVERITY OF SCHISTOSOMIASIS (Journal article)
ELRAGHY, I., BACK, D. J., OSMAN, F., NAFEH, M. A., & ORME, M. L. (1985). THE PHARMACOKINETICS OF ANTIPYRINE IN PATIENTS WITH GRADED SEVERITY OF SCHISTOSOMIASIS. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 20(4), 313-316. doi:10.1111/j.1365-2125.1985.tb05069.xDOI: 10.1111/j.1365-2125.1985.tb05069.x
THE PHARMACOKINETICS OF MEFLOQUINE IN MAN - LACK OF EFFECT OF MEFLOQUINE ON ANTIPYRINE METABOLISM (Journal article)
RIVIERE, J. H., BACK, D. J., BRECKENRIDGE, A. M., & HOWELLS, R. E. (1985). THE PHARMACOKINETICS OF MEFLOQUINE IN MAN - LACK OF EFFECT OF MEFLOQUINE ON ANTIPYRINE METABOLISM. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 20(5), 469-474. doi:10.1111/j.1365-2125.1985.tb05099.xDOI: 10.1111/j.1365-2125.1985.tb05099.x
1984
Isotretinoin and contraception. (Journal article)
Orme, M., Back, D. J., Shaw, M. A., Allen, W. L., Tjia, J., Cunliffe, W. J., & Jones, D. H. (1984). Isotretinoin and contraception.. Lancet (London, England), 2(8405), 752-753. doi:10.1016/s0140-6736(84)92659-xDOI: 10.1016/s0140-6736(84)92659-x
AN INVESTIGATION OF THE EFFECTS OF PHENOBARBITONE ON THE PHARMACOKINETICS OF NORETHINDRONE IN THE RAT USING LIVER PERFUSION AND EVERTED GUT SACS (Journal article)
BACK, D. J., MACNEE, C. M., ORME, M. L., ROWE, P. H., & SMITH, E. (1984). AN INVESTIGATION OF THE EFFECTS OF PHENOBARBITONE ON THE PHARMACOKINETICS OF NORETHINDRONE IN THE RAT USING LIVER PERFUSION AND EVERTED GUT SACS. BIOCHEMICAL PHARMACOLOGY, 33(10), 1595-1600. doi:10.1016/0006-2952(84)90279-XDOI: 10.1016/0006-2952(84)90279-X
OVERESTIMATION OF LOW PROGESTERONE CONCENTRATIONS BY A COMMERCIAL RADIOIMMUNOASSAY KIT (Journal article)
ALLEN, W. L., BACK, D. J., & SHAW, M. A. (1984). OVERESTIMATION OF LOW PROGESTERONE CONCENTRATIONS BY A COMMERCIAL RADIOIMMUNOASSAY KIT. CLINICAL CHEMISTRY, 30(3), 495-496. Retrieved from https://www.webofscience.com/
DRUG-METABOLISM AND TROPICAL DISEASE (Journal article)
BRECKENRIDGE, A., AWADZI, K., BACK, D. J., EDWARDS, G., GILLES, H., ORME, M., & WARD, S. (1984). DRUG-METABOLISM AND TROPICAL DISEASE. BIOCHEMICAL SOCIETY TRANSACTIONS, 12(1), 90-95. doi:10.1042/bst0120090DOI: 10.1042/bst0120090
Pharmacokinetic and "potency" of contraceptive steroids. (Journal article)
Back, D. J., Breckenridge, A., Orme, M., & Shaw, M. A. (1984). Pharmacokinetic and "potency" of contraceptive steroids.. Lancet (London, England), 1(8369), 171. doi:10.1016/s0140-6736(84)90113-2DOI: 10.1016/s0140-6736(84)90113-2
2-HYDROXYLATION OF ETHINYLESTRADIOL IN RELATION TO THE OXIDATION OF SPARTEINE AND ANTIPYRINE (Journal article)
BACK, D. J., MAGGS, J. L., PURBA, H. S., NEWBY, S., & PARK, B. K. (1984). 2-HYDROXYLATION OF ETHINYLESTRADIOL IN RELATION TO THE OXIDATION OF SPARTEINE AND ANTIPYRINE. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 18(4), 603-607. doi:10.1111/j.1365-2125.1984.tb02511.xDOI: 10.1111/j.1365-2125.1984.tb02511.x
DISTRIBUTION OF ESTRONE SULFATASE ACTIVITY IN THE INTESTINE OF GERMFREE AND CONVENTIONAL RATS (Journal article)
HUIJGHEBAERT, S. M., SIM, S. M., BACK, D. J., & EYSSEN, H. J. (1984). DISTRIBUTION OF ESTRONE SULFATASE ACTIVITY IN THE INTESTINE OF GERMFREE AND CONVENTIONAL RATS. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 20(5), 1175-1179. doi:10.1016/0022-4731(84)90363-7DOI: 10.1016/0022-4731(84)90363-7
INHIBITION OF HEPATIC-MICROSOMAL ENZYMES BY GOSSYPOL IN THE RAT (Journal article)
MA, X. N., & BACK, D. J. (1984). INHIBITION OF HEPATIC-MICROSOMAL ENZYMES BY GOSSYPOL IN THE RAT. CONTRACEPTION, 30(1), 89-97. Retrieved from https://www.webofscience.com/
INTERINDIVIDUAL VARIABILITY IN ORAL-CONTRACEPTIVE DISPOSITION (Journal article)
BACK, D. J., & ORME, M. L. (1984). INTERINDIVIDUAL VARIABILITY IN ORAL-CONTRACEPTIVE DISPOSITION. TRENDS IN PHARMACOLOGICAL SCIENCES, 5(11), 480-483. doi:10.1016/0165-6147(84)90514-5DOI: 10.1016/0165-6147(84)90514-5
PHARMACOKINETICS OF ORAL-CONTRACEPTIVE STEROIDS FOLLOWING THE ADMINISTRATION OF THE ANTIMALARIAL-DRUGS PRIMAQUINE AND CHLOROQUINE (Journal article)
BACK, D. J., BRECKENRIDGE, A. M., GRIMMER, S. F. M., ORME, M. L. E., & PURBA, H. S. (1984). PHARMACOKINETICS OF ORAL-CONTRACEPTIVE STEROIDS FOLLOWING THE ADMINISTRATION OF THE ANTIMALARIAL-DRUGS PRIMAQUINE AND CHLOROQUINE. CONTRACEPTION, 30(3), 289-295. doi:10.1016/0010-7824(84)90092-1DOI: 10.1016/0010-7824(84)90092-1
TOLBUTAMIDE AS A MODEL-DRUG FOR THE STUDY OF ENZYME-INDUCTION AND ENZYME-INHIBITION IN THE RAT (Journal article)
BACK, D. J., SUTCLIFFE, F., & TJIA, J. F. (1984). TOLBUTAMIDE AS A MODEL-DRUG FOR THE STUDY OF ENZYME-INDUCTION AND ENZYME-INHIBITION IN THE RAT. BRITISH JOURNAL OF PHARMACOLOGY, 81(3), 557-562. doi:10.1111/j.1476-5381.1984.tb10109.xDOI: 10.1111/j.1476-5381.1984.tb10109.x
1983
Drug interactions with oral contraceptive steroids. (Journal article)
Back, D. J., Breckenridge, A. M., & Orme, M. L. (1983). Drug interactions with oral contraceptive steroids.. IPPF medical bulletin, 17(1), 1-2.
INHIBITION OF DRUG-METABOLISM BY THE ANTI-MALARIAL DRUGS CHLOROQUINE AND PRIMAQUINE IN THE RAT (Journal article)
BACK, D. J., PURBA, H. S., STAIGER, C., ORME, M. L., & BRECKENRIDGE, A. M. (1983). INHIBITION OF DRUG-METABOLISM BY THE ANTI-MALARIAL DRUGS CHLOROQUINE AND PRIMAQUINE IN THE RAT. BIOCHEMICAL PHARMACOLOGY, 32(2), 257-263. doi:10.1016/0006-2952(83)90553-1DOI: 10.1016/0006-2952(83)90553-1
ADSORPTION OF PREGNANEDIOL 3-ALPHA-GLUCURONIDE BY PLASTICS AND GLASS (Journal article)
SHAW, M. A., & BACK, D. J. (1983). ADSORPTION OF PREGNANEDIOL 3-ALPHA-GLUCURONIDE BY PLASTICS AND GLASS. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 19(5), 1681-1682. doi:10.1016/0022-4731(83)90391-6DOI: 10.1016/0022-4731(83)90391-6
CLINICAL PHARMACOKINETICS OF ORAL-CONTRACEPTIVE STEROIDS (Journal article)
ORME, M. L., BACK, D. J., & BRECKENRIDGE, A. M. (1983). CLINICAL PHARMACOKINETICS OF ORAL-CONTRACEPTIVE STEROIDS. CLINICAL PHARMACOKINETICS, 8(2), 95-136. doi:10.2165/00003088-198308020-00001DOI: 10.2165/00003088-198308020-00001
EFFECT OF CHLOROQUINE AND PRIMAQUINE ON ANTIPYRINE METABOLISM (Journal article)
BACK, D. J., PURBA, H. S., PARK, B. K., WARD, S. A., & ORME, M. L. (1983). EFFECT OF CHLOROQUINE AND PRIMAQUINE ON ANTIPYRINE METABOLISM. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 16(5), 497-502. doi:10.1111/j.1365-2125.1983.tb02206.xDOI: 10.1111/j.1365-2125.1983.tb02206.x
GASTROINTESTINAL ABSORPTION OF ESTRONE SULFATE IN GERMFREE AND CONVENTIONAL RATS (Journal article)
SIM, S. M., HUIJGHEBAERT, S., BACK, D. J., & EYSSEN, H. J. (1983). GASTROINTESTINAL ABSORPTION OF ESTRONE SULFATE IN GERMFREE AND CONVENTIONAL RATS. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 18(4), 499-503. Retrieved from https://www.webofscience.com/
ORAL-CONTRACEPTIVES AND ASCORBIC-ACID METABOLISM (Journal article)
BACK, D. J., & EORME, M. L. (1983). ORAL-CONTRACEPTIVES AND ASCORBIC-ACID METABOLISM. AMERICAN JOURNAL OF CLINICAL NUTRITION, 37(2), 330. doi:10.1093/ajcn/37.2.330DOI: 10.1093/ajcn/37.2.330
Potential problems with aqueous steroid solutions. (Journal article)
Sim, S. M., Back, D. J., & Tjia, J. F. (1983). Potential problems with aqueous steroid solutions.. The Journal of pharmacy and pharmacology, 35(3), 200. doi:10.1111/j.2042-7158.1983.tb04312.xDOI: 10.1111/j.2042-7158.1983.tb04312.x
Sulphaphenazole and drug oxidation in man. (Journal article)
Back, D. B., Park, B. K., Tjia, J. F., & Newby, S. N. (1983). Sulphaphenazole and drug oxidation in man.. British journal of clinical pharmacology, 16(4), 460-461. doi:10.1111/j.1365-2125.1983.tb02199.xDOI: 10.1111/j.1365-2125.1983.tb02199.x
THE EFFECT OF CO-TRIMOXAZOLE ON ORAL-CONTRACEPTIVE STEROIDS IN WOMEN (Journal article)
GRIMMER, S. F. M., ALLEN, W. L., BACK, D. J., BRECKENRIDGE, A. M., ORME, M., & TJIA, J. (1983). THE EFFECT OF CO-TRIMOXAZOLE ON ORAL-CONTRACEPTIVE STEROIDS IN WOMEN. CONTRACEPTION, 28(1), 53-59. doi:10.1016/S0010-7824(83)80005-5DOI: 10.1016/S0010-7824(83)80005-5
URINARY CONCENTRATIONS OF STEROID GLUCURONIDES IN WOMEN TAKING ORAL-CONTRACEPTIVES (Journal article)
SHAW, M. A., BACK, D. J., AIRD, S. A., GRIMMER, S. F. M., & ORME, M. C. L. (1983). URINARY CONCENTRATIONS OF STEROID GLUCURONIDES IN WOMEN TAKING ORAL-CONTRACEPTIVES. CONTRACEPTION, 28(1), 69-75. doi:10.1016/S0010-7824(83)80007-9DOI: 10.1016/S0010-7824(83)80007-9
1982
AN ANTIBIOTIC INTERACTION WITH ETHINYLESTRADIOL IN THE RAT AND RABBIT (Journal article)
BACK, D. J., BRECKENRIDGE, A. M., CROSS, K. J., ORME, M. L., & THOMAS, E. (1982). AN ANTIBIOTIC INTERACTION WITH ETHINYLESTRADIOL IN THE RAT AND RABBIT. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 16(3), 407-413. doi:10.1016/0022-4731(82)90053-XDOI: 10.1016/0022-4731(82)90053-X
INTERACTION BETWEEN ETHINYLESTRADIOL AND ASCORBIC-ACID (Journal article)
BACK, D. J., BRECKENRIDGE, A. M., MACIVER, M., ORME, M. L., PURBA, H., & ROWE, P. H. (1982). INTERACTION BETWEEN ETHINYLESTRADIOL AND ASCORBIC-ACID. CONTRACEPTION FERTILITE SEXUALITE, 10(9), 547-549. Retrieved from https://www.webofscience.com/
ORAL-CONTRACEPTIVE STEROID PLASMA-CONCENTRATIONS IN SMOKERS AND NON SMOKERS (Journal article)
CRAWFORD, F. E., BACK, D. J., ORME, M. L. E., & BRECKENRIDGE, A. M. (1982). ORAL-CONTRACEPTIVE STEROID PLASMA-CONCENTRATIONS IN SMOKERS AND NON SMOKERS. CONTRACEPTION FERTILITE SEXUALITE, 10(3), 143-148. Retrieved from https://www.webofscience.com/
THE EFFECTS OF AMPICILLIN ON ORAL-CONTRACEPTIVE STEROIDS IN WOMEN (Journal article)
BACK, D. J., BRECKENRIDGE, A. M., MACIVER, M., ORME, M., ROWE, P. H., STAIGER, C., . . . TJIA, J. (1982). THE EFFECTS OF AMPICILLIN ON ORAL-CONTRACEPTIVE STEROIDS IN WOMEN. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 14(1), 43-48. doi:10.1111/j.1365-2125.1982.tb04932.xDOI: 10.1111/j.1365-2125.1982.tb04932.x
THE ENZYME INDUCING EFFECT OF RIFAMPICIN IN THE RHESUS-MONKEY AND ITS LACK OF INTERACTION WITH ORAL-CONTRACEPTIVE STEROIDS (Journal article)
BACK, D. J., BARKFELDT, J. O., BRECKENRIDGE, A. M., ODLIND, V., ORME, M., PARK, B. K., . . . VICTOR, A. (1982). THE ENZYME INDUCING EFFECT OF RIFAMPICIN IN THE RHESUS-MONKEY AND ITS LACK OF INTERACTION WITH ORAL-CONTRACEPTIVE STEROIDS. CONTRACEPTION, 25(3), 307-316. doi:10.1016/0010-7824(82)90054-3DOI: 10.1016/0010-7824(82)90054-3
THE GUT WALL METABOLISM OF ETHINYLESTRADIOL AND ITS CONTRIBUTION TO THE PRE-SYSTEMIC METABOLISM OF ETHINYLESTRADIOL IN HUMANS (Journal article)
BACK, D. J., BRECKENRIDGE, A. M., MACIVER, M., ORME, M., PURBA, H. S., ROWE, P. H., & TAYLOR, I. (1982). THE GUT WALL METABOLISM OF ETHINYLESTRADIOL AND ITS CONTRIBUTION TO THE PRE-SYSTEMIC METABOLISM OF ETHINYLESTRADIOL IN HUMANS. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 13(3), 325-330. doi:10.1111/j.1365-2125.1982.tb01382.xDOI: 10.1111/j.1365-2125.1982.tb01382.x
1981
INTERACTION OF ETHINYLESTRADIOL WITH ASCORBIC-ACID - REPLY (Journal article)
BACK, D. J., BRECKENRIDGE, A. M., & ORME, M. L. E. (1981). INTERACTION OF ETHINYLESTRADIOL WITH ASCORBIC-ACID - REPLY. BRITISH MEDICAL JOURNAL, 282(6281), 2057. doi:10.1136/bmj.282.6281.2057-aDOI: 10.1136/bmj.282.6281.2057-a
ORAL-CONTRACEPTIVE STEROID PLASMA-CONCENTRATIONS IN SMOKERS AND NON-SMOKERS (Journal article)
CRAWFORD, F. E., BACK, D. J., ORME, M. L. E., & BRECKENRIDGE, A. M. (1981). ORAL-CONTRACEPTIVE STEROID PLASMA-CONCENTRATIONS IN SMOKERS AND NON-SMOKERS. BRITISH MEDICAL JOURNAL, 282(6279), 1829-1830. doi:10.1136/bmj.282.6279.1829DOI: 10.1136/bmj.282.6279.1829
INTERACTION OF ETHINYLESTRADIOL WITH ASCORBIC-ACID IN MAN (Journal article)
BACK, D. J., BRECKENRIDGE, A. M., MACIVER, M., ORME, M. L., PURBA, H., & ROWE, P. H. (1981). INTERACTION OF ETHINYLESTRADIOL WITH ASCORBIC-ACID IN MAN. BRITISH MEDICAL JOURNAL, 282(6275), 1516. doi:10.1136/bmj.282.6275.1516DOI: 10.1136/bmj.282.6275.1516
ABSORPTION OF ESTRONE SULFATE FROM THE GASTROINTESTINAL-TRACT OF THE RAT (Journal article)
BACK, D. J., CHAPMAN, C. R., MAY, S. A., & ROWE, P. H. (1981). ABSORPTION OF ESTRONE SULFATE FROM THE GASTROINTESTINAL-TRACT OF THE RAT. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 14(4), 347-356. doi:10.1016/0022-4731(81)90153-9DOI: 10.1016/0022-4731(81)90153-9
INTERINDIVIDUAL VARIATION AND DRUG-INTERACTIONS WITH HORMONAL STEROID-CONTRACEPTIVES (Journal article)
BACK, D. J., BRECKENRIDGE, A. M., CRAWFORD, F. E., MACIVER, M., ORME, M. L. E., & ROWE, P. H. (1981). INTERINDIVIDUAL VARIATION AND DRUG-INTERACTIONS WITH HORMONAL STEROID-CONTRACEPTIVES. DRUGS, 21(1), 46-61. doi:10.2165/00003495-198121010-00003DOI: 10.2165/00003495-198121010-00003
INTESTINAL-ABSORPTION OF ESTRONE SULFATE IN THE RAT (Journal article)
BACK, D. J., BRECKENRIDGE, A. M., CHAPMAN, C. R., CRAWFORD, F. E., ORME, M. L., & ROWE, P. H. (1981). INTESTINAL-ABSORPTION OF ESTRONE SULFATE IN THE RAT. BRITISH JOURNAL OF PHARMACOLOGY, 72(3), P541. Retrieved from https://www.webofscience.com/
METABOLISM OF NORETHISTERONE OENANTHATE INVITRO (Journal article)
BACK, D. J., BRECKENRIDGE, A. M., CHAPMAN, C. R., CRAWFORD, F. E., ORME, M. L., & ROWE, P. H. (1981). METABOLISM OF NORETHISTERONE OENANTHATE INVITRO. BRITISH JOURNAL OF PHARMACOLOGY, 72(3), P538. Retrieved from https://www.webofscience.com/
STUDIES ON THE ENZYMATIC CLEAVAGE OF NORETHISTERONE OENANTHATE (Journal article)
BACK, D. J., BRECKENRIDGE, A. M., CHAPMAN, C. R., CRAWFORD, F. E., OLSEN, K. A., ORME, M. L. E., & ROWE, P. H. (1981). STUDIES ON THE ENZYMATIC CLEAVAGE OF NORETHISTERONE OENANTHATE. CONTRACEPTION, 23(2), 125-132. doi:10.1016/0010-7824(81)90098-6DOI: 10.1016/0010-7824(81)90098-6
THE EFFECT OF CIGARETTE-SMOKING ON PLASMA-CONCENTRATIONS OF ORAL-CONTRACEPTIVE STEROIDS (Journal article)
CRAWFORD, F. E., BACK, D. J., ORME, M. L., & BRECKENRIDGE, A. M. (1981). THE EFFECT OF CIGARETTE-SMOKING ON PLASMA-CONCENTRATIONS OF ORAL-CONTRACEPTIVE STEROIDS. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 11(4), P438-P439. Retrieved from https://www.webofscience.com/
THE INVITRO METABOLISM OF ETHINYLESTRADIOL, MESTRANOL AND LEVONORGESTREL BY HUMAN JEJUNAL MUCOSA (Journal article)
BACK, D. J., BATES, M., BRECKENRIDGE, A. M., ELLIS, A., HALL, J. M., MACIVER, M., . . . ROWE, P. H. (1981). THE INVITRO METABOLISM OF ETHINYLESTRADIOL, MESTRANOL AND LEVONORGESTREL BY HUMAN JEJUNAL MUCOSA. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 11(3), 275-278. doi:10.1111/j.1365-2125.1981.tb00534.xDOI: 10.1111/j.1365-2125.1981.tb00534.x
THE PHARMACOKINETICS OF ESTRONE SULFATE IN THE RAT (Journal article)
BACK, D. J., BRECKENRIDGE, A. M., CRAWFORD, F. E., GILES, M., ORME, M. L. E., & ROWE, P. H. (1981). THE PHARMACOKINETICS OF ESTRONE SULFATE IN THE RAT. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 14(10), 1045-1047. doi:10.1016/0022-4731(81)90214-4DOI: 10.1016/0022-4731(81)90214-4
THE PHARMACOKINETICS OF LEVONORGESTREL AND ETHYNYLESTRADIOL IN WOMEN - STUDIES WITH OVRAN AND OVRANETTE (Journal article)
BACK, D. J., BATES, M., BRECKENRIDGE, A. M., HALL, J. M., MACIVER, M., ORME, M. L. E., . . . ROWE, P. H. (1981). THE PHARMACOKINETICS OF LEVONORGESTREL AND ETHYNYLESTRADIOL IN WOMEN - STUDIES WITH OVRAN AND OVRANETTE. CONTRACEPTION, 23(3), 229-239. doi:10.1016/0010-7824(81)90045-7DOI: 10.1016/0010-7824(81)90045-7
1980
Influence of environmental chemicals on drug therapy in humans: studies with contraceptive steroids. (Journal article)
Breckenridge, A. M., Back, D. J., Cross, K., Crawford, F., MacIver, M., Orme, M. L., . . . Smith, E. (1980). Influence of environmental chemicals on drug therapy in humans: studies with contraceptive steroids.. Ciba Foundation symposium, 76, 289-306. doi:10.1002/9780470720592.ch16DOI: 10.1002/9780470720592.ch16
INTERACTION OF ANTIBIOTICS WITH ETHINYLESTRADIOL IN THE RAT AND RABBIT (Journal article)
BACK, D. J., BRECKENRIDGE, A. M., CRAWFORD, F. E., CROSS, K. J., ORME, M. L. E., & ROWE, P. H. (1980). INTERACTION OF ANTIBIOTICS WITH ETHINYLESTRADIOL IN THE RAT AND RABBIT. BRITISH JOURNAL OF PHARMACOLOGY, 68(1), P118. Retrieved from https://www.webofscience.com/
Clinical pharmacology of oral contraceptive steroids: drug interactions (Journal article)
Back, D. J., Breckenridge, A. M., Orme, M., & Rowe, P. H. (1980). Clinical pharmacology of oral contraceptive steroids: drug interactions. Journal of Obstetrics and Gynaecology, 1(2), 126-138. doi:10.3109/01443618009067363DOI: 10.3109/01443618009067363
EFFECT OF ORAL-CONTRACEPTIVE STEROIDS AND ENZYME INDUCING DRUGS ON SEX-HORMONE BINDING GLOBULIN CAPACITY IN WOMEN (Journal article)
BACK, D. J., BRECKENRIDGE, A. M., CRAWFORD, F. E., MACIVER, M., ORME, M. L. E., PERUCCA, E., . . . SMITH, E. (1980). EFFECT OF ORAL-CONTRACEPTIVE STEROIDS AND ENZYME INDUCING DRUGS ON SEX-HORMONE BINDING GLOBULIN CAPACITY IN WOMEN. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 9(1), P115. doi:10.1111/j.1365-2125.1980.tb04817.xDOI: 10.1111/j.1365-2125.1980.tb04817.x
EFFECT OF RIFAMPICIN ON THE PHARMACOKINETICS OF ETHYNYLESTRADIOL IN WOMEN (Journal article)
BACK, D. J., BRECKENRIDGE, A. M., CRAWFORD, F. E., HALL, J. M., MACIVER, M., ORME, M. L. E., . . . WATTS, M. J. (1980). EFFECT OF RIFAMPICIN ON THE PHARMACOKINETICS OF ETHYNYLESTRADIOL IN WOMEN. CONTRACEPTION, 21(2), 135-143. doi:10.1016/0010-7824(80)90125-0DOI: 10.1016/0010-7824(80)90125-0
INVITRO METABOLISM OF ETHINYLESTRADIOL, LEVONORGESTREL AND MESTRANOL BY HUMAN JEJUNAL MUCOSA (Conference Paper)
BACK, D. J., BATES, M., BRECKENRIDGE, A. M., CRAWFORD, F. E., ELLIS, A., HALL, J. M., . . . ROWE, P. H. (1980). INVITRO METABOLISM OF ETHINYLESTRADIOL, LEVONORGESTREL AND MESTRANOL BY HUMAN JEJUNAL MUCOSA. In BRITISH JOURNAL OF CLINICAL PHARMACOLOGY Vol. 9 (pp. P281-P282). doi:10.1111/j.1365-2125.1980.tb04841.xDOI: 10.1111/j.1365-2125.1980.tb04841.x
PHARMACOKINETICS OF A LARGE (3 MG) ORAL DOSE OF ETHYNYLESTRADIOL IN WOMEN (Journal article)
BACK, D. J., BOLT, H. M., BRECKENRIDGE, A. M., CRAWFORD, F. E., ORME, M. L. E., ROWE, P. H., & SCHINDLER, A. E. (1980). PHARMACOKINETICS OF A LARGE (3 MG) ORAL DOSE OF ETHYNYLESTRADIOL IN WOMEN. CONTRACEPTION, 21(2), 145-153. doi:10.1016/0010-7824(80)90126-2DOI: 10.1016/0010-7824(80)90126-2
PHENOBARBITONE INTERACTION WITH ORAL-CONTRACEPTIVE STEROIDS IN THE RABBIT AND RAT (Journal article)
BACK, D. J., BRECKENRIDGE, A. M., CRAWFORD, F. E., ORME, M. L., & ROWE, P. H. (1980). PHENOBARBITONE INTERACTION WITH ORAL-CONTRACEPTIVE STEROIDS IN THE RABBIT AND RAT. BRITISH JOURNAL OF PHARMACOLOGY, 69(3), 441-452. doi:10.1111/j.1476-5381.1980.tb07033.xDOI: 10.1111/j.1476-5381.1980.tb07033.x
REDUCTION OF THE ENTEROHEPATIC CIRCULATION OF NORETHISTERONE BY ANTIBIOTICS IN THE RAT - CORRELATION WITH CHANGES IN THE GUT FLORA (Journal article)
BACK, D. J., BRECKENRIDGE, A. M., CRAWFORD, F. E., CROSS, K. J., ORME, M. L. E., PERCIVAL, A., & ROWE, P. H. (1980). REDUCTION OF THE ENTEROHEPATIC CIRCULATION OF NORETHISTERONE BY ANTIBIOTICS IN THE RAT - CORRELATION WITH CHANGES IN THE GUT FLORA. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 13(1), 95-100. doi:10.1016/0022-4731(80)90118-1DOI: 10.1016/0022-4731(80)90118-1
THE INTERACTION OF PHENOBARBITAL AND OTHER ANTICONVULSANTS WITH ORAL-CONTRACEPTIVE STEROID-THERAPY (Journal article)
BACK, D. J., BATES, M., BOWDEN, A., BRECKENRIDGE, A. M., HALL, M. J., JONES, H., . . . SMITH, E. (1980). THE INTERACTION OF PHENOBARBITAL AND OTHER ANTICONVULSANTS WITH ORAL-CONTRACEPTIVE STEROID-THERAPY. CONTRACEPTION, 22(5), 495-503. doi:10.1016/0010-7824(80)90102-XDOI: 10.1016/0010-7824(80)90102-X
1979
PHARMACOKINETICS OF ETHINYLESTRADIOL IN WOMEN (Journal article)
BACK, D. J., BOLT, H. M., BRECKENRIDGE, A. M., CRAWFORD, F. E., MACIVER, M., ORME, M. L. E., . . . SMITH, E. (1979). PHARMACOKINETICS OF ETHINYLESTRADIOL IN WOMEN. BRITISH JOURNAL OF PHARMACOLOGY, 66(3), P441-P442. Retrieved from https://www.webofscience.com/
EFFECT OF RIFAMPICIN ON NORETHISTERONE PHARMACOKINETICS (Journal article)
BACK, D. J., BRECKENRIDGE, A. M., CRAWFORD, F., MACIVER, M., ORME, M. L., PARK, B. K., . . . SMITH, E. (1979). EFFECT OF RIFAMPICIN ON NORETHISTERONE PHARMACOKINETICS. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 15(3), 193-197. doi:10.1007/BF00563105DOI: 10.1007/BF00563105
EFFECT OF RIFAMPICIN ON LIVER BLOOD-FLOW, MICROSOMAL-ENZYME ACTIVITY AND BILE-FLOW IN THE RAT (Journal article)
BACK, D. J., CROSS, K. J., HILEY, C. R., & YATES, M. S. (1979). EFFECT OF RIFAMPICIN ON LIVER BLOOD-FLOW, MICROSOMAL-ENZYME ACTIVITY AND BILE-FLOW IN THE RAT. BIOCHEMICAL PHARMACOLOGY, 28(8), 1293-1296. doi:10.1016/0006-2952(79)90427-1DOI: 10.1016/0006-2952(79)90427-1
THERAPY WITH ORAL-CONTRACEPTIVE STEROIDS AND ANTIBIOTICS (Journal article)
LEORME, M., & BACK, D. J. (1979). THERAPY WITH ORAL-CONTRACEPTIVE STEROIDS AND ANTIBIOTICS. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 5(2), 124-126. doi:10.1093/jac/5.2.124DOI: 10.1093/jac/5.2.124
EFFECTS OF PHENOBARBITONE ON HEPATIC MICROSOMAL-ENZYME ACTIVITY AND LIVER BLOOD-FLOW IN SPONTANEOUSLY HYPERTENSIVE RATS (Journal article)
YATES, M. S., HILEY, C. R., & BACK, D. J. (1979). EFFECTS OF PHENOBARBITONE ON HEPATIC MICROSOMAL-ENZYME ACTIVITY AND LIVER BLOOD-FLOW IN SPONTANEOUSLY HYPERTENSIVE RATS. LIFE SCIENCES, 24(6), 535-540. doi:10.1016/0024-3205(79)90175-9DOI: 10.1016/0024-3205(79)90175-9
INTERACTIONS BETWEEN ORAL-CONTRACEPTIVES AND OTHER DRUGS (Journal article)
BRECKENRIDGE, A. M., BACK, D. J., & ORME, M. (1979). INTERACTIONS BETWEEN ORAL-CONTRACEPTIVES AND OTHER DRUGS. PHARMACOLOGY & THERAPEUTICS, 7(3), 617-626. doi:10.1016/0163-7258(79)90044-5DOI: 10.1016/0163-7258(79)90044-5
INVESTIGATION OF THE PHARMACOKINETICS OF ETHYNYLESTRADIOL IN WOMEN USING RADIOIMMUNOASSAY (Journal article)
BACK, D. J., BRECKENRIDGE, A. M., CRAWFORD, F. E., MACIVER, M., ORME, M. L. E., ROWE, P. H., & WATTS, M. J. (1979). INVESTIGATION OF THE PHARMACOKINETICS OF ETHYNYLESTRADIOL IN WOMEN USING RADIOIMMUNOASSAY. CONTRACEPTION, 20(3), 263-273. doi:10.1016/0010-7824(79)90098-2DOI: 10.1016/0010-7824(79)90098-2
PLASMA XA INHIBITORY ACTIVITIES AND PLASMA-CONCENTRATIONS OF NORGESTREL AND ETHINYLESTRADIOL IN WOMEN ON ORAL-CONTRACEPTIVE STEROIDS (Journal article)
BACK, D. J., BATES, M., BURKE, M. W., BRECKENRIDGE, A. M., CRAWFORD, F. E., MACIVER, M., . . . WEBSTER, S. (1979). PLASMA XA INHIBITORY ACTIVITIES AND PLASMA-CONCENTRATIONS OF NORGESTREL AND ETHINYLESTRADIOL IN WOMEN ON ORAL-CONTRACEPTIVE STEROIDS. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 8(5), 505-506. doi:10.1111/j.1365-2125.1979.tb01034.xDOI: 10.1111/j.1365-2125.1979.tb01034.x
1978
Drug interactions with oral contraceptives. (Journal article)
Back, D. J., & Breckenridge, A. M. (1978). Drug interactions with oral contraceptives.. IPPF medical bulletin, 12(4), 1-2.
First-pass effect of norethindrone in rabbits and rats. (Journal article)
Back, D. J., Breckenridge, A. M., Crawford, F. E., Orme, M. L., Rowe, P. H., & Smith, E. (1978). First-pass effect of norethindrone in rabbits and rats.. The Journal of pharmacology and experimental therapeutics, 207(2), 555-565.
REDUCTION OF ENTEROHEPATIC CIRCULATION OF NORETHISTERONE BY ANTIBIOTICS IN RAT (Journal article)
BACK, D. J., BRECKENRIDGE, A. M., CROSS, K. J., ORME, M. L., PERCIVAL, A., & ROWE, P. H. (1978). REDUCTION OF ENTEROHEPATIC CIRCULATION OF NORETHISTERONE BY ANTIBIOTICS IN RAT. BRITISH JOURNAL OF PHARMACOLOGY, 64(3), P401. Retrieved from https://www.webofscience.com/
BILIARY-EXCRETION OF SYNTHETIC SEX STEROIDS IN HETEROZYGOUS AND HOMOZYGOUS GUNN RATS (Journal article)
BACK, D. J., BRECKENRIDGE, A. M., CRAWFORD, F. E., CROSS, K. J., ORME, M. L., ROWE, P. H., . . . TODD, K. (1978). BILIARY-EXCRETION OF SYNTHETIC SEX STEROIDS IN HETEROZYGOUS AND HOMOZYGOUS GUNN RATS. LIFE SCIENCES, 23(10), 1053-1056. doi:10.1016/0024-3205(78)90666-5DOI: 10.1016/0024-3205(78)90666-5
EFFECT OF URETHANE AND PENTOBARBITAL ANESTHESIA AND HEPATIC PORTAL-VEIN CATHETERIZATION ON LIVER BLOOD-FLOW IN RAT (Journal article)
HILEY, C. R., YATES, M. S., & BACK, D. J. (1978). EFFECT OF URETHANE AND PENTOBARBITAL ANESTHESIA AND HEPATIC PORTAL-VEIN CATHETERIZATION ON LIVER BLOOD-FLOW IN RAT. EXPERIENTIA, 34(8), 1061-1062. doi:10.1007/BF01915348DOI: 10.1007/BF01915348
INTERACTION OF ANTIBIOTICS WITH SYNTHETIC STEROIDS IN RAT (Journal article)
BACK, D. J., BRECKENRIDGE, A. M., CHALLINER, M., CRAWFORD, F. E., ORME, M. L. E., ROWE, P. H., & SMITH, E. (1978). INTERACTION OF ANTIBIOTICS WITH SYNTHETIC STEROIDS IN RAT. BRITISH JOURNAL OF PHARMACOLOGY, 62(3), P441. Retrieved from https://www.webofscience.com/
DIFFERENTIAL EFFECTS OF HEPATIC MICROSOMAL-ENZYME INDUCING AGENTS ON LIVER BLOOD-FLOW (Journal article)
YATES, M. S., HILEY, C. R., ROBERTS, P. J., BACK, D. J., & CRAWFORD, F. E. (1978). DIFFERENTIAL EFFECTS OF HEPATIC MICROSOMAL-ENZYME INDUCING AGENTS ON LIVER BLOOD-FLOW. BIOCHEMICAL PHARMACOLOGY, 27(22), 2617-2621. doi:10.1016/0006-2952(78)90336-2DOI: 10.1016/0006-2952(78)90336-2
EFFECT OF ANTIBIOTICS ON ENTEROHEPATIC CIRCULATION OF ETHINYLESTRADIOL AND NORETHISTERONE IN RAT (Journal article)
BACK, D. J., BRECKENRIDGE, A. M., CHALLINER, M., CRAWFORD, F. E., ORME, M. L., ROWE, P. H., & SMITH, E. (1978). EFFECT OF ANTIBIOTICS ON ENTEROHEPATIC CIRCULATION OF ETHINYLESTRADIOL AND NORETHISTERONE IN RAT. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 9(6), 527-531. doi:10.1016/0022-4731(78)90118-8DOI: 10.1016/0022-4731(78)90118-8
ETHYNYLESTRADIOL AND NORETHINDRONE METABOLISM BY EVERTED SACS OF RAT ILEUM (Journal article)
BACK, D. J., BATES, M. W., BRECKENRIDGE, A. M., CRAWFORD, F. E., ORME, M. L. E., ROWE, P. H., . . . SMITH, E. (1978). ETHYNYLESTRADIOL AND NORETHINDRONE METABOLISM BY EVERTED SACS OF RAT ILEUM. CONTRACEPTION, 18(2), 127-135. doi:10.1016/0010-7824(78)90088-4DOI: 10.1016/0010-7824(78)90088-4
KINETICS OF NORETHINDRONE IN WOMEN .1. RADIOIMMUNOASSAY AND CONCENTRATIONS DURING MULTIPLE DOSING (Journal article)
BACK, D. J., BRECKENRIDGE, A. M., CRAWFORD, F. E., MCIVER, M., ORME, M. L. E., PARK, B. K., . . . SMITH, E. (1978). KINETICS OF NORETHINDRONE IN WOMEN .1. RADIOIMMUNOASSAY AND CONCENTRATIONS DURING MULTIPLE DOSING. CLINICAL PHARMACOLOGY & THERAPEUTICS, 24(4), 439-447. Retrieved from https://www.webofscience.com/
KINETICS OF NORETHINDRONE IN WOMEN .2. SINGLE-DOSE KINETICS (Journal article)
BACK, D. J., BRECKENRIDGE, A. M., CRAWFORD, F. E., MCIVER, M., ORME, M. L. E., ROWE, P. H., & SMITH, E. (1978). KINETICS OF NORETHINDRONE IN WOMEN .2. SINGLE-DOSE KINETICS. CLINICAL PHARMACOLOGY & THERAPEUTICS, 24(4), 448-453. Retrieved from https://www.webofscience.com/
METABOLISM OF NORETHISTERONE AND ETHINYLESTRADIOL BY RAT GUT WALL (Journal article)
BACK, D. J., BATES, M. W., BRECKENRIDGE, A. M., CRAWFORD, F. E., ORME, M. L. E., ROWE, P. H., . . . SMITH, E. (1978). METABOLISM OF NORETHISTERONE AND ETHINYLESTRADIOL BY RAT GUT WALL. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 9(9), 823. doi:10.1016/0022-4731(78)90751-3DOI: 10.1016/0022-4731(78)90751-3
PHARMACOKINETICS OF TRITIATED ETHINYLESTRADIOL IN RABBIT (Journal article)
BACK, D. J., BRECKENRIDGE, A. M., CRAWFORD, F. E., ORME, M. L. E., ROWE, P. H., SLOAN, T. P., & SMITH, E. (1978). PHARMACOKINETICS OF TRITIATED ETHINYLESTRADIOL IN RABBIT. STEROIDS, 32(4), 423-433. doi:10.1016/0039-128X(78)90056-9DOI: 10.1016/0039-128X(78)90056-9
PLASMA ETHINYLESTRADIOL CONCENTRATION IN RABBITS AND WOMEN (Journal article)
BACK, D. J., BRECKENRIDGE, A. M., CRAWFORD, F. E., ORME, M. L. E., ROWE, P. H., SLOAN, T. P., & SMITH, E. (1978). PLASMA ETHINYLESTRADIOL CONCENTRATION IN RABBITS AND WOMEN. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 9(9), 863. doi:10.1016/0022-4731(78)90942-1DOI: 10.1016/0022-4731(78)90942-1
1977
PHARMACOKINETICS OF NORETHISTERONE IN RABBIT AND RAT AFTER SYSTEMIC AND ORAL-ADMINISTRATION - EFFECT OF PHENOBARBITONE (Journal article)
BACK, D. J., BRECKENRIDGE, A. M., GAY, F. E., ORME, M. L., ROWE, P. H., & SMITH, E. (1977). PHARMACOKINETICS OF NORETHISTERONE IN RABBIT AND RAT AFTER SYSTEMIC AND ORAL-ADMINISTRATION - EFFECT OF PHENOBARBITONE. BRITISH JOURNAL OF PHARMACOLOGY, 60(2), 279. Retrieved from https://www.webofscience.com/
LSD - DISTRIBUTION OF [LSD[H-3] IN REPRODUCTIVE-SYSTEM OF MALE RAT AND PLACENTAL-TRANSFER IN FEMALE RAT (Journal article)
BACK, D. J., & SINGH, J. K. G. (1977). LSD - DISTRIBUTION OF [LSD[H-3] IN REPRODUCTIVE-SYSTEM OF MALE RAT AND PLACENTAL-TRANSFER IN FEMALE RAT. EXPERIENTIA, 33(4), 501-502. doi:10.1007/BF01922236DOI: 10.1007/BF01922236
SOME EFFECTS OF CYPROTERONE AND CYPROTERONE-ACETATE ON REPRODUCTIVE PHYSIOLOGY OF MALE RAT (Journal article)
BACK, D. J., GLOVER, T. D., SHENTON, J. C., & BOYD, G. P. (1977). SOME EFFECTS OF CYPROTERONE AND CYPROTERONE-ACETATE ON REPRODUCTIVE PHYSIOLOGY OF MALE RAT. JOURNAL OF REPRODUCTION AND FERTILITY, 49(2), 237-243. Retrieved from https://www.webofscience.com/
Drug interactions with oral contraceptive steroids (Journal article)
Back, D. J., & L'E Orme, M. (1977). Drug interactions with oral contraceptive steroids. Prescribers' Journal, 17(6), 137-142.
INFLUENCE OF .A. ROUTE OF ADMINISTRATION AND .B. PHENOBARBITONE ON PHARMACOKINETICS OF NORETHISTERONE IN RABBIT AND RAT (Journal article)
BACK, D. J., BRECKENRIDGE, A. M., GAY, F. E., ORME, M. L., PARK, B. K., ROWE, P. H., & SMITH, E. (1977). INFLUENCE OF .A. ROUTE OF ADMINISTRATION AND .B. PHENOBARBITONE ON PHARMACOKINETICS OF NORETHISTERONE IN RABBIT AND RAT. ACTA ENDOCRINOLOGICA, 85, 67. Retrieved from https://www.webofscience.com/
PHARMACOKINETICS OF NORETHISTERONE DURING SINGLE AND MULTIPLE DOSING IN WOMEN AND CHANGES CAUSED BY RIFAMPICIN (Journal article)
BACK, D. J., BRECKENRIDGE, A. M., GAY, F. E., ORME, M. L. E., PARK, B. K., ROWE, P. H., & SMITH, E. (1977). PHARMACOKINETICS OF NORETHISTERONE DURING SINGLE AND MULTIPLE DOSING IN WOMEN AND CHANGES CAUSED BY RIFAMPICIN. ACTA ENDOCRINOLOGICA, 85, 149. Retrieved from https://www.webofscience.com/
PHARMACOKINETICS OF NORETHISTERONE IN WOMEN (Journal article)
BACK, D. J., BRECKENRIDGE, A. M., GAY, F. E., MCIVER, M., ORME, M. L., PARK, B. K., . . . SMITH, E. (1977). PHARMACOKINETICS OF NORETHISTERONE IN WOMEN. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 4(6), P729-P730. Retrieved from https://www.webofscience.com/
1976
BILIARY-EXCRETION OF [H-3] LYSERGIC-ACID DIETHYLAMIDE IN WISTAR AND GUNN RATS (Journal article)
BACK, D. J., & SINGH, J. K. G. (1976). BILIARY-EXCRETION OF [H-3] LYSERGIC-ACID DIETHYLAMIDE IN WISTAR AND GUNN RATS. EXPERIENTIA, 32(5), 616-617. doi:10.1007/BF01990195DOI: 10.1007/BF01990195
RELEASE OF MICROQUANTITIES OF CYPROTERONE-ACETATE FROM SUBCUTANEOUS SILASTIC CAPSULES - FAILURE TO PRODUCE AN ANTIFERTILITY EFFECT (Journal article)
BACK, D. J., & SHENTON, J. C. (1976). RELEASE OF MICROQUANTITIES OF CYPROTERONE-ACETATE FROM SUBCUTANEOUS SILASTIC CAPSULES - FAILURE TO PRODUCE AN ANTIFERTILITY EFFECT. CONTRACEPTION, 14(1), 17-24. doi:10.1016/S0010-7824(76)80004-2DOI: 10.1016/S0010-7824(76)80004-2
1975
EFFECTS OF ALPHA-CHLOROHYDRIN ON COMPOSITION OF RAT AND RABBIT EPIDIDYMAL PLASMA - POSSIBLE EXPLANATION OF SPECIES-DIFFERENCE (Journal article)
BACK, D. J., GLOVER, T. D., SHENTON, J. C., & BOYD, G. P. (1975). EFFECTS OF ALPHA-CHLOROHYDRIN ON COMPOSITION OF RAT AND RABBIT EPIDIDYMAL PLASMA - POSSIBLE EXPLANATION OF SPECIES-DIFFERENCE. JOURNAL OF REPRODUCTION AND FERTILITY, 45(1), 117-128. Retrieved from https://www.webofscience.com/
COMPARISON OF COMPOSITION OF EPIDIDYMAL PLASMA FROM CAUDA EPIDIDYMIDIS OF RAT, HAMSTER AND GUINEA-PIG (Journal article)
BACK, D. J., & SHENTON, J. C. (1975). COMPARISON OF COMPOSITION OF EPIDIDYMAL PLASMA FROM CAUDA EPIDIDYMIDIS OF RAT, HAMSTER AND GUINEA-PIG. EXPERIENTIA, 31(4), 464-465. doi:10.1007/BF02026381DOI: 10.1007/BF02026381
PRESENCE OF METABOLITES OF H-3-TESTOSTERONE IN LUMEN OF CAUDA EPIDIDYMIDIS OF RAT (Journal article)
BACK, D. J. (1975). PRESENCE OF METABOLITES OF H-3-TESTOSTERONE IN LUMEN OF CAUDA EPIDIDYMIDIS OF RAT. STEROIDS, 25(3), 413-420. doi:10.1016/0039-128X(75)90097-5DOI: 10.1016/0039-128X(75)90097-5
1974
The composition of epididymal plasma from the cauda epididymidis of the rat. (Journal article)
Back, D. J., Shenton, J. C., & Glover, T. D. (1974). The composition of epididymal plasma from the cauda epididymidis of the rat.. Journal of reproduction and fertility, 40(1), 211-214. doi:10.1530/jrf.0.0400211DOI: 10.1530/jrf.0.0400211
The pharmacokinetics of (14C)-edrophonium in normal wistar rats and homozygous Gunn rats with ligated renal pedicles. (Journal article)
Back, D. J., & Calvey, T. N. (1974). The pharmacokinetics of (14C)-edrophonium in normal wistar rats and homozygous Gunn rats with ligated renal pedicles.. British journal of pharmacology, 51(1), 61-65. doi:10.1111/j.1476-5381.1974.tb09632.xDOI: 10.1111/j.1476-5381.1974.tb09632.x
1973
Proceedings: The passage of (3H) testosterone into the cauda epididymidis of the rat. (Journal article)
Back, D. J. (1973). Proceedings: The passage of (3H) testosterone into the cauda epididymidis of the rat.. Journal of reproduction and fertility, 35(3), 586-587. doi:10.1530/jrf.0.0350586DOI: 10.1530/jrf.0.0350586
Biliary excretion of 14 C-edrophonium and its glucuronide metabolite in Gunn rats. (Journal article)
Calvey, T. N., & Back, D. J. (1973). Biliary excretion of 14 C-edrophonium and its glucuronide metabolite in Gunn rats.. Archives internationales de pharmacodynamie et de therapie, 201(1), 147-153.
1972
The influence of secretin on the elimination of 14 C-endrophonium in bile. (Journal article)
Back, D. J., & Calvey, T. N. (1972). The influence of secretin on the elimination of 14 C-endrophonium in bile.. Experientia, 28(11), 1332-1334. doi:10.1007/bf01965328DOI: 10.1007/bf01965328
Excretion of 14 C-edrophonium and its metabolites in bile: role of the liver cell and the peribiliary vascular plexus. (Journal article)
Back, D. J., & Calvey, T. N. (1972). Excretion of 14 C-edrophonium and its metabolites in bile: role of the liver cell and the peribiliary vascular plexus.. British journal of pharmacology, 44(3), 534-543. doi:10.1111/j.1476-5381.1972.tb07290.xDOI: 10.1111/j.1476-5381.1972.tb07290.x
The removal of 14 C-edrophonium from the circulation. (Journal article)
Back, D. J., & Calvey, T. N. (1972). The removal of 14 C-edrophonium from the circulation.. British journal of pharmacology, 46(2), 355-357. doi:10.1111/j.1476-5381.1972.tb06882.xDOI: 10.1111/j.1476-5381.1972.tb06882.x
1971
Infusion of secretin into the hepatic arterial circulation of the rat. (Journal article)
Back, D. J., & Calvey, T. N. (1971). Infusion of secretin into the hepatic arterial circulation of the rat.. The Journal of physiology, 219(2), 14P.
The influence of secretion on the elimination of drugs in bile. (Journal article)
Back, D. J., & Calvey, T. N. (1971). The influence of secretion on the elimination of drugs in bile.. The Journal of physiology, 219(2), 13P.
The effect of organic anions on the biliary excretion of tri (14C) methyl-(3-hydroxyphenyl) ammonium O-glucuronide. (Journal article)
Calvey, T. N., & Back, D. J. (1971). The effect of organic anions on the biliary excretion of tri (14C) methyl-(3-hydroxyphenyl) ammonium O-glucuronide.. The Biochemical journal, 121(3), 41P-42P. doi:10.1042/bj1210041pbDOI: 10.1042/bj1210041pb
The effect of bile pigments on the excretion of 14C-trimophonium glucuronide. (Journal article)
Calvey, T. N., & Back, D. J. (1971). The effect of bile pigments on the excretion of 14C-trimophonium glucuronide.. European journal of pharmacology, 13(2), 262-265. doi:10.1016/0014-2999(71)90159-2DOI: 10.1016/0014-2999(71)90159-2
